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Chapter
G E N E R A L  I N T R O D U C T I O N
G E N E R A L  I N T R O D U C T I O N
1.1 Epidemiology
Psoriasis is a common skin disease which equally affects men and women [1-4]. Approxi­
mately 1-3% of the general population in Europe, North America, East Africa, and South 
Asia suffers from this chronic disorder [5,6]. However, there are differences in the preva­
lence of psoriasis between several racial groups, which suggests the involvement of gene­
tic factors [7]. In native Americans, Eskimos, Samoans, and Laps for example, psoriasis is 
hardly seen [5,8]. Psoriasis may appear at every age, from birth or even at the age of 108 
years [9,10], but two peaks in the age of onset are present: one occurring in adolescence, 
at an average age of 16 years in women and 22 years in men, and another peak at 
middle age: at 60 years in women and at 57 years in men [11]. However, in most patients 
the first symptoms appear in the second decade of life [12,13].
1.2 Clinical aspects
1.2.1 Classification of psoriasis
Psoriasis is the name for a disease that in fact comprises 4 different forms of lesions [14].
1. The most common form is chronic plaque psoriasis, also designated as psoriasis 
vulgaris, accounting for 90% of all cases. In this form of psoriasis, lesions are 
symmetrically distributed over the body showing classical psoriatic aspects such as 
erythema, induration and silvery scaling. The scalp, elbows, knees and the sacral 
region are sites of predilection, although this form can appear on the entire body.
This thesis is about this chronic plaque type psoriasis, and where ‘psoriasis' is 
mentioned, this form of psoriasis is meant.
2. A second form of psoriasis is the guttate form: psoriasis guttata. In this form of 
psoriasis, the lesions appear as small droplet-like lesions, disseminated over the body. 
They hardly show scaling. This form is often preceded by an upper respiratory tract 
infection, and it is mostly seen in children and adolescents.
3. Pustular psoriasis is a collective name for those forms of psoriasis which show macro­
scopic pustules. A localised and a generalised form can be distinguished. The loca­
lised form comprises pustulosis palmoplantaris, acrodermatitis continua of Hallopeau, 
and other non acral, non palmoplantar localised forms. The generalised form can be 
divided into the acute generalised pustular psoriasis of Von Zumbusch, impetigo 
herpetiformis, annular pustular psoriasis, juvenile, and infantile pustular psoriasis [15].
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4. A rare form of psoriasis is psoriatic erythroderma, or simply erythroderma. In this form 
the skin becomes entirely erythematous with variable scaling. Erythroderma may 
occur in patients with no history of psoriasis, but this form is often seen in patients 
with chronic plaque psoriasis after withdrawal of corticosteroids, after irritation by 
dithranol or phototherapy, or it is triggered by other drugs. It is a severe condition, 
with a risk of hypothermia, dehydration, and protein loss. Therefore, admission is 
often required.
Figure 1 Typical psoriatic lesions: sharply demarcated erythematosquamous plaques.
1.2.2 General description of psoriasis vulgaris
Chronic plaque psoriasis is an erythematosquamous disorder which is so characteristic 
that its clinical appearance often permits a diagnosis ‘a vue' (Figure 1). The lesions are 
sharply demarcated and may vary in size between pinpoint lesions and large plaques. 
Larger lesions have developed out of smaller lesions by centrifugal expansion. Lesions 
may coalesce and thus form polycyclic, annular or gyratory configurations of plaques 
(Figure 2). Usually, the plaques are distributed symmetrically on the predilection sites.
Clinically, the most important hallmarks of psoriasis are erythema, scaling and thicke­
ning of the skin. The erythema may vary between a slight pink discoloration and very 
intense redness with almost a livide aspect. Sometimes, a clear peripheral zone can be
Figure 2 Annular lesions as a result of central healing.
observed. This is called the halo or ring of Woronoff [16,17]. The amount of scales varies 
as well: from no scales or discrete scales such as in early guttata lesions and in the 
flexures, to very profound scaling such as in rupoid psoriasis and elephantine psoriasis 
[14]. The scales have a typically silvery white aspect. Characteristic for the scaling in 
psoriasis is the so-called ‘signe de la tache de bougie', or ‘candle phenomenon'. This 
means that if scales are scratched off from a lesion, the scales cohere similar as the wax 
flakes scraped from a candle. When all the scales are scratched off, characteristic pin­
point bleedings can be observed. This phenomenon is called ‘signe d'Auspitz'. Thickening 
of the skin is also an important feature of psoriasis, and the thickness may vary between 
a slight elevation to profoundly indurated plaques. Because of this thickening, the lesions 
are easily palpable.
The clinical picture of psoriasis depends on the localisation of the lesions. Very thick 
plaques with rather severe scaling are generally observed on the scalp, whereas inter- 
triginous psoriasis is more mild and generally without scaling. Fissures and lichenification 
are typically seen in psoriasis of the sacral region. As a rule, psoriatic plaques are sharply 
demarcated, but lesions can be less clearly defined such as the involvement of the hands 
and feet.
Psoriasis is not only limited to the skin. Extracutaneous manifestations are well 
known and may cause considerable problems. This holds true especially for psoriatic 
arthro-pathy. This is a frequent complication of severe psoriasis, occurring in 6 to 10
13
G
E
N
E
R
A
L
 
IN
T
R
O
D
U
C
T
IO
N
14
G
E
N
E
R
A
L
 
IN
T
R
O
D
U
C
T
IO
N
percent of all psoriatic patients [18]. This type of arthropathy may occur without 
cutaneous manifestations of psoriasis. Psoriatic arthropathy equally effects men and 
women, although differences exist: in men, distal arthritis and spinal disease are pre­
dominantly seen, whereas in women mainly symmetrical polyarthritis occurs [19]. The 
nail is also commonly affected in psoriasis (Figure 3). If looked for carefully, nail changes 
are present in 25 to 50 percent of all cases [20]. Nail psoriasis is associated with all 
types of psoriasis, and is frequently present in patients with psoriatic arthropathy [21,22]. 
Pitting of the nail is the most frequent change seen, but discoloration, subungual hyper­
keratosis, onycholysis, splinter haemorrhages, as well as crumbling and grooving of nails 
are also common [23-25]. A characteristic sign of psoriatic nails is the ‘oil drop' sign: 
circular areas of discoloration of the nail bed and hyponychium may resemble an ‘oil 
drop' below the nail [26]. The problems that nail psoriasis may cause are underestimated. 
Many patients suffer from pain caused by nail changes, and a large group of patients is 
restricted in their daily activities, housekeeping and/or profession [27].
Figure 3 Nail psoriasis: subungual hyperkeratosis and onycholysis.
1.2.3 Differential diagnosis
Although the characteristics as described above are usually sufficient to enable the right 
diagnosis, doubt may arise in atypical cases, in particular sites, and when psoriasis is 
complicated by or alternates with other diseases [14,28].
All erythematosquamous disorders should be considered in the differential diagnosis 
of psoriasis [29]. Seborroeic dermatitis may be similar in its clinical presentation as 
psoriasis. However, in seborroeic dermatitis lesions are lighter in colour (more yellowish), 
are less well defined, and show a more dull and greasy scale. Moreover, the distribution 
over the body is different from that in psoriasis. Seborroeic dermatitis is more seen 
presternally, interscapularly, in the face, and in the intertriginous areas. Eczema may have 
a psoriatic appearance, especially on the legs. A common misdiagnosis is hyperkeratosis 
of the palms, caused by hyperkeratotic eczema. In this disorder, colour, scratch-evoked 
scaling and the well-defined margins are suggestive for psoriasis. Lichen simplex may 
resemble psoriasis closely, especially on the scalp and around the elbows. The rather ill 
defined edge and the marked itching are characteristic, and the point of the elbow is 
usually not affected.
Several infections may present as psoriatiform lesions. Secondary syphilis may look 
like guttata psoriasis. However, the preferential localisation of secondary syphilis is the 
face, the palms and the soles. Condylomata lata and other signs of secondary syphilis are 
usually found, if sought. A candida infection can be confused with flexural psoriasis. 
However, candidiasis is characterised by collerette scaling and pustules in the margin. 
Other dermatophytic infections may resemble psoriasis as well. Again, the collarette 
scaling and an elevated margin may give a clue for the diagnosis. If the diagnosis is 
doubtful, mycological investigations can be decisive.
Parapsoriasis or a cutaneous lymphoma may be misdiagnosed as psoriasis. If 
increased infiltration is observed, pruritis is intense, sharp demarcation fails, and in case 
of a marked adenopathy, brownish discoloration, and a cigarette paper like atrophy, these 
diagnoses should be considered.
1.2.4 Clinical course
Psoriasis is a chronic disease with an unpredictable course. “It is impossible to say, in any 
particular case, how long the disease will last, whether a relapse will occur, or for what 
period of time the patient will remain free from psoriasis" [30]. This 130 years old quote 
still holds true. Although psoriasis can remain stable for some years and long lasting 
remissions have been reported [31], every patient will experience several exacerbations 
and remissions during lifetime. Triggering factors are important in the development of
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new lesions or exacerbations, and these will be discussed in section 1.4.2. Environmental 
factors such as sunlight and hot weather are favourable for many patients [31]. Psoriasis 
is an incurable disease, and the treatment modalities available can only suppress the 
symptoms of the disease. By trying to establish the most effective treatment for each 
individual patient, clearance and prolonged remission can be achieved and the prognosis 
with respect to the clinical symptoms may be good [32]. However, unless the effective­
ness of whatever therapy, relapse is the rule [28].
Figure 4
Histological appearence of 
psoriasis: hypertrophic dermal 
papillae, elongated rete- 
ridges, and a parakeratotic, 
thickened horny layer.
1.3 Histological aspects
The epidermal changes as seen in early psoriasis, are preceded by dilated tortuousity of 
the capillaries in the dermal papillae, by oedema of the papillary dermis, and by leuco­
cyte infiltrates, predominantly polymorphonuclears [33-39]. Subsequently, some lympho­
cytes move upward into the suprabasal compartment of the epidermis and slight inter­
cellular oedema develops. Above these spongiotic foci, the granular layer disappears, the 
cornified layer becomes compact, and parakeratosis and epidermal hyperplasia develop 
[33]. Neutrophils may accumulate in the basal and suprabasal layer, and together with 
remnants of eosinophilic epidermal strands form characteristic spongiform pustules: the 
micropustules of Kogoj [40-42]. Sometimes, small abscesses develop, the so-called Munro 
microabscesses. On the interface between the dermis and epidermis, the dermal papillae 
are hypertrophic, and the epidermal rete-ridges are elongated and thickened at the base. 
A representative histological picture of a psoriatic lesion is depicted in Figure 4.
1.4 Aetiology and pathogenesis
1.4.1 Genetics
It had been thought for a long time that hereditary factors play an important role in the 
aetiology of psoriasis. Population surveys, twin studies and other family analyses, as well 
as HLA studies have indisputably proven that psoriasis is a hereditary disorder [28]. 
However, the genetic basis of psoriasis is complicated and there is still controversy over 
the mode of inheritance. This makes appropriate genetic counselling difficult [43]. For an 
overview of genetic studies in psoriasis, review articles are recommended [43,44].
A marked familial aggregation of psoriasis has been demonstrated by several studies 
[2,5,31,45-49]. The risk to get psoriasis depends upon the number of family members 
involved with this disease [31]: If one parent suffers from psoriasis, and no brothers or 
sisters, the risk to become affected is 10%. If one parent and one brother or sister is 
affected, the risk is 16%, and if both parents are affected, the risk of getting psoriasis is 
even 50%. If second or third grade family is affected, the risk is 4 and 2 percent 
respectively [50].
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1.4.2 Triggering factors
Several factors are known which can provoke new episodes of psoriasis or exacerbate an 
already existing disease [7,51].
Trauma
The best known factor that can induce psoriasis is an injury of the skin [7]. The fact that 
trauma may elicit psoriasis in previously uninvolved skin was first described by Kobner 
and is therefore called the Kobner phenomenon [52]. Any physical injury of the skin may 
induce a Kobner reaction, such as adhesive tape stripping, electrodesiccation, excoria­
tions, freezing, incision, laceration, pressure, radiation, rubbing, scarification, shaving, 
and surgery. Other conditions that disturb the structure of the epidermis can induce a 
Kobner reaction as well. These include sunburn, chemical burns and skin disorders such 
as contact dermatitis [53]. The Kobner reaction usually occurs 7 to 14 days after the 
injury [54]. It occurs in about 38 to 76 percent of all psoriatic patients at some time 
during the course of their disease [2,31].
Climate
Climate is another factor that might act as a trigger. The prevalence of psoriasis has been 
reported to be higher in colder regions and lower in warmer, humid countries. Patients 
can experience an aggravation of their psoriasis when they move into colder climates, 
whereas a warmer environment with a lot of sun generally improves the disease 
[31,48,55]. On the other hand, sunlight may also induce an exacerbation: the prevalence 
of photosensitivity in psoriasis has been estimated at 5,5% [56].
Infections
Infections have also been noted as triggering factors for psoriasis. Tonsillitis, especially 
caused by streptococcal infection, may provoke an acute guttate psoriasis [57-60]. Con­
tinuing, subclinical streptococcal infection might also be responsible for refractory 
chronic plaque psoriasis [61]. Viral infections are associated with induction of psoriasis 
as well. Especially the association between human immunodeficiency virus (HIV) and 
severe psoriasis is well known [62-71]. An already existing psoriasis can severely aggra­
vate due to HIV infection, and it seems that the more immunocompromised the patient 
is, the worse the psoriasis [72]. Not rarely, HIV infection is detected after a sudden onset 
of severe psoriasis. Therefore, the sudden appearance of severe psoriasis should prompt 
evaluation for HIV [64].
Endocrine and metabolic factors 
There is evidence that endocrinological factors may play a role in the onset of psoriasis, 
as the incidence shows peaks at puberty and at the menopause [11,73]. However, 
psoriasis does not aggravate during pregnancy; there is even a tendency of improvement. 
On the other hand, postpartum psoriasis tends to detoriate [31,55,74]. Metabolically, 
hypocalcaemia and dialysis have been reported to worsen psoriasis [75,76].
Drugs
Any drug that has the potential to induce a drug eruption can exacerbate psoriasis as a 
Kobner reaction [53]. More than 200 drugs have been described that either exacerbate 
psoriasis or demonstrate initiation of psoriasis [77,78]. Although lots of drugs have 
psoriatogenic potentials, some groups of drugs have a marked increased risk to aggravate 
psoriasis. These include lithium [79-81], beta-adrenergic blocking drugs [82], antimala- 
rials [83,84], nonsteroidal anti-inflammatory drugs [85], the withdrawal of corticoste­
roids [15], indomethacin [86], and interferon-alpha [87-89].
Stress
The role of stress in the induction and severity of psoriasis has been suggested and docu­
mented by several authors [90-95]. Psychological stress may be associated with a dimi­
nished capacity to cope with regular treatment, and this may lead to detoriation, espe­
cially in severe cases [28]. There is evidence that reduction of stressing factors may 
improve psoriasis and that therefore it could be regarded as part of antipsoriatic treat­
ment [92,95].
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1.4.3 Cellular aspects
Psoriasis is clinically characterised by erythema, scaling and thickening of the skin. These 
are the results of three major processes in the skin: inflammation, disturbed differen­
tiation and hyperproliferation respectively. Before a lesion can develop, changes in both 
dermis and epidermis are required [96]. In this section, different aspects of these 
processes in the epidermis will be discussed.
Inflammation
Changes in the skin after challenge may cause inflammation. However, the challenge to 
inflammation varies considerably. The challenge can be a microbial infection, trauma, 
ultraviolet radiation, chemical injury, and antigen challenge. The process between the 
challenge and the clinical response is complex. Numerous mediators of inflammation can 
be released and many different cell types may be involved [97].
Cellular infiltrate
The cellular infiltrate as seen in psoriasis involves the upper dermis, the dermo- 
epidermal junction zone, and the epidermis [98]. It consists of T lymphocytes, mono­
cytes, polymorphonuclear leucocytes (PMN) and occasionally eosinophils and plasma 
cells [36]. However, this infiltrate varies with the stage of the lesion [98].
In a pinpoint papule, mainly monocytes and lymphocytes can be observed [99,100], 
whereas in fully developed lesions the infiltrate is mainly composed of T lymphocytes 
[101-104].
T Lymphocytes
The mononuclear cell infiltrate in psoriasis is dominated by T lymphocytes, whereas B 
lymphocytes are rarely found in lesional skin. The major part of the T lymphocytes are 
T-helper cells (CD4+). T-suppressor cell (CD8+) account for only 25% of all T cells in 
lesional skin of chronic plaque psoriasis [105]. However, the CD4/CD8 ratio varies 
with the different activity stages of the lesion: active psoriasis is associated with 
CD4+ T lymphocytes in the epidermis, whereas CD8+ T lymphocytes are mainly found 
in regressive plaques [106-108].
Polymorphonuclear leucocytes 
The presence of polymorphonuclear leucocytes (PMN) in spongiform pustules in the 
epidermis (pustules of Kogoj) and in microabscesses in the stratum corneum (micro­
abscesses of Munro) is a hallmark of psoriasis. The infiltration of PMN is more pro­
nounced in early stages of the disease, such as in guttata psoriasis and in incipient
lesions, and is maximal in pustular psoriasis [98,109]. The pustules caused by the 
infiltration of PMN are sterile. As microabscesses of Munro were only found in para- 
keratotic areas of the epidermis, accumulation of PMN seems to be associated with 
parakeratosis in chronic plaque type psoriasis [41]. In 49% of patients with this type 
of psoriasis, a clear infiltrate of PMN has been observed. This may be explained by a 
cyclic change in neutrophil exocytosis [41]. A number of inflammation mediators can 
activate PMN. These mediators include cytokine mediators such as interleukin-8 
[110], and metabolites of arachidonic acid such as leukotriene B4 (LTB4) [111,112].
Proliferation
It has been known since long time that psoriasis is partly due to a defect in epidermal 
cell proliferation. A grossly decreased cell cycle time of the proliferating keratinocytes has 
been suggested as a hallmark for psoriatic lesional skin for years. However, recent studies 
have conclusively shown that the major abnormality is an increased recruitment of 
cycling epidermal cells from the resting G0-compartment, and not an intrinsic 
abnormality in the cell cycle [113]. The role of epidermal proliferation in the patho­
genesis of psoriasis has not been fully understood yet. In order to find out this role, it is 
important to study epidermal growth during induction and therapeutic regression of the 
psoriatic lesion [113].
Keratinisation and changes in keratin expression 
In normal skin, as the epidermal keratinocytes move through the epidermis after losing 
their attachment to the basal lamina, they undergo the complex process of terminal diffe­
rentiation to produce the stratum corneum. The stratum corneum cells have lost their 
nuclei and other recognisable organelles, and comprise 65% insoluble cyteine-rich, di­
sulphide cross-linked, fibrous proteins or keratins [114]. The series of changes whereby 
keratin filaments aggregate into bundles through the action of the histidine-rich basic 
protein filaggrin is the process of keratinisation. Keratin intermediate filaments charac­
terise all epithelial cells. It is well recognised that changes occur in the expression of 
keratin intermediate filaments during epidermal differentiation [115]. In addition, epider­
mal differentiation involves the synthesis of new envelope proteins, including involucrin, 
specific enzymes involved in envelope cross-linking, such as transglutaminase, and altera­
tions in membrane glycoproteins [114].
The family of epithelial keratins consists of at least 20 polypeptides [116,117], with 
an additional eight major trichocyte (hair) keratins [118], which have all been numbered 
according to their position on two-dimensional gel electrophoresis [116]. They can be 
subdivided into basic (type II, numbered 1 to 8) and acidic (type I, numbered 9 to 20) 
subgroups, each the product of a distinct keratin gene [116,119]. All epithelial cells 
express keratins as obligate heterodimers of particular acidic and basic pairs in a tissue-
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specific, differentiation-related pattern [120]. In skin, suprabasal keratins 1 and 10 are 
characteristic of epidermal differentiation as they are only expressed in suprabasal 
keratinocytes, whereas keratins 5 and 14 are synthesised and expressed in basal 
keratinocytes [121].
In psoriasis, differentiation is disturbed: the number of cell layers in the basal and 
suprabasal compartment is expanded and mitoses are detected in the suprabasal layers. 
The keratinisation is incomplete and parakeratosis is observed [122]. Because of the 
altered differentiation process in psoriasis, the pattern of expression of keratins is also 
disturbed. Keratins 1 and 10 are largely replaced by keratins 6 and 16, and therefore, 
cells show less expression of keratin 1 and 10 compared to normal skin [123-126]. 
Keratins 6 and 16 are keratins that are associated with hyperproliferative conditions, and 
are only found suprabasally [127,128]. Because of the hyperproliferation which appears 
in psoriasis, keratins 6 and 16 can be observed in psoriatic epidermis, although these 
keratins are absent in normal skin [129-134]. Keratins 17 and 20 are also associated with 
hyperproliferation, and in psoriasis expression of keratin 17 and 20 has been observed 
[131].
1.4.4. Transition between uninvolved and lesional skin
The transition zone of a psoriatic plaque is an interesting site, because several cellular 
biological changes have been described in the transition between symptomless and 
lesional skin [135].
Although the symptomless skin immediately adjacent to lesional skin has a normal 
histological appearance [135], numerous abnormalities have been described in several 
compartments of this clinically uninvolved skin [129,136-138]. In the initial stage of 
psoriasis, changes in the stroma and in the epidermis are seen. A brief summary of these 
changes is outlined in Table 1 [135]. Although the studies which describe these changes 
have increased the knowledge about pathogenic processes in psoriasis, the relevance of 
individual changes in the whole pathogenic process remains unclear. To obtain more 
insight in the time course of the psoriatic process and to differentiate between secondary 
and primary changes, further studies on the transition from (distant) clinically uninvolved 
skin to lesional skin are important [135]. In chapter 3, a study will be described which 
focused on this transition.
Table 1 Changes in the symptomless skin preceding psoriatic lesions.
Epidermis 
Thymidine units
%  basal cells in the SG2M-phase 
Protein kinase C activity 
Ornithine decarboxylase activity 
Arachidonic acid release 
Phospholipase A 2 activity
Increased
Increased
Decreased
Increased
Increased
Increased
Stroma
Fibroblast proliferation 
Glycosaminoglycan release 
Vasodilatation 
High endothelial venules 
Endoglin expression
Increased
Increased
Increased
Increased
Decreased
T lymphocyte trafficking
Number of CD4 and CD8 positive cells
Number of HLA-DR + /  CD1a subclass
Increased
Increased
of antigen presenting cells
1.5 Therapy
As stated before, psoriasis is an incurable disease. However, several modalities are availa­
ble for symptomatic treatment of the lesions, and often these treatments result in a com­
plete clearance of the lesions, although in most patients the lesions will reappear after 
some time [28]. Unfortunately, not every therapy is effective in every patient: there is a 
large interindividual variation in the treatment response. Therefore, it is often necessary 
to change the therapy modality in order to achieve the most satisfactory clinical result. 
The combination of several treatments often shows a beneficial effect. In this section, 
several treatments for psoriasis are briefly discussed. As in this thesis studies have been 
performed on topical corticosteroids and vitamin D3 analogues, these therapies will be 
discussed in more detail.
1.5.1. Topical treatm ents
Emollients such as vaseline, lanette wax cream, and oil baths are sometimes considered 
as a placebo therapy as they are often used as a vehicle for pharmacologically active
Emollients
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compounds. However, emollients are itself an active, but weak, treatment for psoriasis 
[139]. They hydrate the skin, which is dry and rough in psoriasis, and thus soften the 
scaly, hyperkeratotic surface of the psoriatic plaques [139,140]. Emollients are often 
applied as maintenance therapy and approximately 35% of all patients experience a sig­
nificant reduction of itching, soreness, redness, and pain if applied twice daily [141]. A 
reversal of the inflammatory consequences of damage to the stratum corneum may 
account for this effect [142]. The greasier the emollient, the more effective it will be, but 
from a cosmetic point of view this can not always be achieved, as greasy emollients are 
less well accepted by patients [139].
Keratolytics
Keratolytics are drugs that counter hyperkeratosis by promoting desquamation of the 
stratum corneum. Salicylic acid and urea are agents with well-known keratolytic proper­
ties. They can be combined with several other therapeutics such as dithranol, coal tar, 
and corticosteroids. Keratolytics have proved to enhance the absorption and penetration 
of the drugs with which they are combined, which makes them more effective [139]. Oint­
ments containing salicylic acid (2 to 10 percent) are a safe therapy, but prudence is 
called for high concentrations on large body areas because of the risk of salicylic 
intoxication [143].
Tar
Tar is one of the oldest treatments for psoriasis. It can be derived from three sources: 
coal, plants (wood), and animals (primarily fish). For dermatological purposes, coal tars 
are most frequently used [144]. The mechanism of tar therapy is unknown. Coal tar is 
applied on psoriatic plaques as pure coal tar (pix lithantracis: 1-10%) or as a tar solution 
(solutio carbonis detergens: 5-20%). The combination with ultraviolet B phototherapy is 
a widely used application. It can be manufactured into a greasy ointment, like yellow soft 
paraffin, white vaseline, or a mixture of white vaseline with lanette wax cream [144]. 
Pharmaceutical and cosmetic industries have developed lotions, gels, and shampoos in 
which tar has been dissolved. Coal tar is a safe and well tolerated drug, although it has 
slight carcinogenic and teratogenic properties [145]. Therefore, it should not be given to 
pregnant women and nursing mothers. The beneficial effect on psoriasis is mainly 
through a reduction of itch. Therefore, it is useful in unstable psoriasis and in guttata 
psoriasis. Because of its irritative potential, coal tar is not suitable for erythrodermic and 
pustular psoriasis. A major drawback of tar therapy is the intense and typical odour, and 
the irreversible staining of clothes.
Dithranol
Dithranol is a chemically synthesised analogon of chrysarobin, a substance obtained from 
the aroroba tree [146,147]. Since in 1878 Squire described his accidental finding that
dithranol is effective in psoriasis, dithranol has had an important place in the treatment 
of this disease. Although its mode of action has not yet been fully understood, the effec­
tiveness of dithranol is undisputed. It has been shown that the induction of free radicals 
is responsible for the antipsoriatic effect [148,149]. However, these free radicals also 
cause skin irritation, which is one of the most important limitations of dithranol therapy. 
Even in very small doses, patients may show irritations similar to burns. By application of 
dithranol in short-contact therapy, these side effects are minimised. Besides these local 
side effects, dithranol is a very safe treatment. A disadvantage, however, is the fact that 
dithranol stains textiles and hair, which make it less suitable for self-administered appli­
cation of widespread lesions.
Corticosteroids
Topical corticosteroids remain central in the management of psoriasis [150]. If applied 
correctly, they are generally effective, and have no primary irritative potential. Cosmeti­
cally, corticosteroids are very acceptable, because of the large variety of formulations: not 
only ointments, cremes, lotions, and gels are available, but also emulsions, crelos, foams, 
and powders [150]. Therefore, corticosteroids can be applied on virtually every site of the 
body.
The relative potency of topical corticosteroids varies. Four classes of potency can be 
distinguished: from class I, which are mild corticosteroids, to class IV, which are the most 
potent topical steroids. To determine the potency of new or established topical corticoste­
roids, the vasoconstrictor assay is performed [151]. The ability to bleach the skin is a 
measure for the anti-inflammatory effect of the drug, and, as a rule, the results of this 
assay correlate well with the potency of steroids in clinical use [152,153].
Topical corticosteroids exert anti-inflammatory, antiproliferative, and immunosuppres­
sive properties [150]. The mode of action is via glucocorticoid receptors. After applica­
tion, the steroid binds to the glucocorticoid receptor in the cytoplasm of cells, where it 
forms a complex which is then transported to the nucleus of the cell. Then, the complex 
binds to a region on the DNA that is known as the glucocorticoid responsive element 
(GRE). After binding, the complex is activated and stimulates or inhibits the transcription 
of the genes adjacent to the GRE. In this way, the inflammatory process is regulated 
[154]. Targets of glucocorticoids include T-cell proliferation, T-cell dependent immunity, 
and cytokine gene transcription, including the genes for the interleukins IL-1, IL-2, IL-6, 
interferon gamma, and tumour necrosis factor [155]. Moreover, the anti-inflammatory 
effects of glucocorticosteroids include the inhibition of dermal oedema, capillary dilata­
tion, and the movement of inflammatory cells within the skin. Steroids also suppress the 
function of fibroblasts, endothelial cells, and leucocytes, and they diminish the endocri­
nological aspects of inflammation [150].
The combination of topical corticosteroids with other antipsoriatic therapies is well 
known and combinations are often complementary. Widely used combinations are
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steroids combined with vitamin D3 analogues, keratolytics, and phototherapy [156-158], 
but steroids can also be combined with acitretin, cyclosporin, methotrexate, coal tar, and 
dithranol [159]. Moreover, the combination with an occlusive dressing such as a hydro­
colloid dressing has proved to be a very effective method to enhance the penetration of 
topical steroids and thus the effectiveness of the steroid. The use of potent topical cor­
ticosteroids under occlusion may result in healing of even recalcitrant plaques as pene­
tration through the skin is markedly enhanced [160-163].
Despite their strong clinical effect, topical corticosteroids have side effects. The most 
prominent cutaneous side effect is skin atrophy, which microscopically already starts 
after 3 to 14 days of applying topical steroids. However, at first, these changes are 
rapidly reversible, but if steroids are applied chronically, dermal changes will become 
evident. This dermal atrophy is a result of the direct antiproliferative effect of steroids on 
the fibroblast [150]. As a result of the atrophic changes, vascular dilatation, striae, tele­
angiectases, and purpura may also be seen. Other local side effects of chronic application 
of topical corticosteroids are hypertrichosis and hypopigmentation. It has been proved 
that topically applied steroids are also absorbed systemically, and that they are able to 
suppress the pituitary-adrenal axis [164]. Because of the risk of these side effects, the 
use of steroids should be limited to a maximum of 50 grams a week for very potent ste­
roids, and to a maximum of 100 grams a week for potent topical steroids [163].
Vitamin D3 analogues 
In 1985, Morimoto and Kumahara described a patient with senile osteoporosis and 
psoriasis, whose psoriasis cured after oral administration of 1a hydroxyvitamin D3, a 
prodrug of calcitriol [165]. Following this observation, several studies on the anti­
psoriatic effect of vitamin D analogues have been performed, and since then, several 
effective vitamin D3 analogues have been developed as a treatment for psoriasis [166].
Similar to corticosteroids, active vitamin D3 binds to a nuclear receptor, the vitamin 
D3 receptor (VDR) [167]. The VDR is induced by vitamin D3. The VDR-vitamin D3 complex 
modulates the transcription of target genes by binding to specific DNA binding sites, the 
so-called ‘vitamin D response elements'. The vitamin D3 receptor is a member of the so- 
called nuclear receptor superfamily, which, among others, includes the glucocorticoid 
receptor [168]. There is evidence that the vitamin D3 receptor also interacts with other 
members of this nuclear receptor superfamily [169]. In hyperproliferative cell systems, 
VDRs may be upregulated. Active vitamin D3 has shown to induce an increased influx of 
calcium into the cell via a non-nuclear mechanism [170,171].
In culture, active vitamin D3 inhibits proliferation of keratinocytes [172-175]. Vitamin 
D3 analogues inhibit epidermal proliferation in vivo as well [176-179]. Other in vivo 
effects of active vitamin D3 are also very substantial [180]. Epidermal differentiation is 
modulated by active vitamin D3. At concentrations of 10-9 M or higher, cornified 
envelope formation is enhanced and transglutaminase activity is increased in vitro [172-
178,181]. Vitamin D3 analogues have a plethora of effects on cutaneous inflammation as 
well [167]. They inhibit the production of interleukins IL-1, IL-2, and IL-6. Moreover, the 
release of arachidonic acid by PMN is inhibited by active vitamin D3 [166,167]. In vivo, 
several analogues of active vitamin D3 have shown to inhibit the expression of cellular 
inflammation markers [181-183].
At this moment, two topical vitamin D3 analogues are available for the treatment of 
psoriasis: calcipotriol and tacalcitol, although the latter has not been registered in The 
Netherlands yet. Calcipotriol (1a,25 dihydoxy vitamin D3, Daivonex/Dovonex®) has 
proved to be very effective at a dose of 50 pg/g twice daily. In a long-term study of 12 
months, a substantial improvement was reported in 90% of all patients [184]. Calcipo- 
triol is a very safe compound and hardly any side-effects are to be expected. However, 
calcipotriol is an irritant, and lesional and perilesional skin irritation makes calcipotriol 
less suitable for application in the face. Because of its favourable side-effect profile, cal- 
cipotriol is now the treatment of first choice for psoriasis in a primary health care setting 
in The Netherlands. Moreover, the lack of serious side effects makes calcipotriol a good 
maintenance therapy. To induce a quick remission of lesions and to maintain this 
clearance, a combination protocol is often prescribed with corticosteroids. At the depart­
ment of Dermatology where the studies as described in this thesis were carried out, a 
regime of 3 days clobetasol twice daily, followed by 4 days of calcipotriol twice daily is 
often advised. To enhance the effect of calcipotriol, for example in treatment resistant 
plaques, the combination with an occlusive dressing is beneficial [185,186].
Tacalcitol (1a,24 dihydoxy vitamin D3, Curatoderm®) was recently introduced in 
several European countries [187]. Its major advantage is that it is already effective if 
applied only once daily. Moreover, tacalcitol has been suggested to be less irritative com­
pared to calcipotriol, which makes it suitable for facial application [188]. However, a 
comparative study between calcipotriol (50 pg/g twice daily) and tacalcitol (4 pg/g  
once daily) revealed that calcipotriol is slightly more effective and has similar irritancy 
[189]. A clinical and immunohistochemical study on the long-term use of tacalcitol 
showed a significant decrease of the clinical severity, and both inflammation and prolife­
ration parameters were maintained at a significantly reduced level [178,190]. A quanti­
tative study on the long-term effects of tacalcitol will be presented in chapter 4.
Retinoids
The retinoid that is available for topical use in The Netherlands is tretinoin. Isotretinoin, 
motretinoin, adapalene, and acetylenic retinoid are available in several European 
countries [191]. Although these retinoids are generally effective in acne, their efficacy in 
psoriasis is disappointing. However, the newly developed compound tazarotene is an 
effective and safe treatment modality for psoriasis. It normalises differentiation and pro­
liferation of keratinocytes and has an anti-inflammatory effect [192,193]. Tazarotene has 
been registered for the topical treatment of psoriasis in several European countries, but
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not in The Netherlands. Therefore, the place of topical retinoids in the armamentarium of 
first-line antipsoriatic therapies is still limited in The Netherlands. The mode of action of 
retinoids will be discussed in section 1.5.3.
1.5.2 Phototherapy
The beneficial effect of sun exposure in psoriasis is well established. Although most 
patients can be treated satisfactory by using only topical agents, approximately 25% of 
all patients require more aggressive forms of therapy. However, the use of systemic 
therapy should be reserved only for those patients with a disabling psoriasis that has not 
responded to topical therapy. Prior to systemic therapy, phototherapy is a good option for 
patients that have shown an insufficient response to topical drugs [194].
Phototherapy comprises all forms of therapy which use the ultraviolet radiation (UVR) 
spectrum for therapeutic purposes. Both UVB (290-320 nm) and UVA (320-400 nm) have 
substantial photodynamic effects, although the mode of action of ultraviolet radiation 
therapy has not yet been fully understood [195]. UVR can result in a photochemical reac­
tion, if absorbed by biological molecules, and thus initiate biochemical and biological 
responses. The mode of action may be through DNA, because DNA is the most important 
chromophore in the UVB range for photobiological response [195]. After UVR treatment, 
erythema due to inflammation is often observed. This may be a result of activation of the 
arachidonic acid pathway [196].
UVA radiation causes markedly less erythema than UVB radiation, and it requires an 
almost 1000 fold higher intensity than UVB to be therapeutically effective. This limits the 
therapeutic use of UVA as a monotherapy, but the addition of psoralens as a skin sensi- 
tiser to UVA light enhances the therapeutic effect of UVA dramatically. PUVA (psoralens 
+ UVA) has become a well-established approach for the treatment of severe psoriasis 
[197]. Because of the addition of psoralens, this type of phototherapy is called photoche­
motherapy.
When UVB and PUVA are assessed by trained staff, few acute side effects are encoun­
tered. These side effects include erythema, itch and sometimes nausea, and are generally 
mild [195,197]. Long-term treatment with UVR is not encouraged as UVR therapy accele­
rates photoaging and increases the risk of UVR-induced carcinomas [145,195].
1.5.3 Systemic therapies
Corticosteroids
As a rule, systemic corticosteroids are contraindicated in the treatment of psoriasis. Very 
occasionally, its use is justified in the treatment of generalised pustular psoriasis or in
erythrodermic psoriasis [140]. It is only reserved for those patients who are unresponsive 
to other treatments. Paradoxically, systemic corticosteroids can prolong generalised 
pustular and erythrodermic psoriasis, and after withdrawal a significant rebound can be 
seen. Systemic corticosteroids should not be used for treatment of chronic plaque psoria­
sis because of the risk of precipitating the pustular form, and because there are several 
less toxic and more effective therapies available [150].
Methotrexate
In 1951, Gubner described the effect of the folic acid antagonist aminopterin on psoriasis 
for the first time [198]. The folic acid antagonist methotrexate (amethopterin, MTX) was 
then developed, and since 1971, MTX has been registered for the treatment of severe 
psoriasis [199,200]. After three decades, MTX is still one of the most effective treatments 
for severe psoriasis [201]. It has been generally accepted for years that in psoriasis MTX 
inhibits de novo epidermal DNA synthesis and decreases mitotic activity [202-204]. The 
keratinocytes remain in the Gr phase of the cell cycle, and the cells in the S-phase are 
killed. Thus, the total number of cycling cells is reduced by MTX [205]. However, several 
observations indicate that mechanisms of action other than a direct effect on keratino­
cytes could be more important [206]. With respect to inflammation, MTX inhibits the 
chemotaxis of PMN [207]. Several studies have focused on the mode of action of MTX, 
but it is still unknown which of the suggested mechanisms is the most valid for the 
clinical response [206].
Although MTX may be very effective in severe psoriasis, its side-effects cause serious 
limitations. The most commonly reported side effects of MTX in psoriasis include malaise, 
gastrointestinal tract effects, and headaches [208]. More serious side effects are hepatic 
impairment, leukopenia, and thrombopenia. In order to monitor side-effects, laboratory 
studies should be performed during the entire course of MTX therapy for psoriasis, and 
these should include complete blood cell counts, haemoglobin, haematocrite, and liver 
chemistry [208]. It is recommended to obtain liver biopsies after an interval in which the 
patient has used 1,5 grams MTX [208].
Patients with moderate to severe psoriasis, defined as a body involvement of 20% or 
more, who are unresponsive to topical therapy, can be treated with methotrexate. Also 
patients with a less extended body involvement but with very recalcitrant lesions which 
do not respond to other treatments may be treated with MTX. Moreover, patients with 
erythrodermic psoriasis and pustular psoriasis are particular candidates for MTX. Con­
traindications for MTX are abnormalities in renal and liver function, pregnancy, hepatitis, 
cirrhosis, severe anaemia, leukopenia, thrombocytopenia, excessive alcohol consumption, 
infectious disease, and non-compliance of the patient [208]. To minimise the toxicity of 
methotrexate, combinations or rotational therapy should be considered.
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Retinoids
Systemic retinoids have become indispensable in modern psoriasis therapy [191]. They 
are the treatment of first choice for patients with pustular or erythrodermic psoriasis 
[191,209]. Also in the treatment of chronic plaque type psoriasis, retinoids can be con­
sidered in moderate to severe cases, preferably in combination with other treatments 
[209].
Retinoids, of which etretinate and acitretin are the most widely used, exert their 
antipsoriatic effect through cytoplasmic retinoid binding proteins and nuclear retinoid 
receptors. Two kinds of retinoid receptors are known: RARs and RXRs, which both have 3 
subclasses: alpha, beta, and gamma [191]. Etretinate and acitretin have an 
antiproliferative effect on psoriatic skin [210,211]. Moreover, the migration of PMN into 
psoriatic epidermis is inhibited by retinoids, as well as the release of reactive oxygen 
species from PMNs [212-215].
Acitretin and retinoids in general have a characteristic spectrum of side effects, which 
are similar to chronic hypervitaminosis A syndrome. Cheilitis is generally unavoidable and 
occurs rapidly, but is dose-dependent. Other side-effects include dryness of mucosa, such 
as the nasal mucosa and mucosa of the mouth, peeling of palms and soles, skin xerosis, 
pruritis, and the feeling of a burning, or rather sticky skin. Hair loss and brittle nails are 
also frequently observed. All these side effects are reversible after stopping the retinoids, 
but sometimes the treatment should be stopped because of these effects [191].
An increase of serum triglycerids is commonly noticed during treatment with retinoids. 
Hepatotoxicity is very rare, but has been described [216,217]. If retinoids have been given 
for years, serious bone damage may occur, including diffuse idiopathic skeletal hyper­
ostosis (DISH syndrome), degenerative spondylosis, arthritis of the vertebral articulations, 
and osteoporosis [191,218]. Teratogenicity of retinoids remains a major problem: 
Etretinate accumulates in fatty tissues up to two years. Due to re-esterification of 
acitretin to etretinate, safe contraceptive measures are required up to two years after 
cessation of acitretin.
Absolute contraindications are pregnancy, a desire for pregnancy within two years 
after discontinuation of acitretin, nursing, severe hepatic dysfunction, and an insufficient 
patient compliance [191].
Cyclosporin
Since T lymphocytes play an important role in the pathogenesis of psoriasis, T-cell specific 
immunomodulating drugs for the treatment of psoriasis have been developed during the 
last decade. Cyclosporines are the best known immunomodulators, and especially cyclo­
sporin A has an established position in the spectrum of antipsoriatic therapies [219-221]. 
It is indicated in patients with severe psoriasis, in whom conventional therapy is either 
ineffective or inappropriate [222].
Cyclosporin A binds with cyclophilin, and this complex inhibits the enzyme calcineurin.
Calcineurin is a key enzyme in calcium-dependent signalling processes. By inhibiting 
calcineurin, the triggering of the transcription of many cytokines, including T-cell growth 
factors IL-2 and IL-4 is inhibited [223].
The side effects of cyclosporin A, in particular nephrotoxicity, require careful admini­
stration. Therefore, guidelines have been developed [224,225]. The minimum effective 
dose should be used, and this should not exceed 5 mg cyclosporin A per kg per day.
Major contraindications for cyclosporin A treatment are impaired kidney function, 
uncontrolled hypertension, past or present malignancy, infection, pregnancy and lacta­
tion, concomitant immunosuppressive therapy, immunodeficiency, and hypersensitivity 
[222].
1.5.4 Combination treatment
In order to enhance the clinical efficacy of certain therapies, and to limit their side 
effects, combinations of several antipsoriatic therapies are often worthwhile. For a good 
overview of the pros and cons of combination therapies, the reader is referred to overview 
articles [159,226]. In the topical treatment of psoriasis, a very well known combination 
treatment is the alternated regime of potent topical corticosteroids and vitamin D3 ana­
logues. Corticosteroids induce a fast clearance of the psoriatic lesion, whereas vitamin D3 
analogues are then able to maintain this effect and to prevent relapse. In fact, cortico­
steroids can be combined with almost every other topical treatment. The addition of an 
occlusive dressing to topical antipsoriatic agents can also be seen as a combination treat­
ment. Again, the effect of the topical drug is enhanced, and the frequency of application 
of the drug can be diminished, which is more comfortable for the patient. Because of the 
potentially dangerous side effects, systemic therapies are normally not combined. How­
ever, the addition of a topical agent to the systemic therapy is encouraged because it 
increases the therapeutical effect and allows a lower dose of the systemic drug, and thus 
less side-effects [227]. Combination treatments of phototherapy with both topical and 
systemic forms of therapy are well known. Again, the clinical effect is enhanced, and 
adverse events tend to be less.
Whatever effective combinations of therapies may be, individualisation is crucial for 
an optimal treatment result. Both the severity of the psoriasis and its significance in the 
psychosocial context of each individual patient should be considered [159].
1.5.5 New developments in the treatment of psoriasis
Receptor specific retinoids have been developed for the treatment of psoriasis. Recently, a 
new topical antipsoriatic compound, tazarotene, proved to be effective in psoriasis [228].
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Other RXR-a,p,y-specific agonists are investigated.
Because of the important role of T-lymphocytes, immunomodulating drugs are developed 
for the treatment of psoriasis. Tacrolimus (FK-506), ascomycin, and sirolimus (rapamycin) 
are examples of such newly developed immunomodulators with a clear potential for the 
treatment of psoriasis [229].
Drugs that modulate the inflammation cascade, for example by blocking the LTB4 
receptor or by inhibiting 5-lipoxygenase, are studied as well. VM L 295, a specific and 
selective LTB4 antagonist, will be considered further in this thesis.
1.6 Aims and phasing of the thesis
The central issue of this thesis is the dynamics of epidermal cell populations during 
pathogenesis and treatment of psoriasis. In particular the dynamics of inflammation, ep i­
dermal proliferation, and keratinisation as a concerted action will be addressed. To study 
these dynamics, flow cytometry was used. The following aims and questions were defined:
I. To confirm the usability of an existing three-parameter flow cytometric protocol for 
the assessment of epidermal cell characteristics and to develop a new multiparameter 
flow cytometric protocol which supplies additional information on cellular processes 
in psoriasis.
Chapter 2 targets on this first aim. In section 2.1 an introduction into flow cytometry will 
be given. The following 2 sections provide an outline on methods and methodologies of 
flow cytometric assessment of epidermal cell characteristics. A  triple parameter protocol 
for the simultaneous assessment of keratin 10, vimentin and DNA content will be des­
cribed in section 2.4. This methodology has been developed during a previous thesis. As 
an extension of this methodology, a novel protocol has been developed which included a 
marker for hyperproliferation, keratin 6. This novel methodology will be presented in 
section 2.5.
II. To assess key markers for epidermal differentiation, inflammation and proliferation in 
symptomless and lesional psoriatic skin, and in the transitional phases.
Both in chapter 3 and in chapter 4, studies will be presented which compared the in­
volved skin of psoriatic patients with the uninvolved skin of psoriatic patients with 
respect to cellular parameters for differentiation, inflammation, and proliferation. Compa­
risons with skin of healthy volunteers will be documented as well. In order to study events 
as seen in psoriasis and to study the changes as observed in incipient psoriasis, several
models were used, which are discussed in section 7 of this introduction.
III. To study to what extent both existing and experimental antipsoriatic therapies inter­
fere with epidermal (hyper)proliferation, differentiation, and inflammation, using the 
techniques mentioned in aim I.
In chapter 4, the effects of several antipsoriatic treatments on the expression of keratin 6, 
keratin 10, vimentin, and on the proliferative activity of the epidermal subpopulations 
will be documented. This has been performed for existing therapies (a potent topical cor­
ticosteroid, a vitam in D3 derivative, and occlusive dressings), and for an experimental 
therapy (an oral Leukotriene B4 antagonist).
1.7 Clinical and experimental approaches
1.7.1 Study models
As mentioned in the aims, several models were used to study to what extent markers for 
epidermal inflammation, differentiation, and proliferation modulate during growth and 
regression of psoriatic plaques, with or without therapy. In the next three paragraphs, 
these models will be discussed.
The margin zone of stable and spreading psoriatic plaques 
Several authors showed that the margin zone of a psoriatic plaque provides an adequate 
model for sequential analysis of cellular and subcellular processes from clinically unin­
volved to lesional skin [135]. The margin is of great pathogenic interest as lesions 
enlarge by centrifugal expansion [33,99,137,230]. The common belief is that the margin 
of psoriatic plaques as a whole is an active site, not only in relapsing psoriasis, but also 
in patients with stable plaque psoriasis [35,42,136,231,232]. Therefore, in this thesis, the 
margin zone of both stable and incipient psoriatic plaques was studied to document the 
sequence of changes in the evolution of psoriatic lesions.
tape stripping
In 1951, Pincus described that a mitotic response of epidermal cells occurs after inducing 
an injury by applying multiple strips of cellophane tape to normal skin [233,234]. 
Repeated application of tape removes the corneocytes layer by layer. A t a certain point, 
exsudate will prevent further removal of the living cell layers. Because this point is 
approximately the same in each individual person, tape stripping is a standardised 
method to remove a standardised number of cell layers. After the stripping, the epidermis
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starts to regenerate. After 48-72 hours, a burst of mitoses in the basal layer and in the 
lower region of the stratum spinosum can be observed, with a peak around 48 hours 
[233,235]. The dynamics of this response has proved to be well reproducible. The appli­
cation of multiple strips of adhesive tape is now a widely accepted method to induce a 
standardised injury. 12 Hours after tape stripping, the stratum granulosum is lost, and 
after 24 hours, a parakeratotic layer starts to form. Beneath these parakeratotic cells the 
stratum granulosum starts to regenerate [235]. The burst of mitotic activity and the 
altered differentiation as represented by the formation of a parakeratotic cell layer are 
events which are also seen in psoriasis. Therefore, tape stripping of the healthy human 
skin provides a useful model to study synchronised epidermal growth, and thus to study 
the effects of topical drugs on the proliferative aspects of psoriasis in the absence of a 
significant degree of inflammatory infiltrate [236-238].
Remission induction, and relapse of psoriasis
after therapeutically induced remission 
It is known that there are great differences between acute and chronic psoriatic lesions. 
Early lesions are characterised by the presence of large numbers of PMN, monocytes and 
mast cells, whereas these cells are only modestly present in chronic plaques [98,99,239]. 
These differences may be of therapeutic relevance. In order to study the changes in cellu­
lar parameters during treatment, we used a model in which a stable psoriatic plaque is 
treated with very potent corticosteroids, resulting in a fast clearing of the plaque. There­
after, a relapse will occur, and by assessing the changes prior to treatment, at clearing, 
and after relapse, insight can be obtained in the behaviour of several cellular subpopula­
tions during the course of this regression of the lesion and its reappearance [240].
1.7.2 Clinical assessment
Several studies which are described in this thesis include the clinical assessment of 
psoriatic plaques. For this clinical assessment, we used the Psoriasis Area and Severity 
Index (PASI) [241]. In the PASI, the head, trunk, upper limbs, and lower limbs are 
assessed separately for erythema, induration, and desquamation. The average degree of 
severity of each symptom in each of the four body parts is assigned a score of 0-4. A 
score of 0 represents no involvement and a score of 4 represents the worst possible in­
volvement. The area covered by lesions on each body part is estimated as a percentage of 
the total area of that particular body part and a score of 0-6 is then assigned as well. 
The score for each body part is obtained by multiplying the sum of the severity scores of 
the three basic lesions by the area score, then multiplying the result by the constant 
weighted value assigned to that body part: 0.1 for the head , 0.3 for the trunk, 0.2 for 
the upper limbs, and 0.4 for the lower limbs. The sum of the individual body parts gives
the PASI. Theoretically, the PASI can range from 0 to 72.
Although the PASI is a widely used and accepted way of assessing the clinical severity of 
psoriatic lesions, it has some important limitations. Even experienced clinical observers 
show wide variation when attempting to record clinical severity by the PASI [242-244]. 
The extent of psoriasis is possibly the most important factor in deciding treatment 
options and in evaluating different treatments. Therefore, more objective methods to 
assess the severity of psoriasis are necessary. Flow cytometric assessment of psoriatic 
epidermis, using markers for inflammation, differentiation, and proliferation, which repre­
sent erythema, scaling, and induration respectively, has proved to be such an objective 
method [245]. By using this method, the effect of involved body area can not be assessed 
however. For this reason, both PASI and flow cytometric assessment are performed in 
clinical studies as described in this thesis.
1.7.3 Flow cytometric assessment
For assessing epidermal cell characteristics, flow cytometry was used in the studies of this 
thesis. Flow cytometry is a method that enables quantitative measurement of cells and 
cellular parameters. The supply of quantitative data is the major advantage of flow cyto­
metry compared to conventional microscopic cytometry, which is semi-quantitative. 
However, for flow cytometric analysis of certain tissue, single cell suspensions of that 
tissue are required, which implies that information on the architecture of the skin is lost. 
Epidermal cell suspensions are prepared from skin biopsies. The epidermal cells in the 
suspension are than stained with fluorescent dyes which attach to the cellular markers 
that have to be quantified. Using specific software, the proportion of these cellular mar­
kers can be calculated. In the next chapter, a general introduction on flow cytometry will 
be given, as well as a description of the biopsy procedure and the method to obtain epi­
dermal cell suspensions. Moreover, an overview will be provided of the monoclonal anti­
bodies which have been used in this thesis. Finally, chapter 2 comprises a study which 
describes a novel method for simultaneous assessment of a differentiation and a hyper­
proliferation marker.
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Chapter
F L O W  C Y T O M E T R I C  M E T H O D S  
F OR  T H E  A S S E S S M E N T  OF  
E P I D E R M A L  C E L L  C H A R A C T E R I S T I C S
This chapter was partly based on the following publication:
Mommers JM , Goossen JW , van Erp PEJ, van de Kerkhof PCM.
A  novel functional multiparameter flow cytometric assay to characterize proliferation in skin. 
Communications in Clinical Cytometry 1999; (In Press)
F L O W  C Y T O M E T R I C  M E T H O D S
2.1 Flow cytometry
Introduction
Flow cytometry (FCM), also designated as fluorescence activated cell sorting (FACS), is a 
technique that enables analysis and quantification of physical and /  or chemical charac­
teristics of cells or other particles. Quantification of certain cell characteristics may 
provide valuable scientific or diagnostic data. Applications of flow cytometry are 
multiple. Especially in clinical oncology, in clinical haematology, immunology, and in 
research, the use of flow cytometry is widespread. An overview of the most important 
applications is provided in Table 2 [1]. Over the past 25 years, FCM has also been 
employed in the studies of keratinocyte diseases, such as psoriasis. Measurement of DNA 
ploidy and proliferative activity, as well as assessment of epidermal differentiation and 
inflammation parameters have contributed to the insight of the pathological mechanisms 
of this disease. Moreover, flow cytometry has proved to be a valuable tool in the 
evaluation of antipsoriatic therapies [2].
Table 2 Clinical and research applications of flow cytometry.
Clinical oncology
1. Diagnosis and classification 
of lymphomas
2. Classification of acute leukaemias
3. DNA analysis in breast cancer
4. DNA analysis in 
gynaecological cancer
5. DNA analysis in urological cancer
6. DNA analysis in colorectal cancer
7. DNA analysis in 
paediatric solid tumours
8. Grading of soft-tissue sarcomas
Clinical haematology and immunology
1. Evaluation of acquired 
immunodeficiencies; monitoring HIV
2. Analysis of red blood cells
3. Analysis of platelets
4. Analysis of granulocytes
5. Crossmatching for transplantation
Emerging clinical and
research applications
1. Monitoring of cellular resistance to 
cancer chemotherapy
2. Cell-associated receptor quantitation
3. Detection of minimal residual disease
4. Assessment of cell-mediated 
cytotoxicity
5. Measurement of cell physiology: 
ionized calcium, pH, and glutathione
6. Characterization of epiderma cell 
characteristics in skin disorders
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General principles [3,4]
Flow cytometry literally means: measuring of cells in a flow. Single cells pass through a 
fluid stream in the measuring apparatus and different characteristics of these cells can 
be measured using a light source and photomultipliers. Because the fluid stream should 
carry the cells one by one, a good cell suspension with truly single cells is required. For 
whole blood, this is easy to perform, because blood in itself is already a suspension of 
cells. However, for solid tissue such as the human skin, single cell suspensions should be 
prepared. Our department has developed a protocol which enables the preparation of 
single cell suspensions from normal and diseased epidermis. Using this technique, human 
epidermis is suitable for flow cytometric analysis. This protocol will be described more in 
detail in section 2.2.
Sheath
Fluid
Sample il
%
\
Data Processing 
and Analysis
FSC
Waste
PMT, ÜÜ
: ssc  :
-I--I..\AAA~Qi
- Filters FSC
Laser
figure 5
The principle of flow 
cytometry.
The principle of flow cytometry is depicted in Figure 5. The particles which should be 
investigated (i.e. cells, viruses, bacteria, fungi, chromosomes, et cetera) are labelled with 
monoclonal antibodies which attach to those cellular markers which have been selected 
as parameters to be studied. Fluorescent dyes are attached to these antibodies. When
several cellular markers are studied simultaneously, different monoclonal antibodies have 
to be used. Moreover, fluorochromes with a specific and different emission spectrum have 
to be used. The most well used fluorochromes (also designated as stains or dyes) are fluo- 
rescein-isothiocyanate (FITC) and phycoerythrin (PE), with an emission spectrum of 500­
570 nm and 560-630 nm respectively. After staining with the monoclonal antibodies and 
the fluorochromes, the stained particles are brought in a liquid solution (‘Sheath fluid'; 
Figure 5) and flow rapidly through a small column of this solution. While flowing through 
this liquid column, the particles pass one or more laser beams at a rate of several hun­
dreds of particles per second. The laser light excites the fluorochromes, which means that 
they absorb the monochromatic light of the laser beam and emit light of a different 
wavelength. Every fluorochrome has its specific emission spectrum. Thus, signals of diffe­
rent wavelengths are produced, representing the different fluorochromes. Moreover, the 
laser light will be scattered when each particle passes the laser light separately. The 
scatter depends on the shape, size and granularity of the particles. Forward scatter sig­
nals (FSC) and side scatter signals (SSC) can be distinguished. Optical filters conduct the 
emitted light of every fluorochrome to a photomultiplier tube (PMT). This photomultiplier 
takes in the photons of the emitted light, amplifies them and puts them out as electrons. 
The electrons are converted into pulses and than into digital information. This digital 
information is transduced to a computer which stores the data and which enables further 
analysis of the data. The intensity of a light signal is a measure for the quantity of the 
fluorochrome that emitted the light. Because the fluorochromes are specifically attached 
to a cellular marker, the light intensity is also a direct measure for the quantity of that 
marker. In this way, flow cytometry supplies quantitative information about cellular para­
meters. This quantification of data is the major advantage of flow cytometry. Because of 
this possibility to quantify data, flow cytometry is an objective method to assess several 
cellular parameters. A major drawback however is the fact that because of the necessity 
of single cell suspensions, all morphological structure is lost, so that topographical infor­
mation of the measured parameters can not be obtained. For this purpose, microscopic 
immunohistochemistry remains to be the most important technique.
2.2 Preparation of cell suspensions of human skin
As discussed in the previous section, single cell suspensions are required for flow cytome­
tric analysis of tissue. For human skin, this means that first of all small skin specimens 
have to be obtained. Epidermal skin samples can be obtained by several methods: by 
inducing blisters, by shaving a small piece of skin using a razor blade or a keratotome, or 
by punching a small piece of skin like a corer. For the studies of this thesis, skin samples 
had to be taken from patients with psoriasis and from healthy volunteers, which attended
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the outpatient department. In this setting, a method which is patient-friendly and which 
can be performed routinely is preferential. Therefore, only punch biopsies were taken for 
the studies as described in this thesis: punch biopsies are easy to obtain and are well 
tolerated by the patient as they are taken after local anaesthesia with lidocaine/adrena- 
line 1:100000. The small wound generally heals quickly without complications, but 
sometimes some hypopigmentation will remain. Moreover, punch biopsies provide the 
best skin samples, as all layers of the epidermis are present with an equal diameter. For 
flow cytometric use, biopsies with a diameter of 3 mm generally supply enough cells for 
reliable assessment. An advantage of these small biopsies is that they do not have to be 
stitched.
If a good epidermal cell suspension is required, an accurate cell separation technique 
is necessary. Several techniques have been described which supply single epidermal cell 
suspensions, based upon proteolytic, thermic, or mechanic separation of the individual 
epidermal cells. In a previous thesis, an optimised protocol has been described to achieve 
purely epidermal cell suspensions [5,6]. Using this protocol, we can obtain approximately 
500.000 cells from a 3-mm punch biopsy of normal skin. A 3-mm punch biopsy of psoria­
tic skin provides approximately treble number of cells. The procedure is as follows. After 
the biopsy procedure has been carried out, biopsies are put in phosphate buffered saline 
(PBS, NPBI, Emmer-Compascuum, The Netherlands) at 5°C. Than, biopsies are put in 2.5 
ml thermolysin solution (0.5 mg thermolysin (Protease type X; P-1512: Sigma, St. Louis, 
MO, USA) per ml PBS with Mg2+/Ca2) and incubated overnight at 5°C. This incubation 
step with thermolysin dissolves the lamina lucida in the basal membrane and thus sepa­
rates the dermis from the epidermis. After 16-20 h of incubation, the dermis and epider­
mis can be separated using fine forceps. Than, the epidermis is incubated for 30 minutes 
in 2.5 ml 0.025% trypsin (T-8253; Sigma) and 0.3% dithioerythritol (DTE; D-8161; 
Sigma) in PBS. This trypsination step severs the desmosomes between the epidermal cells. 
To stop the incubation, 250 pl PBS containing 10% heat-inactivated newborn calf serum 
(HINCS, Life Technologies, Paisley, UK) is added to each skin specimen. The cell suspen­
sion is than mixed on a vortex and the stratum corneum is discarded. Thus, a single epi­
dermal cell suspension remains. The cells are fixed in ice-cold ethanol (70%) and stored 
at -20°C until the staining procedure and the flow cytometric analysis will be carried out.
2.3 Suitable markers to assess 
epidermal cell characteristics
This thesis focuses on epidermal differentiation, inflammation, and (hyper)proliferation. 
In order to assess these parameters represented by specific cellular markers, monoclonal 
antibodies are required which are directed against these cellular markers. For every mar-
ker, a set of antibodies is available. However, not every antibody is suitable for flow cyto­
metric use. Therefore, the range of available antibodies for flow cytometric assessment of 
the cellular markers of interest is limited. In Table 3, an overview is given of the anti­
bodies as used in this thesis.
Table 3 Overview of antibodies used in this thesis for flow cytometry.
Antibody Directed against Isotype Dilution Manufacturer
LHK6B Keratin 6 lgG2a 01 50 Novocastra Laboratories, Newcastle upon Tyne, UK
RKSE60 Keratin 10 IgGI 01 05 Dept. of Molecular Biology, University of Maastricht
RKSE60 Keratin 10 IgG1 01 20 Monosan, Uden, The Netherlands
DE-K10 Keratin 10 IgG1 01 05 Monosan, Uden, The Netherlands
LHP1 Keratin 10 IgG1 01 05 Novocastra Laboratories, Newcastle upon Tyne, UK
K8.12 Keratin 13, 15, and 16 lgG1 01 20 Sigma, Zwijndrecht, The Netherlands
LL025 Keratin 16 IgG1 01 20 Novocastra Laboratories, Newcastle upon Tyne, UK
Vim3B4 Vimentin IgG2a 01 15 Novocastra Laboratories, Newcastle upon Tyne, UK
To assess epidermal inflammation, we focused on vimentin. Vimentin is an intermediate 
filament-type protein that occurs in all mesenchymal cells [7-9]. Mesenchymal cells in 
human epidermis comprise all nonkeratinocytes, i.e. poly-morphonuclear leucocytes 
(PMN), lymphocytes, monocytes, macrophages, melanocytes, and Langerhans cells. There­
fore, vimentin does not exclusively stain inflammatory cells. However, studies from our 
group have shown that the expression of vimentin correlates highly significant with the 
clinical scores for inflammation, i.e. erythema, and that it is therefore a good marker for 
epidermal inflammation [2,10-12]. For staining of all vimentin expressing cells, the mono­
clonal antibody Vim3B4 was used. This is an antibody of the IgG2a isotype. Other epider­
mal inflammation markers which can be used for flow cytometric use include CD11b; an 
adhesion molecule attached to PMN, CD2, CD1a, CD14 and CD29. However, these mar­
kers are at the surface of the keratinocyte, whereas keratins and vimentin are cytoplasmic 
markers. The assessment of surface markers requires specific conditions with respect to 
fixation of cells and preparing cell suspensions. Therefore, it is generally not possible to 
assess surface markers and cytoplasmic markers simultaneously. Because a cytoplasmic 
inflammation marker was required as it should be assessed simultaneously with the cyto­
plasmic markers for keratinisation, we had to focus on vimentin.
For flow cytometric assessment of epidermal differentiation, a panel of differentiation 
markers can be used. The most important marker for epidermal differentiation is keratin 
10. Keratin 10 is an intermediate filament-type protein that is expressed in suprabasal 
keratinocytes [6,8]. In normal skin, its proportion is approximately 60 percent 
[6,10,13,14]. Under pathological conditions in which differentiation is disturbed, such as 
in psoriasis, this proportion is considerably lower. In stable psoriasis, it varies between 29
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and 44 percent. Moreover, the expression of keratin 10 per individual cell is remarkably 
lower in psoriasis, as represented by the intensity of the emitted fluorescence signal 
[6,11,15]. Basal cells mainly express keratin 5 and keratin 14. As the expression of kera­
tins 5 and 14 disappears as cells start to differentiate and migrate to suprabasal layers, 
this keratin pair is not a good marker for differentiation. The best-known monoclonal 
antibody for staining of keratin 10 is RKSE60 [13]. This is an antibody of the IgG1 iso­
type. Other known antibodies are DE-K10 and LHP1.
To measure proliferative activity in human epidermal keratinocytes, a fluorochrome is 
required which intercalates in the DNA. For flow cytometric use, several DNA-dyes are 
known. The best described is propidium iodide (PI). For many decades, this dye has been 
widely used as a dye for measuring relative DNA content in both single and multiparame­
ter flow cytometry [13,16-18]. This DNA-fluorochrome has a broad excitation spectrum 
and can be excited using ultra-violet light sources as well as light sources with visual 
wavelengths (350-600 nm). Another DNA-dye is TO-PRO-3 iodide (TP3). This stain has 
another spectrum. It is exited at approximately 633 nm and emits light at 675 nm. Fluo­
rescence of TP3, like PI, depends on intercalation to double stranded nucleic acids, DNA 
as well as RNA. When TP3 or PI is used for DNA content estimation in cells containing 
large amounts of RNA, broad fluorescence distributions are obtained due to the contribu­
tion of RNA-bound dye to the “DNA" fluorescence signal. The accuracy and precision of 
DNA measurements made with TP3 and PI are improved when cells are treated with 
RNase prior to analysis [19,20]. Because of the large spectral overlap of PE and PI 
fluorescence, simultaneous measurement of FITC, PE, and PI is considered to be difficult 
[21-23]. By using the DNA-dye TP3, with an excitation and emission spectrum which does 
not overlap the emission spectrum of PE, this problem can be overcome. However, because 
of the different excitation spectrum of TP3 this requires a second, Helium-Neon, laser.
For flow cytometric assessment of hyperproliferation, hyperproliferation-associated 
keratins are the most logic and suitable markers. The most important hyperproliferation- 
associated keratins are keratins 6 and 16, and in this thesis, these were the keratins that 
were focused on. Keratin 6 and 16 form a pair: keratin 6 is a basic keratin, whereas kera­
tin 16 belongs to the acidic group of keratins. Both keratin 6 and 16 are keratins which 
are associated with pathological situations: it is not expressed in normal skin, although 
these keratins are to some extent present in hair follicles [24-26]. Keratins 6 and 16 are 
expressed in skin diseases which are characterised by hyperproliferation such as psoriasis, 
but also in skin which has been injured and thus show hyperproliferation as a repair 
mechanism, such as in wound healing and in the tape-strip model [27-30]. The expres­
sion of hyperproliferation-associated keratins in psoriasis, more in particular keratin 16, 
has been studied extensively [30-35]. Simultaneous measurement of a hyperproliferation- 
associated keratin, a normo-differentiation keratin such as keratin 10, and DNA content 
has been recently established, and this is described in section 2.5.
2.4 Triple flow cytometric assessment of keratin 10, 
vimentin, and DNA content
As discussed in section 1.7, the clinical assessment of psoriasis using the PASI has limita­
tions as it is subjective to some extent. Therefore, more objective methods to document 
the extension of erythema, scaling, and induration are desirable. For this reason, Glade et 
al. developed a flow cytometric protocol that enabled simultaneous assessment of mar­
kers for epidermal differentiation, inflammation, and proliferation. The expression of mar­
kers for these parameters, i.e. keratin 10, vimentin, and relative DNA-content respectively, 
proved to correlate with the clinical parameters scaling, erythema, and induration. In 
view of this strong correlation, this method to evaluate antipsoriatic therapies is regarded 
to be adequate [2]. In this thesis, this methodology has been used to evaluate the long­
term efficacy of the vitamin D3 analogue tacalcitol and of the LTB4 receptor antagonist 
VML 295. In sections 4.3 and 4.5, which present these efficacy studies, a description of 
this triple parameter flow cytometric method is provided.
2.5 A novel functional multiparameter flow 
cytometric assay to characterise proliferation in skin.
Abstract
Keratins are a group of cytoskeletal proteins that are found in human epidermis and 
other stratified squamous epithelia. Several different types of keratins have been 
described. Keratin 10 (K10) is a keratin that is expressed in well differentiated, 
suprabasal keratinocytes, and keratin 6 (K6) is a keratin which is associated with hyper­
proliferation. Psoriasis is a chronic inflammatory skin disease, and besides inflammation, 
disturbed differentiation and hyperproliferation are its hallmarks. In order to study the 
hyperproliferation associated keratinisation in both well differentiated and disturbed 
differentiated keratinocytes, and in order to assess the proliferative activity of all K10 
and K6 subpopulations, simultaneous assessment of K6, K10, and DNA content is re­
quired. So far, a triple staining protocol had not been available. In the present study, we 
established a novel protocol for simultaneous measurement of K6, K10, and DNA con­
tent, which enables the characterisation of the proliferative activity of several cellular 
subpopulations in epidermis.
From 16 patients with psoriasis and from 15 healthy volunteers, punch biopsies were 
obtained. After preparation of single cell suspensions, cells were stained with the anti­
keratin 10 IgG1-isotype monoclonal antibody RKSE60, with the anti-keratin 6 IgG2a-iso-
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type monoclonal antibody LHK6B, and with the DNA fluorochrome TO-PRO-3 iodide. Iso­
type specific secondary antibodies conjugated with PE and FITC were used as the second 
step in the staining procedure. Controls were measured omitting the primary antibodies, 
and gates were set in order to differentiate between the K10 and K6 subpopulations. 
Samples from both psoriatic patients and healthy volunteers were than measured.
Owing to the IgG specificity of RKSE60 and LHK6B, no cross-reactivity was observed 
between these antibodies. The triple staining with RKSE60, LHK6B, and TO-PRO-3 iodide 
showed subpopulations of K10 expressing cells, K10/K6 co-expressing cells, and K6 only 
expressing cells. There was a significant difference in the proportion of K6 expression and 
K10/K6 co-expression between psoriatic and normal skin. Moreover, the proliferative acti­
vity of these subpopulations could be quantified by this protocol.
We concluded that a triple staining protocol for the assessment of K6, K10, and DNA 
content, using the monoclonal antibodies LHK6B, RKSE60, and TO-PRO-3 iodide, supplies 
reliable and reproducible data for cellular studies on these keratins and for studying the 
proliferative activity of the subpopulations of these keratins in epidermis. Moreover, the 
present study showed that with respect to the proportion of K6, significant differences 
are present between psoriatic and healthy human skin.
Introduction
Cytokeratins comprise a diverse group of intermediate filament proteins that are 
expressed as pairs in both keratinized and non-keratinized epithelial tissue [36-40]. 
Keratins play a critical role in differentiation and tissue specialisation, and function to 
maintain the overall structural integrity of epithelial cells. In human skin, several diffe­
rent types of keratins have been described [36]. Besides keratins which are expressed in 
normal epidermis, keratins that are expressed under pathological conditions are also 
known. Both during normal and disturbed differentiation, changes in keratin expression 
can be observed. The keratinocytes of the basal layer of the epidermis for example 
express keratin 5 and 14, but not keratin 1 and 10, whereas suprabasal cells express kera­
tin 1 and 10, but not keratin 5 and 14. On the other hand, keratins 6 and 16 are 
expressed only under hyperproliferative conditions. Thus, both normal skin and several 
skin diseases can be characterised by the expression of certain keratins [41].
In psoriasis, disturbed differentiation, hyperproliferation, and inflammation are hall­
marks that are clinically represented by scaling, plaque thickening, and erythema, respec­
tively. Because differentiation is impaired, cells show less expression of keratin 1 and 10 
compared to normal skin [6,8,15,42]. Moreover, because of the hyperproliferation, kerati­
nocytes in psoriatic epidermis express keratin 6 and 16 [30-35].
In order to quantify the severity of psoriatic plaques at the cellular level, a flow cyto­
metric triple parameter method has been developed by Van Hooijdonk et al [20], and
Glade et al [2] using markers for keratin 10 (RKSE60), mesenchymal cells (vimentin), and 
DNA content (TO-PRO-3 iodide). These three parameters are assessed in epidermal cell 
suspensions and have proved to correlate highly significant with the clinical parameters 
for scaling, erythema, and plaque thickening respectively, as represented by the Psoriasis 
Area and Severity Index (PASI [43]) [2]. They have proved to be very useful in quantifying 
the efficacy of antipsoriatic drugs [10-12]. However, the effect of drugs on inflammation 
is only studied to a limited extent by this method, and restricted to the inflammatory 
changes of the epidermis. Therefore, the inflammation parameter vimentin has appeared 
to supply little additional information. On the other hand, it is interesting to be able to 
assess the hyperproliferative subpopulation. Not only with respect to what extent these 
hyperproliferative cells are influenced by several therapies, but also to study their propor­
tion under several pathological conditions, and to study the proliferative activity of the 
subpopulations which express hyperproliferation-associated keratins.
Hyperproliferation is represented by expression of keratin 6 and 16 and has been 
studied in human epidermis for decades, especially in psoriasis [30-35], but also in other 
pathological skin conditions such as in wound healing [27,28]. In immunohistochemical 
studies, hyperproliferation-associated keratins have shown to be located suprabasally 
[44]. They are almost absent in normal human skin, but they are present in hair follicles 
to some extent [24-26,45]. A protocol which enables simultaneous measurement in 
single cells of a normo-differentiation parameter (keratin 10), a hyperproliferation marker 
(keratin 6 or 16), and DNA content (TO-PRO-3 iodide or propidium iodide) has not been 
established until now. A major advantage of such a protocol would be that quantitative 
data can be obtained, not only from cells which express keratin 1/10, or keratin 6/16, 
but also from cells which co-express keratin 1/10 and keratin 6/16. Some studies already 
have suggested that cells are able to this co-expression, but these were all qualitative or 
semi-quantitative studies [46,47]. Moreover, the addition of a DNA intercalating dye 
would enable the assessment of the proliferative activity of both the keratin 1/10 and 
keratin 6 /16  expressing cells in such a protocol.
The aim of the present study was to establish a new flow cytometric protocol with 
simultaneous staining for keratin 1/10, keratin 6/16, and DNA content, in order to be 
able to assess the dynamics of all keratin 1 /10  and keratin 6 /16  subpopulations, and to 
assess the proliferative activity of these subpopulations. In particular, we tried to adapt 
the protocol of Van Hooijdonk et al. [20] and Glade et al. [2] by replacing the inflamma­
tion marker vimentin by a hyperproliferation marker.
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Materials and methods
Subjects and biopsy procedure 
From 16 patients, (10 males, 6 females, age-range 31-75 years, mean 56,6) with psoriasis 
vulgaris, 3-mm punch biopsies (Stiefel, Offenbach am Main, Germany) were obtained 
from lesional skin, which had not been treated during the last two weeks. In some 
patients lesions were stable, whereas in other patients lesions were incipient. All lesions 
were mild to moderate, with a sum of scores on a five-point scale for erythema, scaling 
and induration, analogous to the PASI, of at least 6. Moreover, biopsies were taken from 
15 healthy volunteers (11 males, 4 females, age-range 25-55 years, mean 29,9). All sub­
jects gave informed consent prior to the start of the study. Biopsies were obtained after 
local anaesthesia with lidocaine/adrenaline 1:100000 (Astra Pharmaceutica, Zoetermeer, 
The Netherlands), and were put in phosphate buffered saline (PBS, NPBI, Emmer-Compas- 
cuum, The Netherlands) at 5°C immediately after the biopsy procedure.
Single epidermal cell suspensions were prepared using an optimised thermolysin- 
trypsin protocol [6]. In short, biopsies were put in a 2.5 ml thermolysin solution (0.5 mg 
thermolysin (Protease type X; P-1512: Sigma, St. Louis, MO, USA) per ml PBS with 
Mg2+/Ca2). After overnight incubation at 5°C, the dermis and epidermis were gently 
separated using fine forceps and incubated for 30 minutes in 2.5 ml 0.025% trypsin (T- 
8253; Sigma) and 0.3% dithioerythritol (DTE; D-8161; Sigma) in PBS. Then, 250 pl PBS 
containing 10% heat-inactivated newborn calf serum (HINCS; Life Technologies, Paisley, 
UK) was added to each skin specimen. Finally, the remaining epidermis was mixed on a 
vortex, and the stratum corneum was discarded. After centrifuging and removing the 
supernatant, the cells were fixed in ice-cold ethanol (70%) and stored at -20°C until stai­
ning and flow cytometric analysis.
Staining procedure
For simultaneous measurement of the IgG1 specific anti-keratin 10 marker RKSE60 and a 
hyperproliferation marker, we focused on a hyperproliferation marker which was not IgG1 
specific. Although the anti-keratin 16 marker LL025 is a well-documented hyperprolifera­
tion marker, we were not able to use this marker as it is IgG1 specific. LHK6B (NCL-CK6, 
Novocastra Laboratories, Newcastle upon Tyne, UK) is a IgG2a specific monoclonal anti­
body which is directed against the hyperproliferation-associated keratin 6 [48-52]. As 
LHK6B is of the IgG2a isotype and as it is a well described hyperproliferation marker, we 
focused on this label. In a concentration curve we estimated the optimum concentration 
of LHK6B for flow cytometric use at 1:50 (data not published).
Before the cells were stained, cell suspensions were washed in 2,5 ml PBS and centri­
fuged for 5 minutes at 3000 rotations per minute. Then, the supernatant was removed 
and the cells were resuspended on a vortex. To every sample, 150 pl RKSE60 (Depart­
ment of Molecular Biology, University of Maastricht, The Netherlands), an IgG1-type
monoclonal antibody which is directed against keratin 10 [6,8,42], was added at a 1:20 
dilution. Another 150 pl of LHK6B was added at a dilution of 1:50. After 30 minutes of 
incubation in the dark at room temperature, 2,5 ml of a 1% Heat Inactivated Normal 
Calf Serum in PBS solution (HINCS; Life Technologies, Paisley, UK) was added, and cells 
were washed again. For the second step of the indirect immunostaining, we used fluoro- 
chromes conjugated to Goat-anti-mouse antibodies, which were isotype specific. From 
each fluorochrome, 150 pl was added to each specimen. For RKSE60, phycoerythrin con­
jugated with IgG1 specific Goat F(ab')1 anti-mouse antibodies was added at a dilution of 
1:250 (GAM-PE, Southern Biotechnology Associates, Birmingham, AL, USA). For LHK6B, 
the fluorochrome fluorescein-isothiocyanate conjugated with monoclonal goat antibodies 
against mouse IgG2a was used at a dilution of 1:50 (GAM-FITC, Southern Biotechnology 
Associates). After an incubation of 15 minutes at 5°C, 2,5 ml 1% HINCS was added, and 
cells were washed and centrifuged. Then, a stock of TO-PRO-3 iodide of 1 x 10'3 M (TP3, 
Molecular Probes, Eugene, OR, USA) was diluted 500 times and 300 pl of this solution 
was then added to each sample, resulting in a final concentration of 2 x 10'5 M. TP3 
gives good results with no spectral overlap with phycoerythrin. Moreover, compared with 
propidium iodide, often considered the standard for DNA staining, TP3 shows similar 
results [20,53,54]. TP3 intercalates with double-stranded regions of nucleic acids, but it 
also affects RNA. For this reason, 50 pl of a solution of 1% RNase (Ribonuclease-A, type 
I-A, R-4875, Sigma) in PBS was added to each specimen. Finally, after RNase was added 
and cells were incubated for at least 10 minutes in the dark at room temperature, flow 
cytometric analysis was performed.
Flow cytometric analysis 
After staining, the cells were measured and analysed with an EPICS® Elite flow cytometer 
(Beckman Coulter, Luton, UK) with a dual laser system. An air-cooled argon ion laser exci­
ted both FITC and PE at a wavelength of 488 nm at 20 mW. A second Helium-Neon laser 
(10 mW, 633 nm) excited TP3. Because of the difference in emission wavelength of PE 
and TP3, there was no spectral overlap. Fluorescence was measured using bandpass fil­
ters at 525 nm (FITC, green signal), 575 nm (PE, orange signal) and 675 nm (TP3, red 
signal).
Data were collected in list-mode with debris elimination gates set: To discriminate 
between doublets of diploid cells and real tetraploid cells, the ratio area/peak of the red 
signal (TP3, DNA) was used, combined with scatter parameters. Although the issue of 
appropriate hardware gating versus software compensation for aggregate corrections 
remains controversial [55], we have used this hardware methodology at our department 
for years, and it is in accordance with a method described previously [56].Thus, debris 
was not calculated mathematically from the DNA histogram, but it was rather excluded 
physically by determination of aggregates and debris from the list-mode file. As aggre­
gates and debris had already been excluded, the percentage histogram background
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aggregates and debris (%BAD), defined as the ratio of model estimated aggregates and 
debris to total cellular events in the histogram, could not be calculated. For physical 
debris elimination, we applied criteria for accepting a satisfactory S-phase analysis, being 
less than 20% of aggregates and debris, similar to the guidelines for implementation of 
clinical DNA cytometry [55].
In a histogram in which the fluorescence signals of both FITC and PE were plotted, 
cross reactivity was studied by measuring controls, omitting the primary antibodies. As 
keratin 6 is only expressed in hyperproliferative tissue, cell suspensions derived from 
psoriatic skin were used for these control measurements. Based upon the measurement of 
these controls, gates were set in a way that if a primary antibody was omitted, the 
proportion of the fluorescence-positive signal for this omitted antibody was between 0% 
and 1%.
For DNA histogram standardisation we used both Flow-Check fluorospheres (Coulter 
Corporation, Miami, FL, USA) and human lymphocytes. The equipment was focused in a 
way that if Flow-Check was used, the half peak CV was < 1.5, and if human lymphocytes 
were used the half peak CV was < 3. Moreover, before the assessment of all stained cell 
suspensions, a sample with normal human keratinocytes was assessed for adjusting the 
amplifications of the signals.
After setting the gates, the proportion of keratin 6-positive, keratin 10-positive, kera­
tin 6-negative, keratin 10-negative, and keratin 6 /  keratin 10 co-expressing cells was 
calculated, using WinList software (WinList 4.0, Verity Software House Inc., Topsham, ME, 
USA). A count stop was set at 10,000 keratin 10-negative cells, which are the basal 
keratinocytes. Using ModFit software (ModFit LT 2.0, Verity Software House Inc.), 
the proportion of proliferating basal keratinocytes was calculated from DNA histograms. 
Hereby, we assumed that all cells were diploid. In a stable situation, keratinocytes show a 
low proliferating activity [57]. Even in psoriasis, in which proliferation is increased, a rela­
tively small proportion of the basal keratinocytes is proliferating [58]. Separate assess­
ment of basal cells in the S-phase, and of basal cells in the G2M-phase may results in pro­
portions that are too low to be reliable [59]. By assessing the sum of the cells which are 
in S-phase and of those which are in the G2M-phase of the cell-cycle, the proportion will 
be steadily higher, and assessment of the proliferative activity will thus be more reliable. 
Therefore, for assessing proliferation, we focused on the basal cells in the SG2M-phase of 
the cell cycle.
In order to verify the reproducibility of the proportion of keratin 10 and keratin 6 
expressing cells, we performed an additional experiment. For this experiment, we used 
cell suspensions of 5 different skin samples of healthy volunteers. Each cell suspension 
was divided into three parts: one part was stained with only RKSE60 - PE, and TP3, the 
second sample was stained with only LHK6B - FITC and TP3, and the third sample was 
stained with RKSE60 - PE, LHK6B - FITC, and TP3. The proportion of all keratin 10- 
positive cells and of all keratin 6-positive cells of all three series of samples was than 
calculated using WinList software, and the results were compared.
Figure 6 a-d
Figures in which the fluorescence signals of FITC and PE are plotted. The X-axis shows the 
intensity of the FITC signal and therefore represents keratin 6 expression, whereas the Y-axis 
shows the intensity of the PE signal and thus represents keratin 10 expression.
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Figure 6a Depicted of a control measurement Figure 6b Depiction of a control meas-
in which both primary antibodies, RKSE60 
and LHK6B were omitted. Therefore, no posi­
tive signal on both the X-axis and the Y-axis 
can be observed.
urement in which the primary antibody 
LHK6B was omitted, and RKSE60 was added. 
A clear positive signal for PE, which is conju­
gated with anti-RKSE60, can be seen. The 
proportion of the FITC-positive cells is 
between 0%  and 1%.
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Figure 6c Depiction of a control measure­
ment in which the primary antibody RKSE60 
was omitted, and LHK6B was added. A clear 
positive signal for FITC, which is 
conjugated with anti-LHK6B, can be seen. 
The proportion of the PE-positive cells is 
between 0%  and 1%.
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Figure 6d Representative picture of a 
measurement in which both primary 
antibodies, RKSE60 and LHK6B, were added. 
Letter A represents the subpopulation which 
is only keratin 10-positive, letter B represents 
keratin 10 and keratin 6 co-expressing cells, 
letter C represents the subpopulation of cells 
which do express keratin 10 nor keratin 6, 
and letter D represents the cells which only 
express keratin 6.
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Results
The flow cytometric results of the present study are depicted in Figures 6a to 6d. The X- 
axis of these figures shows the intensity of the FITC signal, and therefore represents the 
expression of keratin 6. The Y-axis shows the intensity of the PE signal, which represents 
the expression of keratin 10. Figures 6a, 6b and 6c show the results of the controls, 
omitting the primary antibodies. Figure 6a shows the results of the measurement of cells 
in which both primary antibodies were omitted, and only the secondary antibodies were 
added to the cell suspensions. It can be observed that no positive signal on both the X- 
axis and the Y-axis is present. In Figure 6b, LHK6B has been omitted, and it can be 
clearly seen that only keratin 10 expression is present. The proportion of cells that show a 
positive signal for FITC is less than 1%. Figure 6c shows the results of the measurement 
in which RKSE60 has been omitted. Now, cells only show expression of keratin 6, whereas 
the proportion of cell expressing keratin 10 is less than 1%. Figure 6d shows a represen­
tative picture of simultaneous measurement of both primary antibodies. In this figure, 
letters A to D indicate the several subpopulations which can be derived from this histo­
gram: Letter A represents the cells which are only keratin 10-positive, letter B represents 
individual cells which express both keratin 10 and keratin 6 (co-expression), letter C 
represents cells which do not either express keratin 10 nor keratin 6, and letter D repre­
sents keratinocytes which are only keratin 6-positive.
Table 4 Results (Mean ± SEM) of three-parameter flow cytometric assessment of keratin 6, 
keratin 10, and DNA content in psoriatic and normal human skin.
The letters entered in parentheses refer to the regions as depicted in Figure 6d.
Psoriasis Normal skin
Only keratin 10-positive cells (A) 16,9 ± 3,7 69,6 ± 3,6
Total %  keratin 10-positive cells (A  and B) 27,4 ± 3,2 70,0 ± 3,6
Only keratin 6-positive cells (D) 7,5 ± 2,3 0,2 ± 0,1
Total %  keratin 6-positive cells (B and D) 18,0 ± 3,9 0,6 ± 0,1
Co-expression keratin 10 and keratin 6 (B) 10,5 ± 2,2 0,4 ± 0,1
Keratin 10-negative cells in the SG2M-phase (C) 15,4 ± 1,9 4,7 ± 1,2
The stained cell suspensions of 16 patients with psoriasis and of 15 healthy volunteers 
were measured. The results of these measurements are depicted in Table 4. For all sub­
populations, clear differences between psoriatic and normal skin can be observed. 
Especially the co-expression of keratin 6 and keratin 10 (region B in Figure 6d) was signi­
ficantly higher in psoriatic skin compared to normal skin, but also the proportion of cells 
which exclusively express keratin 6 is significantly higher in psoriatic plaques than in nor­
mal skin (region D in Figure 6d). Another important finding was that normal skin hardly
expressed keratin 6: The proportion of both K6/K10 co-expressing cells and cells which 
only express keratin 6 was less than 1%.
Due to the relatively small number of cells that were counted, we were only able to 
assess the proliferative activity of the keratin 10-negative population, which are the basal 
keratinocytes. For assessment of the proliferative activity of the other subpopulations, a 
larger number of cells is required in order to obtain satisfactory DNA histograms. The 
guide-lines for the implementation of clinical DNA cytometry suggest that 10.000 cells 
are needed for good DNA analysis [55], although the number of events necessary is con­
troversial. To our experience, a number of 2000 gated cells (not including debris and 
aggregates) still shows satisfactory histograms. Unfortunately, the proportions of cells in 
the subpopulations of regions A, B, and D were that low that less than 2000 cells re­
mained for DNA-analysis. Therefore, DNA-analysis for these subpopulations could not be 
performed. For the basal cells (region C), the mean proportion cells in the SG2M-phase 
was 15,4% ± 1,9% for psoriatic skin and 4,7% ± 1,2% for normal skin. A representative 
picture of the DNA-histograms of these subpopulations is depicted in Figure 7. The co­
efficient of variation (CV) ranged from 3.1 to 14.0, with a mean of 9.3 and a SEM of 0.8 
for the histograms derived from the suspensions of psoriatic patients, an from 6.4 to 9.2, 
with a mean of 7.8 and a SEM of 0.3 for the histograms of the basal cells from the 
healthy volunteers.
From the additional experiment to verify the reproducibility, the results were as 
follows. The difference with respect to the proportion of keratin 10-positive cells between 
the samples which were stained with only RKSE60 and the samples which were stained 
with both RKSE60 and LHK6B was 1,0%. With respect to the proportion of keratin 6-posi­
tive cells, the difference was 1,1%.
Discussion
The present study clearly showed that a protocol with a combination of the IgG1-isotype 
antibody RKSE60 and the IgG2a-isotype antibody LHK6B enables simultaneous flow 
cytometric assessment of keratin 10 and keratin 6 respectively. The hyperproliferation 
marker LHK6B as used in the present study is a well described antibody of hyperprolifera­
tive tissue [48-52], and the use of RKSE60 as a normo-differentiation marker has been 
documented by several authors [6,8,13,42]. The combination of these two antibodies 
therefore supplies reliable data on both hyperproliferation and differentiation. The two 
antibodies do not cross-react, as represented by the control measurements, and the pro­
portion of expressed cells dependent on the addition of one versus both primary anti­
bodies, only varies 1%. It has been shown earlier that the maintenance in organ culture 
of small pieces of skin for less than 24 hours can turn on the synthesis of hyperprolifera­
tion-associated keratin [32,60]. However, the protocol for making single cell suspensions
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Figure 7 Representative histogram of all basal cells in the SG2M-phase of the cell cycle, 
derived from psoriatic skin. In this histogram, the proportion of basal cells in the S-phase was 
15.1% and in the G2M-phase 1.6%. Thus, the total proportion of proliferating cells was 16.7% 
for this sample. The CV was 6.63 and a number of 10852 cells was modeled.
as used in the present study apparently does not induce the synthesis of keratin 6, 
because the cells derived from normal healthy skin hardly showed any expression of kera­
tin 6. Although hyperproliferation-associated keratins are absent in normal human epi­
dermis [45], the very low proportion of keratin 6-positive cells as seen in the present 
study can be explained by the possibility that the cell suspensions also contained cells 
which are derived from hair follicles. It is known that hyperproliferation-associated kera­
tins are expressed in hair follicles [24-26].
Data obtained using the method as described in the present study are quantitative 
and reproducible. In addition, the present study showed that in psoriatic skin cells can 
express only keratin 10 and only keratin 6. Moreover, the present study has shown that 
single cells are able to co-express keratin 10 and keratin 6. This co-expression has been
suggested earlier [46], but had never been confirmed quantitatively and simultaneously.
In the present study, we were only able to assess the proportion of cells in the SG2M- 
phase of the keratin 10-negative population, because of the limited number of cells that 
were counted. It would be very interesting to be able to assess the proliferative activity of 
all subpopulations. This is easily possible with the method as described in the present 
study. However, for good DNA analysis, the measurement of a sufficient number of cells 
in these subpopulations is required. As discussed previously in this paper, we have expe­
rienced that a minimum cell number of 2000 cells can still show satisfactory DNA histo­
grams. The requirement of more cells has implications for the size of the biopsies and 
thus for the ethical aspects of clinical studies. Besides the number of cells, the CV is of 
importance for accurate DNA analysis. In the present study, the mean CV of the DNA 
histograms from basal cells derived from skin of healthy volunteers was 7.8. This is in line 
with the guidelines for implementation of clinical DNA cytometry [55], which suggest 
CVs of less than 8. However, the mean CV of the DNA histograms from basal cells derived 
from psoriatic skin was 10.0. The guidelines indicate that the CV of, for example, tumours 
may be higher due to the presence of multiple tumour subpopulations [55]. Psoriatic skin 
is hyperproliferative and in this respect it resembles a tumour. Therefore, it is feasible 
that the CV of psoriatic skin is higher than 8. Other studies on psoriatic skin have used 
CVs up to 10 [11,58]. Nevertheless, the CVs as presented in the present study, with a 
mean of 10,0 are marginal. However, we would like to emphasise that if in future experi­
ments cell suspensions are used which contain a sufficient number of cells, and if accep­
table CVs can be obtained from the DNA histograms of the K6 and K10 subpopulations, 
this would supply valuable information about the DNA distribution in K6/K10 positive 
and negative subpopulations under normal and pathological conditions. In spite of the 
ethical and cellular limitations, which have to be kept in mind, this should be easy to per­
form using the methodology as described in this paper.
The method as described in the present study opens new perspectives in the investi­
gations on the hyperproliferative fraction of psoriasis: The combination of a hyperprolife­
ration marker, a normo-differentiation marker, and a DNA intercalating dye not only 
enables the assessment of the proportion of all combinations of keratin 10 and keratin 6 
expression, but also enables the assessment of the proliferative activity of these subpopu­
lations. It may be worthwhile to investigate the ratio of keratins 6 and 10 in different 
forms of psoriasis, such as stable and incipient lesions including the interface zone 
between affected and unaffected skin, and to study the influence of topical treatment on 
the different subpopulations, using this newly developed protocol.
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A L T E R A T I O N S  I N  P S O R I A T I C  E P I D E R M I S
3.1 Changes in keratin 6 and keratin 10 (co-) expression in 
lesional and symptomless skin of spreading psoriasis
Abstract
Keratin 6 (K6) and keratin 10 (K10) are markers for epidermal hyperproliferation and 
differentiation respectively and are both expressed in the suprabasal layers of the 
epidermis. They may co-express at the cellular level in different stages of the spreading 
psoriatic lesion, but single expression can also occur. The purpose of the present study 
was to investigate to what extent keratinocytes express K6 and K10, and to what extent 
cells co-express K6 and K10 in different stages of the psoriatic disease. We studied this in 
spreading psoriatic plaques. From 8 patients with incipient psoriasis, three 3-mm punch 
biopsies were obtained from the inner involved margin of a spreading lesion, from the 
uninvolved skin immediately adjacent to the spreading plaque, and from the distant 
uninvolved skin. From 9 healthy volunteers, 3-mm punch biopsies were obtained as con­
trols. After preparation of single cell suspensions of these biopsies, a triple staining pro­
tocol was performed with markers for K6 (monoclonal antibody LHK6B), K10 (monoclonal 
antibody RKSE60) and DNA content (TO-PRO-3 iodide). Subsequently, cells were 
measured with a flow cytometer and the proportion of the markers was calculated using 
specific software. We observed a population of K6/K10 co-expressing cells, but also a 
population expressing only K6 and only K10. These subpopulations varied with the 
involvement of the lesion. There was a statistically significant difference between the 
inner margin and the outer margin with respect to the proportion of K6 expressing cells 
and K10 expressing cells. The proportion of K6/K10 co-expressing cells in the inner 
margin was significantly different from the distant uninvolved skin. We confirmed that 
individual keratinocytes can co-express K6 and K10, and that there is a unique subpopu­
lation of cells which express only K6 but not K10. Moreover, the proportion of these 
populations depends on the stage of the pathological process, but more studies are 
required to fully understand the pathogenic relevance of co-expression and single 
expression of K6 and K10.
Introduction
Hyperproliferation and disturbed differentiation are hallmarks of the psoriatic epidermis. 
The abnormalities of proliferation and differentiation are reflected by changes in keratin 
expression, with a decrease of K1/K10 expression and an increase of K6/K16 expression. 
Keratins 1 and 10 are markers for differentiation and are only expressed in well differen­
tiated, suprabasal cells [1-4]. Keratin 6 /16  is a keratin pair which is expressed in hyper-
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proliferative cells and it is also found suprabasally [2,3,5-7]. There is experimental evi­
dence that in psoriasis the keratin 1/10 pair is down regulated when expression of the 
keratin 6 /16  pair is induced [8,9], a relationship which has also been described for other 
skin conditions [10-12]. Leigh et al. already showed immunohistochemically that in 
psoriatic epidermis both keratin 16 and keratin 10 are present, and that some cells 
express both keratins at the same time [1]. Recently, using a flow cytometric protocol for 
simultaneous assessment of keratin 6, keratin 10, and DNA content, our group confirmed 
quantitatively that epidermal keratinocytes can show single expression of keratin 6 or 
keratin 10 and co-expression of keratin 6 and keratin 10 [13]. Other authors already 
emphasised that several pathways exist in the differentiation of keratinocytes. Besides 
mutually exclusive expression of differentiation and hyperproliferation markers [6], an 
alternative pathway exists: cells already possessing differentiation markers appear to be 
able to make hyperproliferation markers [14,15]. Thus, coexistence of differentiation and 
hyperproliferation markers in a single suprabasal keratinocyte may appear [14]. The rela­
tive expression of keratins 1/10 and the expression of hyperproliferative associated kera­
tins such as keratin 6 appear to vary in roughly reciprocal fashion [5,6]. However, the 
question remains what the pathogenic relevance is of a pathway in which cells start to 
express keratin 6 immediately after they have left the basal layer, so before they start to 
express keratin 10.
Several authors already showed that the margin zone of a psoriasis plaque provides 
an adequate model for sequential analyses of cellular and subcellular processes from 
clinically uninvolved to the lesional skin [16]. Therefore, we focused on spreading 
psoriatic plaques, and investigated to what extent lesional and non-lesional psoriatic 
keratinocytes express keratin 10 and keratin 6 and to what extent co-expression of these 
keratins in single cells is present. We compared data of the inner lesional margin of a 
plaque, the outer non-lesional margin, and the distant uninvolved skin of psoriatic 
patients. Moreover, we compared the data of the distant uninvolved skin with those of 
healthy skin. We used a recently developed flow cytometric staining protocol, for simulta­
neous measurement of the proportion of cells expressing keratin 6, keratin 10, and co­
expression of keratin 6 and keratin 10, using specific antibodies for these keratins [13]. 
More-over, we measured the proliferative activity of the keratin 10 negative cells, the 
keratin 6 positive cells, and the cells which co-expressed keratin 10 and keratin 6, using a 
fluorescent DNA intercalating dye.
Materials and methods
Subjects, biopsies, and cell isolation procedure 
After giving informed consent, 8 patients (5 female, 3 male, age range 29-66, mean 
49,4) with psoriasis vulgaris were included in the present study. Patients had at least one 
psoriatic lesion at the trunk, arms or legs, with a diameter of at least 2 cm, and which 
had spread during the last two weeks. Patients had not used any topical treatment in the 
two weeks prior to inclusion, and no systemic or phototherapy in the previous four weeks. 
An other exclusion criterion was the use of medication which may interfere with psoriasis, 
such as systemic corticosteroids, B-blockers, lithium carbonate, anti-malaria medication 
and immunosuppressives. Moreover, 9 healthy paid volunteers were included (1 female, 8 
male, age range 25-27, mean 26,0), with no history or signs of skin disease. The volun­
teers gave informed consent prior to study enrolment as well.
Three 3-mm punch biopsies (Stiefel, Offenbach am Main, Germany) were taken from 
every psoriasis patient after local anaesthesia with xylocaine/adrenaline 1:100000. One 
biopsy was taken from the involved margin of the lesion, one of the uninvolved margin of 
the lesion directly adjacent to the plaque, and one of the distant uninvolved skin. Distant 
uninvolved skin was defined as clinically normal looking skin at a distance of at least 10 
centimetres from the spreading lesion. From every healthy volunteer, one 3-mm punch 
biopsy was taken from the lower back after local anaesthesia.
Immediately after the biopsy procedure, biopsies were stored in phosphate buffered 
saline (PBS, NPBI, Emmer-Compascuum, The Netherlands) at 5°C. In order to obtain 
single cell suspensions with a good separation of dermis and epidermis, we used an opti­
mised thermolysin-trypsin protocol, as previously described in detail by Glade et al. [17].
Staining procedure and flow cytometric analysis 
The staining procedure and the flow cytometric analysis procedure have been previously 
described in detail [13]. In short: to assess epidermal differentiation, RKSE60 (Depart­
ment of Molecular Biology, University of Maastricht, The Netherlands) was used at a dilu­
tion of 1:20. This IgG1 type mouse monoclonal antibody stains keratin 10, an intermedia­
te filament-type protein that is only expressed in suprabasal keratinocytes [17-19]. For 
measuring hyperproliferative cells, we used the IgG2a type mouse monoclonal antibody 
LHK6B (Novocastra Laboratories, Newcastle upon Tyne, UK). LHK6B exclusively stains 
keratin 6, an intermediate filament-type protein that is expressed in suprabasal hyperpro­
liferative keratinocytes [20-23] and to some extent in hair follicles [20,24,25]. Keratin 6 
is expressed in the suprabasal compartment, although there is evidence that K6 is also 
expressed in basal keratinocytes of ridged skin [26]. However, in psoriatic skin K6 is 
expressed only suprabasally , and in normal skin of the lower back of healthy volunteers 
it is not expressed, as shown by immunohistochemical staining of these types of skin by
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Figure 8 Immunohistochemical staining of lesional psoriatic skin with the anti-keratin 6 
marker LHK6B (1:20). The basal layer of the epidermis does not show staining. This indicates 
that LHK6B is found suprabasally in psoriatic skin.
Figure 9 Immunohistochemical staining of normal skin of a healthy volunteer with the anti­
keratin 6 marker LHK6B (1:20). Clearly, no staining is observed. This supports the finding that 
keratin 6 is absent in normal skin.
LHK6B (Figures 8 and 9 respectively). To measure DNA content, and thus to measure pro­
liferative activity, we used the DNA fluorochrome TO-PRO-3 iodide (2 x 10'6 M, TP3; 
Molecular Probes, Eugene, OR, USA) [27-29]. TP3 intercalates with double-stranded 
regions of nucleic acids, and as it also affects RNA, it was used in combination with 
RNase. The second step of the indirect immunofluorescent staining was performed with 
monoclonal goat antibodies against mouse IgG2a and IgG1, conjugated to fluorescein 
isothiocyanate (GAM-FITC, 1:50) and phycoerythrin (GAM-PE, 1:250) respectively 
(Southern Biotechnology Associates, Birmingham, AL, USA). The specificity and cross­
reactivity of these second stage reagents have been described before [17,27].
An EPICS Elite flow cytometer with a dual laser system (Beckman Coulter, Luton, UK) 
was used to measure and analyse the stained cells. To discriminate between doublets of 
diploid cells and real tetraploid cells, the ratio area/peak of the red signal (TP3, DNA) 
was used, combined with scatter parameters. Controls were measured, omitting the pri­
mary antibodies. Gates were set in a way that if a primary antibody was omitted, the pro­
portion of the fluorescence-positive signal for this omitted antibody was between 0% and 
1%. After setting the gates, approximately 15,000 cells were counted. The proportion of 
keratin 10-positive cells, keratin 6-positive cells, and keratin 10 /  keratin 6 co-expressing 
cells was calculated using WinList software (WinList 4.0, Verity Software House, Topsham, 
ME, USA). Using ModFit software (ModFit LT 2.0, Verity Software House), we calculated 
the percentage of proliferative cells of 1) all cells which were keratin 10 and keratin 6 
negative, 2) cells which were keratin 6 positive, 3) cells which were only keratin 10 nega­
tive (exclusively basal cells), and 4), cells which co-expressed both keratin 10 and keratin 6.
Statistical analysis
We performed an analysis of variance (ANOVA) to compare the significance between the 
inner margin, outer margin and distant uninvolved skin, and between the distant uninvol­
ved skin and healthy skin of volunteers. If this appeared to be significant, a post-hoc 
comparison was made using the Duncan multiple range test.
Results
Expression of keratin 6 and keratin 10 
A representative picture of the expression of keratin 6 and keratin 10 is depicted in 
Figure 6d. The results of the present study are shown in Table 5 and depicted in Figure 
10. In Figure 6d it can be seen that cells can express only keratin 10 (A), only keratin 6 
(D), both keratins (B), or neither of both keratins (C).
The total proportion of cells which expressed keratin 10 (A and B in Figure 6d) was 
24.5% ± 5.7% (mean ± SEM) for the inner margin, 49.1% ± 3.0% for the outer margin,
75
A
L
T
E
R
A
T
IO
N
S
 
IN 
P
S
O
R
IA
T
IC
 
E
P
ID
E
R
M
IS
76
A
L
T
E
R
A
T
IO
N
S
 
IN 
P
S
O
R
IA
T
IC
 
E
P
ID
E
R
M
IS
Table 5 Overview of measured parameters (mean ± SEM). 'DUI' = distant uninvolved skin of 
psoriatic patients, 'Normal' = skin of unaffected healthy volunteers.
Letters A - D refer to the regions as depicted in Figure 6d.
Total %  keratin10-positive cells (A and B)
Only keratin 10-positive cells (A)
Total %  keratin 6-positive cells (B and D)
Only keratin 6-positive cells (D)
%  keratin 10 and keratin 6 co-expressing cells (B) 
%  keratin 10-negative cells in the SG2M-phase
Inner Outer D U I Normal
margin margin
24.5 ± 5.7 49.1 ± 3.0 56.3 ± 4.8 72.1 ± 4.7
18.5 ± 6.5 47.4 ± 4.2 56.1 ± 4.7 71.8 ± 4.7
12.7 ± 4.9 2.5 ± 1.9 0.5 ± 0.2 0.4 ± 0.1
6.7 ± 3.2 0.5 ± 0.3 0.2 ± 0.1 0.2 ± 0.0
6.0 ± 2.1 2.0 ± 1.6 0.2 ± 0.1 0.2 ± 0.1
10.0 ± 2.5 3.1 ± 0.5 2.5 ± 0.4 4.4 ± 1.3
«u
oco
o&o
Inner margin 
Outer margin 
Distant uninvolved skin 
Normal skin
All K10 
pos. cells
Only K10 
pos. cells
All K6 
pos. cells
Only K6 
pos. cells
K6 /  K10 co­
expressing 
cells
K10 neg. 
cells in 
SG2M-phase
Figure 10 Overview of the proportions of all keratin 6 and keratin 10 subpopulations in the 
inner lesional margin of psoriatic plaques, in the outer uninvolved margin, in the distant unin­
volved skin, and in normal skin of healthy volunteers. Proportions are Means, error bars depict 
the Standard Error of the Mean (SEM).
and 56.3% ± 4.8% for the distant uninvolved skin. In healthy skin, this proportion was 
72.1% ± 4.7%. The difference between the involved inner margin and the uninvolved 
outer margin was highly significant (p<0.01), as was the difference between the inner 
margin and the distant uninvolved skin (p<0.01). Moreover, the difference in percentages 
between the distant uninvolved skin and normal skin of healthy volunteers was signifi­
cant (p<0.05). However, there was no significant difference between the uninvolved outer 
margin of the lesion and the distant uninvolved skin with respect to keratin 10 
expression. The proportion of only keratin 10 expressing cells (A in Figure 6d) was 18.5% 
± 6.5% for the inner margin, 47.4% ± 4.2% for the outer margin, 56.1% ± 4.7% for the 
distant uninvolved skin, and 71.8% ± 4.7% for healthy skin. The inner margin showed a 
significantly lower proportion of only K10-expressing cells compared to the outer margin 
(p<0.01), and the proportion in the outer margin was significantly lower compared to the 
proportion of the skin of healthy volunteers (p<0.01). Moreover, the difference between 
the distant uninvolved skin of psoriatic patients and the skin of healthy volunteers was 
significantly different (p<0.05). However, the difference between the outer margin and 
the distant uninvolved skin was not significant (p>0.05).
With respect to all the cells which expressed keratin 6 (B and D in Figure 6d), the pro­
portion was 12.7% ± 4.9% for the inner margin, 2.5% ± 1.9% for the outer margin, and 
0.5% ± 0.2% for the distant uninvolved skin. In healthy skin, 0.4% ± 0.1% of all cells 
expressed keratin 6. The differences between the inner margin on one hand, and the 
outer margin and distant uninvolved skin on the other hand were significant (p<0.03). 
The difference between the uninvolved outer margin of the lesion and the distant unin­
volved skin was not significant. Moreover, there was no significant difference between the 
expression of keratin 6 of the distant uninvolved skin and the skin of healthy volunteers. 
The proportion of only keratin 6 expressing cells (D in Figure 6d) was 6.7% ± 3.2% for 
the inner margin, 0.5% ± 0.4% for the outer margin, 0.2% ± 0.1% for the distant unin­
volved skin, and 0.2% ± 0.0% for healthy skin. Again, the difference between the inner 
margin and the outer margin was significant (p<0.05), but there was no statistically 
significant difference between the uninvolved margin, the distant uninvolved skin of 
psoriatic patients, and normal skin.
Regarding the proportion of cells which co-expressed keratin 6 and keratin 10 (B in 
Figure 6d), the following values were observed: 6.0% ± 2.1% for the inner margin, 2.0% 
± 1.6% for the outer margin, 0.2% ± 0.1% for the distant uninvolved skin, and 0.3% ± 
0.1% for healthy skin. There was only a significant difference between the inner involved 
margin and the distant uninvolved skin (p<0.02). The differences between the inner mar­
gin and the outer margin, and between the outer margin and the distant uninvolved skin 
were not significant. The difference between the distant uninvolved skin and healthy skin 
was not significant either.
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Proliferative activity
Due to the relatively low percentages of cells which expressed only keratin 6 and cells 
which expressed both keratin 6 and keratin 10, too small numbers of cells were available 
to measure reliable DNA histograms of these cell populations. Therefore, we were only 
able to calculate the percentage of cells in SG2M-phase of the K6 /  K10 negative popu­
lation (C in Figure 6d), and of the exclusively keratin 10 negative cell population (C and 
D in Figure 6d). The differences with respect to the percentages of cells in SG2M-phase 
between these two cell populations were minimal. Therefore, we chosed to focus only on 
the K6 /  K10 negative population, which are the basal keratinocytes (C in Figure 6d). 
The proportion of basal cells in the SG2M-phase was 10.0% ± 2.5% for the inner involved 
margin, 3.1% ± 0.5% for the outer uninvolved margin, 2.5% ± 0.4% for the distant unin­
volved skin, and 4.4% ± 1.3% for normal skin of volunteers. The proliferative activity of 
the basal cells in the involved inner margin was significantly higher than that of the 
basal cells in the uninvolved outer margin (p<0.01), and in the distant uninvolved skin 
(p<0.01). However, there was no significance between the uninvolved outer margin and 
the distant uninvolved skin. The difference between distant uninvolved skin and normal 
skin with respect to the percentage of basal cells in the SG2M-phase was not significant 
either.
Discussion
In the present study, data of psoriatic patients are compared with data from skin biopsies 
of healthy volunteers. In these volunteers, all biopsies were taken from the lower back, 
whereas the biopsies from uninvolved skin of the psoriatic patients were taken from arms, 
legs, and the trunk, dependent on the site of the psoriatic lesion. It is known that the 
expression of several markers depends on the site of the biopsy: especially foreskin, skin 
of palms and soles, of the groin, axillary folds, and of the scalp show different expression 
with respect to some markers, for example tenascin and keratin 16 [30,31]. However, the 
markers used in the present study show similar proportions in the trunk, arms, and legs of 
normal skin of healthy volunteers, as shown by other authors [4,32,33]. Therefore, the 
data of the uninvolved psoriatic skin can be compared with the skin of healthy volun­
teers.
Recently, using a new flow cytometric protocol, our group showed that co-expression 
of keratin 6 and keratin 10 can occur in individual epidermal cells of psoriatic skin [13]. 
The present study confirms this finding. Moreover, it was shown that the proportion of 
both K6/K10 co-expressing cells and single K6 and K10 expressing cells depends on the 
stage of the disease.
With respect to the percentage of keratin 10 expression, the present study showed a 
significant difference between affected and unaffected skin. The present study also
showed that with respect to keratin 10 expression, percentages do not differ significantly 
between uninvolved skin adjacent to the lesion, and at a distance, whereas keratin 10 
expression in normal skin is significantly higher than in the uninvolved skin of psoriatic 
patients. This suggests that in psoriatic patients keratinisation is impaired, irrespective of 
the location in uninvolved skin.
With respect to the proportion of keratin 6 expression, we documented that in the 
involved margin of spreading psoriasis significantly more cells are keratin 6 expressing 
compared to uninvolved skin immediately adjacent to the plaque, but that the proportion 
of keratin 6 expression in the outer margin was not significantly different from the dis­
tant uninvolved skin. Moreover, the values of the distant uninvolved skin and normal skin 
were comparable. Several authors concluded that keratin 6 expression is absent in normal 
skin, but although the percentages are very low, the present study showed that there are 
cells in distant uninvolved skin of psoriatic patients and in normal skin which do express 
keratin 6. It is possible that these cells represent cells derived from hair follicles, because 
it has been described that keratin 6 is expressed in hair follicles [20,24,25]. However, the 
immunohistochemical section as shown in Figure 9 did not comprise hair follicles and we 
could therefore not confirm this possibility. On the other hand, it is feasible that in a cell 
suspension derived from 3-mm punch biopsies some hair follicles are present.
The methodology used in the present study [13], enables assessment of the DNA con­
tent of the K6 and K10 subpopulations. However, for good DNA analysis, a sufficient 
number of measured cells is required. Unfortunately, due to the relatively small propor­
tions of K6/K10 co-expressing cells and K6 single expressing cells, we were not able to 
perform reliable DNA analysis. The guidelines for the implementation of clinical DNA 
cytometry suggest that 10.000 cells are needed for good DNA analysis [34], although 
the number of events necessary is controversial. To our experience, a minimum cell num­
ber of 2000 cells can still show satisfactory DNA histograms. Due to debris, small propor­
tions of subpopulations, and the desirability of the ability to re-measure the cell suspen­
sions, it may be difficult to obtain even 2000 cells from each subpopulation. Future 
experiments which use the protocol described should reckon with the necessity of a suffi­
cient number of cells of all subpopulations. This may, however, have implications for the 
size of the biopsies and thus for the ethical aspects of such studies.
The ratio of cells co-expressing keratin 6 and keratin 10, and cells expressing keratin 
6 but not keratin 10, is different comparing the inner and outer margin. The inner margin 
of the psoriatic lesion contains relatively more cells expressing keratin 6 but not keratin 
10. This may mean that in the active region of incipient psoriatic lesions some of the 
basal cells start to hyperproliferate directly from the basal layer, without the initiation of 
a differentiation process. This pathway has been described before [14,22], but it remains 
to be studied whether this phenotypically unique subpopulation of hyperproliferative 
keratinocytes is also functionally unique and of pathogenic importance. It is well possible 
that these cells react differently to antipsoriatic therapies than those cells which co­
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express keratin 6 and keratin 10. Therapies that have shown a beneficial effect on diffe­
rentiation, such as retinoids, may stimulate normal keratinisation. It is attractive to hypo­
thesise that cells which express keratin 6 but not keratin 10 are less responsive to these 
types of treatment, and that such treatments are less effective in pathological situations 
in which this subpopulation has pathogenic relevance.
The following conclusions were drawn from the present study: 1) the proportion of 
keratin 6 and keratin 10 subpopulations depends on the stage of the psoriatic process; 2) 
the proportion of co-expressing cells and cells which only express keratin 6 is significantly 
different in the involved margin of a spreading plaque compared to the uninvolved skin, 
and 3) it is well possible that the subpopulation of cells which express only keratin 6 but 
not keratin 10 will respond differently to antipsoriatic therapies; 4) more studies are 
required to fully understand the pathogenic relevance of co-expression and single expres­
sion of keratin 6 and keratin 10.
3.2 Quantification of epidermal cell populations 
in the centre and margin of stable psoriatic plaques
Abstract
The histological picture of psoriasis has been studied extensively. Several authors have 
investigated the differences between the centre and the margin of spreading plaques, 
because the margin is of great pathogenic interest as lesions enlarge by centrifugal 
expansion. However, little is known about the differences between the centre and the 
margin of stable plaques. In the present study we investigated quantitatively the diffe­
rences between the centre and margin of stable psoriatic plaques with respect to diffe­
rentiation, inflammation and proliferation. To quantify these parameters, we used flow 
cytometry. From nine patients with nonspreading, stable psoriasis, we obtained punch 
biopsies from the centre and from the lesional margin of a plaque, and performed a flow 
cytometric assessment, using the markers keratin 10 for differentiation, vimentin for 
inflammation, and TO-PRO-3 iodide for proliferation. We found that the quantitative 
parameters showed a large interindividual variability, and that there was no significant 
difference in the quantitative parameters for inflammation and proliferation between the 
centre and margin of stable plaques. However, the percentage of differentiated cells was 
significantly higher in the margin than in the centre. We conclude that there is a great 
heterogeneity within stable psoriatic plaques with respect to differentiation, inflamma­
tion and proliferation, but further quantitative studies are needed to substantiate the 
pathogenic relevance of the significant difference in keratinisation between the centre 
and the margin of stable psoriatic plaques.
Introduction
Histological and biochemical abnormalities in psoriasis have been studied for decades 
and are well documented. Several authors have investigated the histological appearance 
of the margin of early and spreading lesions. The margin is of great pathogenic interest 
as lesions enlarge by centrifugal expansion [35-39]. The psoriatic plaque in itself has a 
considerable heterogeneity. In stable plaque psoriasis, hot spots and cold spots indica­
ting active and chronic foci are present in a random pattern [40-43]. However, the 
common belief is that the margin of psoriatic plaques as a whole is an active site, not 
only in relapsing psoriasis, but also in patients with stable plaque psoriasis [44-48]. 
Several histological and immunohistochemical studies have been performed to investiga­
te the differences between the centre and the involved edge of stable psoriatic plaques 
[49-51]. However, quantitative data to support these differences are sparse.
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The aim of the present study was to quantify epidermal cell characteristics in the centre 
and the lesional margin of stable psoriatic plaques. We confined our study to the most 
well established hallmarks of the epidermis of the psoriatic lesion; epidermal prolifera­
tion, keratinisation, and inflammation. Thus the differences between the centre and the 
lesional margin of clinically stable plaques were evaluated with respect to inflammation 
(vimentin-positive cells), differentiation (keratin 10-positive cells) and proliferation (per­
centage of keratin 10-negative cells in the SG2M-phase).
We used flow cytometry, which has been proved to be a reproducible method of quan­
tifying epidermal cell characteristics, both in psoriatic and in normal skin [52-54]. 
Recently, an optimised triple parameter flow cytometer assessment has been developed 
to quantify proliferation, differentiation and inflammation in human skin [27]. In the 
present study, we used vimentin, which is expressed by all inflammatory cells, as a marker 
of inflammation. The monoclonal antibody Vim3B4 against vimentin permitted quantifi­
cation of the number of non-keratinocytes. To quantify keratinisation, we determined the 
proportion of keratin 10-positive cells. Keratin 10 is a protein expressed by suprabasal 
keratinocytes [9]. The monoclonal antibody RKSE60 is directed only against keratin 10 
[18]. As an indicator of epidermal proliferation we determined the proportion of basal 
cells in the SG2M-phase from DNA histograms, which were obtained using the DNA 
fluorochrome TO-PRO-3 iodide [27].
Materials and methods
Subjects and biopsy procedure 
After the ethics committee had given approval for the present study, nine psoriasis 
patients (five male, four female) with chronic stable plaque psoriasis were recruited. Their 
age was 48 ± 13 years (mean ± SD), ranging from 33 to 71 years. All the patients had 
given informed consent prior to the study. Each patient had at least one psoriatic lesion 
with a diameter of at least 2 cm, which had not spread during the previous 2 weeks. Pin­
point papules around a lesion were considered to be a sign of a spreading lesion, and 
therefore an exclusion criterion. Other exclusion criteria were: topical anti psoriatic 
therapy during the previous 2 weeks, systemic anti psoriatic therapy or phototherapy 
during the previous 4 weeks, and use of medication which could have interfered with the 
psoriasis, e.g. systemic corticosteroids, B-blockers, lithium carbonate, anti malaria medica­
tion and immunosuppressants. In every patient, we determined the Psoriasis Area and 
Severity Index (PASI) using a five-point scale (0-4) for erythema, induration and 
desquamation [55], and the sum of scores for induration, desquamation and erythema of 
the test lesion.
Two 3-mm punch biopsies (Stiefel, Offenbach am Main, Germany) were taken from 
every subject after anaesthesia with lidocaine/adrenaline 1:100000; one from the centre
of a lesion, and the other from the margin. The marginal biopsy comprised exclusively 
clinically involved skin immediately adjacent to the symptomless skin.
Cell isolation procedure 
Immediately after the biopsy procedure, biopsies were stored in phosphate buffered 
saline (PBS, NPBI, Emmer-Compascuum, The Netherlands) at 5°C. In order to obtain a 
good separation of dermis and epidermis, we used an optimised thermolysin-trypsin pro­
tocol, as previously described by Glade et al. [17]. In brief; biopsies were put in 2.5 ml 
thermolysin solution (0.5 mg thermolysin (Protease type X; P-1512: Sigma, St. Louis, MO, 
USA) per ml PBS with Mg2+/Ca2) and incubated overnight at 5°C. After 16-20 h incuba­
tion, the dermis and epidermis were gently separated using fine forceps and incubated 
for 30 min in 2.5 ml 0.025% trypsin (T-8253; Sigma) and 0.3% dithioerythritol (DTE; D- 
8161; Sigma) in PBS. Then, 250 pl PBS containing 10% heat-inactivated newborn calf 
serum (HINCS; Life Technologies, Paisley, UK) was added to each skin specimen. To 
obtain a single-cell suspension, the remaining epidermis was mixed on a vortex. The stra­
tum corneum was then discarded. After centrifuging and removing the supernatant, the 
cells were fixed in 1000 pl ice-cold ethanol (70%) and stored at -20°C until staining and 
flow cytometric analysis.
Staining procedure
For flow cytometric analysis, triple staining was performed using two antibodies against 
intermediate filaments and a DNA fluorochrome. From each cell suspension sample, 
approximately 2 x 105 cells were stained. This corresponded with approximately 200 pl 
fixed cell suspension.
For studying inflammatory processes, we used the IgG2a-type mouse monoclonal 
antibody Vim3B4 (Novocastra Laboratories, Newcastle upon Tyne, UK) which is directed 
against vimentin, an intermediate filament-type protein that occurs in mesenchymal cells. 
Vim3B4 (dilution 1:15) attaches to all non-keratinocytes, that is polymorphonuclear 
leucocytes, lymphocytes, monocytes, macrophages, melanocytes and Langerhans cells. For 
flow cytometric measurement of Vim3B4, the fluorochrome fluorescein-isothiocyanate 
conjugated with monoclonal goat antibodies against mouse IgG2a was used at a dilution 
of 1:50 (GAM-FITC, Southern Biotechnology Associates, Birmingham, AL, USA).
To quantify differentiation, RKSE60 (Department of Molecular Biology, University of 
Maastricht, The Netherlands) was used at a dilution of 1:5. This IgG1-type mouse mono­
clonal antibody stains keratin 10, an intermediate filament-type protein that is expressed 
in differentiating keratinocytes. For flow cytometric analysis of RKSE60, the fluorochrome 
phycoerythrin conjugated with monoclonal antibodies against mouse IgG1 (GAM-PE, 
Southern Biotechnology Associates) was used at a dilution of 1:250.
To estimate the total amount of DNA, to obtain an indication of proliferative activity, 
we used the DNA fluorochrome TO-PRO-3 iodide (TP3, Molecular Probes, Eugene, OR,
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USA). It has been reported that this fluorochrome gives good results with only very little 
spectral overlap [27]. Although TP3 intercalates with double-stranded regions of nucleic 
acids, it also affects RNA. For this reason, we used TP3 (2 x 10'6 M ) in combination with 
RNase.
Flow cytometric analysis 
After staining, cells were measured and analysed with an EPICS Elite flow cytometer 
(Beckman Coulter, Luton, UK) with a dual laser system. An air-cooled argon ion laser at a 
power of 15 mW excited both FITC and PE at a wavelength of 488 nm. A second helium­
neon laser (10 mW, 633 nm) excited TP3. Because of the difference between the excita­
tion wavelengths of PE and TP3, spectral overlap was minimal, and easily compensated 
for electronically. Fluorescence was measured using bandpass filters at 525 nm (FITC, 
green signal), 575 nm (PE, orange signal) and 675 nm (TP3, red signal). To discriminate 
between doublets of diploid cells and real tetraploid cells, the area/peak ratio of the red 
signal (TP3, DNA) was used. Percentages of vimentin-positive, keratin 10-positive, and 
keratin 10-negative cells were calculated after setting appropriate gates and counting 
5000 gated cells. For gating, controls were measured, omitting primary antibodies. Using 
Multicycle software (Phoenix, Flow Systems, San Diego, CA, USA), the percentage of 
basal keratinocytes in the SG2M-phase of the cell cycle was calculated from DNA histo­
grams.
Statistical analysis
For statistical analysis of the differences in the three parameters between the centre and 
the margin of the lesions, we used the Wilcoxon signed rank's test for matched pairs.
Table 6 Clinical assessment of included patients.
Patient number Involved PASI Sum of scores
body area (%) of test lesion
1 1.0 4.3 6
2 1.1 4.0 6
3 0.7 3.1 5
4 0.6 4.6 7
5 0.7 4.5 6
6 1.0 4.9 6
7 1.1 3.6 5
8 0.5 3.5 8
9 1.1 6.8 8
Mean 0.9 4.4 6.3
SD 0.2 1.1 1.1
Results
Clinical assessment
The clinical assessments of the patients are summarised in Table 6. It can be seen that 
the severity of psoriasis was minimal to moderate, as indicated by the percentages of 
involved body surface and PASI. All test lesions were substantial as indicated by the sum 
of scores for erythema, induration and desquamation.
Flow cytometric assessment 
The results of the flow cytometric analysis are shown in Table 7.
Table 7 Flow cytometric data of differences between the centre and the involved margin of 
stable, non-spreading psoriatic plaques for markers of differentiation, inflammation, and 
proliferation. (*): These data were not reliable because the coefficient of variation 
of the histogram was too high.
Patient Keratin 10-positive cells (%) Vimentin-positive cells (°%) Basal cells in
number SG2M-phase (%>)
Centre Margin Centre Margin Centre Margin
1 32.8 28.5 3.6 4.6 11.4 12.0
2 30.0 52.2 1.7 1.7 13.2 9.2
3 28.3 27.2 1.7 1.0 21.5 25.9
4 26.5 36.1 2.9 2.6 14.5 14.5
5 30.2 41.4 1.0 3.0 15.7 8.2
6 32.0 33.4 2.1 2.7 8.8 14.1
7 35.1 63.8 1.4 0.7 7.1 16.8
8 15.2 18.3 1.4 1.6 * *
9 28.8 53.4 2.0 1.7 19.5 23.1
Mean 28.8 39.4 2.0 2.2 14.0 15.5
SD 5.7 14.7 0.8 1.2 5.0 6.3
P-value 0.038 0.779 0.398
Differentiation
As shown in Table 7, the proportion of keratin 10-positive cells in the centre of the lesions 
was 28.8 ± 5.7% (mean ± SD), and in the margins of lesions was 39.4 ± 14.7%. The 
range of percentages was considerable; from 15.2% to 35.1% for the centre and from 
18.3% to 63.8% for the margin. In seven of nine patients the percentage keratin 10- 
expression was higher in the margin of the lesion than in the centre. The difference 
between the central and marginal expression of keratin 10 was statistically significant 
(P<0.05).
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Inflammation
The proportion of inflammatory cells, as indicated by the percentage vimentin-positive 
cells, was 2.0 ± 0.8% with a range of 1.0 to 3.6% for the centre, and 2.2 ± 1.2% with a 
range of 0.7 to 4.6% for the margin. In four of nine patients, the proportion of vimentin- 
positive cells was higher in the margin than in the centre of the lesions. There was no 
statistically significant difference between the central and marginal percentage of vimen- 
tin-positive cells (P>0.05).
Proliferation
In the centre of the lesions, 14.0 ± 5.0% of the basal keratinocytes were in S-and G2M- 
phases, and in the margin of the lesions, 15.5 ± 6.3% of basal cells were in S- and G2M- 
phases. Percentages ranged from 7.1% to 21.5% for the centre, and from 9.2% to 25.9% 
for the margin. These percentages were based on the data from eight patients, because 
the coefficient of variation of the histogram of one patient was so high that the percen­
tage of basal cells in SG2M-phase could not be calculated. In five of eight patients, the 
percentage of cells in S- and G2M-phases was higher in the margin zone than in the 
centre. The difference between the centre and the margin with respect to proliferation 
was not statistically significant (P>0.05).
Discussion
In this study we found that quantitative parameters for differentiation, inflammation and 
proliferation showed a large interindividual variability (Table 7), although lesions were 
clinically of comparable severity (Table 6). Moreover, the variability between the margin 
and the centre of the lesions was considerable. Indeed, great heterogeneity in psoriatic 
plaques, regardless of the site within the lesions, is well established because of the 
presence of more- and less-active foci (hot spots and cold spots), which occur throughout 
a lesion [40-43,49-51,56]. However, in the present study, a statistically significant 
difference was shown between the centre and the margin with respect to the percentage 
of keratin 10-positive cells.
The percentage of suprabasal keratinocytes as indicated by the expression of keratin 
10 was significantly higher in the margin than in the centre of the lesions: the means 
were 39.4% and 28.8%, respectively. In normal skin, the value is approximately 60% 
[17,32]. A significant quantitative difference between the margin and the centre, as 
observed in the present study, has also been seen in another quantitative study. Bernerd 
et al. [57] found that in the centre of lesions less keratin 10 is expressed than in the mar­
gin. However, other qualitative studies have produced opposite results. The use of quanti­
tative methodologies in the present study and in the study by Bernerd et al. in contrast to 
the use of qualitative methodologies in previous immunohistochemical studies may
account for the differences in differentiation found between the margin and the centre. 
Our findings indicate that the margin has an intermediate position between the 
symptomless skin and the centre.
In the present study, we found no significant differences in the percentages of inflam­
matory cells, as indicated by the expression of vimentin, between the centre and the mar­
gin of stable psoriatic plaques. Neither did we find a significant difference in the propor­
tion of cells in SG2M-phase between the centre and the margin, as derived from DNA 
histograms of keratin 10-negative and vimentin-negative cells using TO-PRO-3 iodide. 
These results are in line with earlier studies on stable plaque psoriasis. For example, Beek 
and Reede [49] found no statistically significant difference with respect to 13 noted 
histopathological changes, including mitosis and inflammation, and Fry and McMinn 
[50] showed that mitotic counts in the centre and at the edge of plaques of psoriasis are 
similar in individual lesions.
Previous histological and immunohistochemical studies of the margin of psoriatic 
plaques are not easy to interpret. Most studies are qualitative, and the nature of the 
psoriatic lesions as spreading or stable is not always indicated. However, most authors 
agree that the margin zone represents the most active site, as indicated by, for example, 
a higher density of micropustules of Kogoj and microabscesses of Munro [41,45]. This 
holds true for both spreading and stable lesions. In this view, with respect to differen­
tiation, the percentage of differentiated cells as indicated by the percentage keratin 10- 
positive cells would be expected to be lower in the margin than in the centre of lesions. 
In contrast, the present study indicates that the percentage of keratin 10-positive cells is 
significantly higher in the margin than in the centre of stable psoriatic plaques. We can 
only speculate on the pathogenic relevance of the difference between the centre and the 
margin of lesions with respect to differentiation. In selecting biopsy sites in studies on 
the cellular characteristics of psoriatic plaques during treatment, it is important to be 
aware of the differences between the centre and the margin as reported in this study. 
Moreover, future quantitative studies are needed to substantiate further the relevance of 
abnormal keratinisation to the chronicity of the central area.
From the present study, the following conclusions can be drawn: 1) there is a great 
heterogeneity within stable psoriatic lesions with respect to expression of markers for pro­
liferation, inflammation and differentiation; 2) there is no difference in proliferation and 
inflammation between the centre and the involved margin of stable plaques; and 3) 
differentiation is significantly higher in the margin than in the centre of stable lesions, 
but future quantitative studies are needed to substantiate the pathogenic relevance of 
this finding.
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E F F E C T S  O F  A  N T I - P S O R I A T  I C T H E R A P I E S
4.1 Multi parameter flow cytometric assessment 
of regenerative epidermis with special reference 
to the antiproliferative effect of occlusion
Abstract
Multi parameter flow cytometrical assays permit simultaneous assessment of prolifera­
tion, differentiation, and inflammation parameters. In this study, the validation of TO- 
PRO-3 iodide (TP3) compared to propidium iodide (PI) and DE-K10 compared to RKSE60 
were evaluated in tape stripping induced hyperproliferation. No occlusion, Duoderm 
(intermediate occlusion) and Blenderm (maximal occlusion) were used as a model to eva­
luate the effect of occlusion on epidermal regeneration. Proliferation in the keratin 10- 
negative compartment measured with TP3 proved to be a good approximation of prolife­
ration measured with PI. Other epidermal subpopulations (keratin 10-dim and -bright 
cells) did not make a relevant contribution to hyperproliferation. DE-K10 is probable more 
sensitive than RKSE60 to distinguish populations that differ in degree of differentiation. 
Occlusion of tape stripped skin resulted in decreased proliferation and increased differen­
tiation. This effect was most pronounced with maximal occlusion. This study showed that 
occlusion is a therapy, which realises normalisation of hyperproliferative skin disorders.
Introduction
Human epidermis is a continuously renewing epithelium and it is known to be composed 
of subpopulations that differ with respect to proliferative and morphological characteris­
tics [1-3]. Some of these subpopulations respond rapidly after a proliferative stimulus, 
whereas others are slow responders. Flow cytometrical characterisation of epidermal sub­
populations proved to be a reproducible and quantitative approach to assess the epider­
mal changes in hyperproliferative skin [4-6]. Previously, multi parameter flow cytometry 
was used to quantify the percentages of suprabasal keratinocytes (keratin 10-positive 
cells), germinative cells (keratin 10-negative cells), and non-keratinocytes (vimentin-posi- 
tive cells). In these studies, TP3 was used to measure DNA content per cell [7,8]. 
Although this methodology proved to be adequate to estimate hyperproliferative chan­
ges, a reappraisal of the validity of this methodology with two modifications was carried 
out in regenerative skin following tape stripping with and without occlusion.
The aim of the present study was to assess characteristics of regenerative epidermis 
with special reference to the antiproliferative effect of occlusion. Therefore, the result of 
two different probes (TP3 and PI) to assess DNA distribution and two different antibodies 
(RKSE60 and DE-K10) to assess keratin 10 expression in hyperproliferative skin with and
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without occlusive treatment were compared. The in vivo model for epidermal hyperprolife­
ration was the tape stripping method. This method has been used as a standardised 
approach since 1951, and is well accepted as a procedure to induce hyperproliferation in 
normal skin [9]. With respect to the development of the flow cytometric methodology, we 
addressed the following questions: 1) To what extent is the hyperproliferative activity in 
epidermal subpopulations measured with TP3 a reflection of total proliferation as mea­
sured by PI? 2) Which antibody against keratin 10 (RKSE60 or DE-K10) has the highest 
sensitivity to distinguish epidermal subpopulations, which differ in degree of differen­
tiation? and 3) To what extent does the keratin 10-dim (weakly positive) subpopulation 
contribute to regenerative epidermal proliferation?
One of the therapeutical options for psoriasis is occlusive treatment. This therapy sti­
mulates regeneration of the disturbed granular layer [10] and reduces the mitotic rate 
[10-12], whereas immunologic abnormalities remain unchanged [12,13]. The results with 
regard to the effect of occlusion on proliferation in tape stripped human skin are not uni­
form. Whereas Van de Kerkhof et al. found no differences with respect to the number of 
cells in the SG2M-phase between uncovered and occluded skin 48 h after tape stripping 
[14], others showed that occlusive dressings decrease the mitotic activity of human skin 
after tape stripping [15,16]. Methodological limitations might account for this difference. 
The question with respect to antiproliferative therapy was the following: To what extent 
does the developed flow cytometric assessment permit quantification of the 
antiproliferative effect of occlusion, with a plastic film and a hydrocolloid, in regenerative 
skin following tape stripping?
Material and methods
Subjects
In this study, 8 healthy volunteers participated. This group, aged between 22 and 58 
years, consisted of two females and six males without signs or previous history of chronic 
inflammatory skin disease.
Sellotape stripping and biopsy procedures 
After informed consent and permission of the ethics committee were obtained, three 
areas on the back (about 1.5 x 2 cm) were marked with a waterproof pencil. Sellotape 
(Sellotape gb Ltd, Dunstable, UK) was applied with gentle pressure to the marked area, 
and then removed [9]. This procedure was repeated until the skin glistened. One of the 
stripped areas was left uncovered, whereas the others were occluded with an adhesive 
polyethylene film (Blenderm; 3M, Zoetermeer, The Netherlands) and a hydrocolloid 
dressing (Duoderm; ConvaTec, Woerden, The Netherlands). After 48 h local anaesthesia 
was induced with xylocaine/adrenaline 1:100000 (Astra Pharmaceutica BV, Zoetermeer,
The Netherlands), and one punch biopsy (3-mm) was taken from each tape-stripped area.
Cell isolation procedure 
The tissue was preserved in phosphate-buffered saline (PBS) until cell isolation, for maxi­
mal 8 h, as described previously [7]. In brief, the biopsies were kept in PBS (with calcium 
and magnesium) containing 0.5 mg/ml protease type x (Sigma, St. Louis, MO, USA) at 
4 °C  during 16-20 h. Subsequently, the dermis and epidermis were separated with two 
forceps, and the epidermis was incubated for 30 min at 3 7 °C  in PBS containing 0.025 
mg/ml trypsin type III (Sigma) and 0.3 mg/ml dithioerythritol (Sigma). After 10% foetal 
calf serum was added, the epidermis was gently mixed on a vortex to detach the keratino- 
cytes. After the stratum corneum was removed, the cells were resuspended and fixed in 
ice-cold ethanol (7 0 %  v/v) and stored at -20°C.
Flow cytometric analysis 
A triple-labelling technique was used to obtain simultaneously information about prolife­
ration, differentiation and inflammation in tape stripped skin with and without occlusion. 
Reference values in normal skin are 7 %  vimentin-positive cells, 40 to 5 0 %  keratin 10- 
negative cells, 50 to 60%  keratin 10-positive cells (among which are very few keratin 10- 
dim cells), and 5 to 10% basal cells in the SG2M-phase. The staining procedure was 
described previously [8]. In brief, inflammation was assessed by using Vim3B4 (Novocast- 
ra Laboratories, Newcastle upon Tyne, UK), a monoclonal antibody directed against 
vimentin. Differentiation was assessed using the monoclonal antibodies RKSE60 (a gift 
from Professor Ramaekers, Department of Molecular Biology, University of Maastricht, 
The Netherlands) and DE-K10 (ICN Biomedicals BV, Zoetermeer, The Netherlands) direc­
ted against keratin 10. The fluorochromes TP3 (Molecular Probes, Eugene, OR, USA) and 
PI (Omnilabo International BV, Breda, The Netherlands) were used for measuring DNA 
content per cell. Samples were divided into three part: one was measured with a combi­
nation of Vim3B4/RKSE60/TP3, the second with Vim3B4/DE-K10/TP3, and the last 
DNA content was measured with PI. As secondary antibodies we used goat anti-mouse 
(GAM) IgG2a conjugated with fluorescein-isothiocyanate (FITC) (Southern Biotechnology 
Associates, Birmingham, AL, USA) and goat anti-mouse IgG1 conjugated with phyco- 
erythrin (PE) (Southern Biotechnology Associates) binding to Vim3B4 and RKSE60/DE- 
K10, respectively.
A sample containing about 2 x 105 cells was taken from each cell suspension, and 
washed with PBS. The suspension was centrifuged during 5 min at 3000 rpm. Subse­
quently, 150 pl Vim3B4 (diluted 1:15 in PBS) and 150 pl RKSE60 (diluted 1:5 in PBS) or 
150 pl DE-K10 (diluted 1:100 in PBS) were added, and the suspension was incubated in 
the dark for 30 minutes at room temperature. Subsequently, the cells were washed with 
PBS containing 1%  heat-inactivated newborn calf serum (HINCS) and centrifuged. A solu­
tion of GAM-FITC (diluted 1:50), GAM-PE (diluted 1:250), normal goat serum, and
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PBS/HINCS was added. After incubation on ice for 15 min, the cells were washed with 
PBS/HINCS, centrifuged and resuspended in 300 pl PBS containing TP3 (2 x 10-6 M) and 
50 pl 1%  RNase solution. DNA-content per cell was also measured with PI (20 mg/ml) 
for all samples.
An EPICS® Elite flow cytometer (Beckman Coulter, Luton, UK) was used to measure 
5000 gated cells. An argon ion laser (15 mW, 488 nm) excited FITC and PE, and a 
helium-neon laser (10 mW, 633 nm) excited TP3. Bandpass filters of 515-535 nm (green, 
FITC), 555-595 nm (orange, PE), 665-685 nm (red, TP3), and a longpass filter of 630 nm 
(red, PI) were used to measure the emitted light. The area /peak ratio in the DNA-histo- 
gram was used to exclude doublets of diploid cells and gate the real single tetraploid 
cells for further analysis [17]. The percentage of cells positive for vimentin was assessed 
by using gates. With respect to keratin 10, cells were classified by gates as negative, dim 
(weakly positive), or bright (strongly positive) based upon their fluorescence. The percen­
tages of cells in S- and G2M-phase were determined with Multicycle™ software (Phoenix 
Flow Systems, San Diego, CA, USA). This program can be used to derive cell cycle parame­
ters from DNA content histograms. The method is based upon recognising that the cell 
cycle histogram is produced as a result of Gaussian broadening of the theoretically per­
fect distribution. By fitting the G r  and G2-peaks as Gaussian curves and the S-phase dis­
tribution as a Gaussian-broadened distribution, the underlying distribution of cells over 
the cell cycle can be recovered. The standard background subtraction, as adjusted in Mul­
ticycle™, was used. DNA-content was measured with TP3 in each of the keratin 10-sub­
populations, whereas PI was used to measure the overall DNA content, i.e. the DNA con­
tent of all subpopulations together.
Statistical analysis
Data with respect to proliferation were statistically tested with multiple regression analy­
sis, and a correlation coefficient was determined. One- and two-way repeated ANOVA 
tests were used to determine differences in number of proliferating cells. A two-way repe­
ated ANOVA test was also used to analyse differences in number of keratin 10 expressing 
and vimentin-positive cells.
Table 8 Correlation coefficients and B-coefficients for proliferation measured with TP3 in 
different epidermal subpopulations; the keratin 10-negative population (TP3N), the keratin 
10-dim population (TP3D), and the keratin 10-bright population (TP3B).
PI TP3N TP3D TP3B B-coefficient
PI 1.00 0.85* 0.40 -0.24
TP3N 0.85* 1.00 0.44* -0.20 0.846
TP3D 0.40 0.44* 1.00 0.17 -0.008
TP3B -0.24 -0.20 0.17 1.00
9«Am
-E&
TP3N TP3D
DNA-markers
TP3B
Figure 11 Proportions of cells in the S-phase measured with PI or TP3. Using TP3, the S-phase 
was assessed for the keratin 10-negative population (TP3N), for keratin 10-dim population 
(TP3D), and for the keratin 10-bright population (TP3B).
PI
Results
Proliferation characteristics (percentage of epithelial cells in S-phase) measured in the 
entire epidermal cell population with PI and those measured in different epidermal sub­
populations with TP3 are shown in Figure 11. It can be seen that proliferation in the kera­
tin 10-negative population measured with TP3 approximates proliferation in the whole 
population measured with PI. In Table 8 it can be seen that the correlation of measured 
proliferation in the keratin 10-dim and -bright population is below the level of statistical 
significance. The measured proliferation in the keratin 10-bright population has a recipro­
cal relation with that measured with PI. A multiple regression analysis showed that the B- 
coefficient of the measured proliferation in the keratin 10-dim population was so low 
that addition of the measured proliferation of this subpopulation to that of the keratin 
10-negative compartment did not result in a better approximation of the proliferation 
measured with PI (Table 8).
Differentiation characteristics were measured with both DE-K10 as well as with 
RKSE60. In the keratin 10-negative compartment, only the antibody used (p < 0.01), and 
not the kind of occlusion, made a statistically significant difference with respect to the 
percentage of measured keratin 10-negative cells (Figure 12a). This percentage was 
higher when RKSE60 was used. This observation did not hold for the keratin 10-dim 
subpopulation; in this compartment only the dressing used made a statistically signifi-
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cant difference (p < 0.01) in the number of keratin 10-dim cells (Figure 12b). Blenderm 
occlusion resulted in a lower number (p < 0.01) of keratin 10-dim cells than did Duoderm 
(means for Blenderm: 4.5 (DE-K10) /  7.9 (RKSE60) and Duoderm: 20.1 (DE-K10) /  20.0 
(RKSE60)). The number of keratin 10-dim cells in skin covered with Blenderm was also 
lower (p < 0.01) than that in uncovered skin (means for Blenderm: 4.5 (DE-K10) /  7.9 
(RKSE60) and for unoccluded skin: 21.1 (DE-K10) /  19.4 (RKSE60)). In the keratin 10- 
bright cells, both the antibody as well as the occlusion made a statistically significant dif­
ference (p < 0.01 and p < 0.05, respectively); when DE-K10 was used the number of 
bright cells was higher than with the use of RKSE60 (Figure 12c). Occlusion with Duo­
derm resulted in a lower percentage (p < 0.05) of keratin 10-bright cells than occlusion 
with Blenderm (means for Duoderm: 47.3 (DE-K10) /  38.8 (RKSE60) and for Blenderm:
70.8 (DE-K10) /  63.4 (RKE60)). In comparing Blenderm to unoccluded skin, the number 
of keratin 10-bright cells was lower (p < 0.05) in unoccluded skin (means for Blenderm:
70.8 (DE-K10) /  63.4 (RKSE60) and for unoccluded skin: 48.3 (DE-K10) /  37.4 
(RKSE60)).
Assessment of proliferation (cells in the SG2M-phase) in the keratin 10-negative com­
partment showed that neither the antibody nor the kind of dressing made a statistically 
significant difference in the number of proliferating cells (Figure 13a). Concerning exclu­
sively the S-phase cells, a difference in the percentage of these cells, caused by different 
dressings, was found in the cells stained with DE-K10 (p < 0.01) but not in those stained 
with RKSE60 (Figure 13b). In the DE-K10-group, the unoccluded skin contained more (p <
0.01) cells in S-phase than skin occluded with Duoderm or Blenderm (means for Duo­
derm: 11.4, for Blenderm: 7.9, and for unoccluded skin: 26.7).
Inflammation parameters were not statistically significant different in the occluded 
and unoccluded groups and were of the same magnitude as in normal skin.
DE-K10 DE-K10 DE-K10 RKSE60 RKSE60 RKSE60 
Duoderm Blenderm Unocccluded Duoderm Blenderm Unocccluded
Figure 12a Proportions of keratin 10-negative cells of unoccluded and occluded skin with Duo­
derm or Blenderm, 48 h after tape stripping. Assessment was performed using both RKSE60 and 
DE-K10.
eu
O
*
DE-K10
Duoderm
DE-K10
Blenderm
DE-K10
Unocccluded
RKSE60
Duoderm
RKSE60
Blenderm
RKSE60
Unocccluded
Figure 12b Proportions of keratin 10-dim cells of unoccluded and occluded skin with Duoderm 
or Blenderm, 48 h after tape stripping. Assessment was performed using both RKSE60 
and DE-K10.
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DE-K10 DE-K10 DE-K10 RKSE60 RKSE60 RKSE60 
Duoderm Blenderm Unocccluded Duoderm Blenderm Unocccluded
Figure 12c Proportions of keratin 10-bright cells of unoccluded and occluded skin with Duo- 
derm or Blenderm, 48 h after tape stripping. Assessment was performed using both RKSE60 and 
DE-K10.
DE-K10 DE-K10 DE-K10 RKSE60 RKSE60 RKSE60 
Duoderm Blenderm Unocccluded Duoderm Blenderm Unocccluded
Figure 13a Proportions of keratin 10-negative cells in the SG2M-phase of unoccluded and 
occluded skin with Duoderm or Blenderm, 48 h after tape stripping.
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0
Figure 13b Proportions of keratin 10-negative cells in the S-phase of unoccluded and occluded 
skin with Duoderm or Blenderm, 48 h after tape stripping.
Discussion
In the present study, proliferation and differentiation characteristics in epidermal sub­
populations of normal skin, uncovered or covered with one of the two kinds of dressing, 
were assessed 48 h after tape stripping. The subpopulations were defined by their diffe­
rent expression of keratin 10, and measured with two antibodies; DE-K10 and RKSE60.
PI has been used widely for a long time in order to measure proliferation [18-20]. In 
this study, we demonstrated that proliferation in the keratin 10-negative, vimentin-nega- 
tive epidermal compartment as measured with TP3 is a good approximation of prolifera­
tion in the total compartment as measured with PI. Proliferation measured in the keratin 
10-dim and -bright compartment did not make a substantial contribution to this approxi­
mation. This can be explained by the fact that the number of keratin 10-dim cells is very 
low so that they do not have an important contribution to proliferation. The keratin 10- 
bright cells, differentiated cells that have lost the ability to divide, were not supposed to 
divide any more, which was seen in the DNA-histograms that were unreliable because of 
high coefficients of variation (CVs). Probably this is a matter of false positive results with 
TP3 caused by different binding properties resulting in a high CV for differentiated cells, 
which was not seen with the use of PI. Although the keratin 10-dim population might 
play a role in some phase of epidermal regeneration, the present study suggests that the
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keratin 10-dim population is irrelevant in stimulated hyperproliferation after tape strip­
ping. Proliferation in the keratin 10-bright compartment also proved to be not relevant in 
this context. This means that it is not necessary to measure proliferation after tape strip­
ping in all cells: only proliferation in the keratin 10-negative compartment is relevant.
The percentage of keratin 10-negative cells in S-phase only differed between un­
occluded, Blenderm and Duoderm occluded skin measured with DE-K10 and not in those 
measured with RKSE60. This phenomenon can be explained by the fact that the keratin 
10-negative population as measured with DE-K10 is smaller and thus more accurate, i.e. 
only comprises negative and no dim cells. This implies that the percentage of S-phase 
cells is higher, so that in this population the kind of occlusion makes a difference: the 
more occlusive the dressing, the less cells in S-phase were present.
In contrast to the cells in S-phase, no differences between occluded and unoccluded 
stripped skin were found in the SG2M-compartment. This can be explained by the syn­
chronising effect of tape stripping on recruited cells; all cells are in S-phase and none of 
them has already reached G2-phase 48 h after tape stripping. From previous studies it is 
known that hyperproliferation is induced in normal skin 40 to 48 h after tape stripping 
[7,14,21,22]. The statistically significant effect that was seen in the S-compartment could 
not be shown in the SG2M-compartment, because addition of G2-cells did not make a 
relevant contribution and only diluted the effect of the difference in the S-compartment.
The number of cells in the different subpopulations (less keratin 10-negative cells, 
more bright cells, and the same number of dim cells) measured with DE-K10 can be an 
indication that this antibody detects positive cells in a more sensitive way than RKSE60 
does. The number of negative cells is lower, because the most fluorescent cells of this 
population are classified as dim cells. As the most fluorescent dim cells were classified as 
bright cells, the percentage of dim cells remains the same as with RKSE60. Another possi­
ble explanation is that DE-K10 causes more aspecific staining, as a result of which more 
cells would be false positive. Although it is not clear which of these explanations is the 
right one, it can be assumed that DE-K10 has no additional value in the determination of 
the keratin 10-dim population. With respect to occlusion, the differences in the keratin 
10-dim and -bright compartment are between unoccluded or partially occluded (Duo- 
derm) skin and maximal occluded (Blenderm) skin. The lower number of keratin 10-dim 
cells and the higher number of bright cells may be caused by the inhibitory effect of 
Blenderm on cell turnover; cells remain longer in the epidermis, so they have more time to 
synthesise keratin 10 and the amount of keratin 10 per cell increases. This effect was not 
seen with the less occlusive Duoderm and in unoccluded skin.
Inflammation characteristics in this study were not different between unoccluded and 
occluded skin. This was also found by earlier studies [12,13].
Data with respect to proliferation and differentiation characteristics show that prolif­
eration parameters are more responsive to occlusion than differentiation parameters. 
Unoccluded skin and Blenderm (maximal occlusive) are the extremes in the spectrum of
occlusion, whereas the partially occlusive dressing Duoderm is intermediate between 
these two. Differences in number of proliferating cells were already present in samples 
covered with Duoderm (intermediate occlusion), whereas differences in percentage of dif­
ferentiated cells were only present in samples covered with Blenderm (maximal occlusion).
It is known that psoriatic skin contains relatively less differentiated cells [7] and more 
proliferative cells than normal skin, although the total number of both cell populations 
per unit of surface is increased. The beneficial effect of occlusive treatment on various 
skin diseases, such as psoriasis is well-known; occlusion stimulates regeneration of the 
disturbed granular layer [10], and reduces the mitotic rate [10-12]. The inhibitory effect 
of occlusion on proliferation was shown before in animal skin. A previous study in mice 
reported that occlusion inhibited the proliferative response after tape stripping [23]. Just 
as in the present study, water vapour-impermeable foil prevented increase in DNA synthe­
sis more than did partially occlusive wraps, which were more effective than the vapour- 
permeable foil. The results with regard to the effect of occlusion on tape stripped human 
skin are not uniform. Van de Kerkhof et al. found no differences with respect to number 
of cells in the SG2M-phase between uncovered and occluded skin 48 h after tape strip­
ping [14]. This is in contrast with the findings of Fischer et al.; they showed that occlusive 
dressings decreased the mitotic activity of human skin 72 h after tape stripping [15]. The 
inhibitory effect of occlusion on mitotic activity in stripped skin was also found in 
another study [16]. In contrast to the present study, Fischer et al. showed that the mate­
rial need not to be highly occlusive, as the adhesive backing was equally effective as 
occlusive dressing, porous (semi-occlusive) tape and plastic film in inhibiting mitotic rate 
[24,25].
From the results of this study, it can be concluded that multi parameter flow cyto­
metry is an adequate approach to evaluate epidermal proliferation and differentiation in 
vivo. Occlusion causes a decrease of stimulated hyperproliferation compared to unocclu­
ded skin. In this respect Blenderm is more effective than Duoderm. This beneficial effect 
was also seen in markers of differentiation: the number of keratin 10-bright (differentia­
ted) cells was the highest in skin samples that were covered with Blenderm. Therefore, it 
can be concluded that occlusion, especially maximal occlusion, causes normalisation of 
hyperproliferative skin.
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4.2 The influence of tacalcitol on cell cycle kinetics of 
human keratinocytes following standardised injury
Abstract
In the last few years, tacalcitol (1a,24-dihydroxy vitamin D3, TV-02) has become widely 
available for the topical treatment of psoriasis. Several studies documented its effect on 
epidermal differentiation, inflammation and proliferation. Especially the effect on epider­
mal proliferation has shown to be most substantial. This finding strongly suggests that 
the antipsoriatic effect of tacalcitol may be mediated by the normalisation of epidermal 
cell cycle kinetics. Aim of the present study was to investigate the effect of tacalcitol 
ointment (4 pg/g) compared with the ointment base on epidermal proliferation following 
tape stripping. In particular, we addressed the question to what extent tacalcitol influen­
ces the recruitment of G0 cells after standardised injury. In 15 healthy volunteers, Sellota- 
pe™ stripping of the epidermis was performed at two places on the lower back. Then, 
tacalcitol ointment (4 pg/g) and the ointment base were applied on the lesions and 
covered by a semiocclusive dressing. Punch biopsies of the lesions were obtained at 24, 
32, 38, 44, 50, and 56 h after tape stripping. Using a flow cytometric staining procedure 
with parameters for epidermal proliferation (DNA content), differentiation (keratin 10 
expression) and nonmesenchymal cells (vimentin expression), quantitative data were 
obtained. There was a statistically significant difference between the time intervals for 
tacalcitol and placebo with respect to the percentage of recruited basal cells in S-phase: 
The peak of recruited basal cells in S-phase was seen at 38 h for the placebo treated 
lesions, whereas this peak was seen at 50 h for the tacalcitol treated lesions. There was 
no significant difference in the total number of recruited cells between tacalcitol and 
placebo. The influence of tacalcitol on epidermal keratinisation and on the percentage of 
nonkeratinocytes did not show any significance compared to placebo. We concluded that 
the mode of action of tacalcitol on proliferation is mainly through an extension of the 
cell cycle time of keratinocytes and/or an extension of the duration of the recruitment 
process of cycling cells, whereas the ability to suppress recruitment of resting keratino- 
cytes is not different from placebo. Moreover, because of the limited effect of tacalcitol 
on epidermal keratinisation, combination treatments with agents which interfere with 
keratinisation and/or inflammation may be attractive.
Introduction
Tacalcitol (1a,24-dihydroxy vitamin D3, TV-02) is a vitamin D3 derivative which has been 
developed for the treatment of psoriasis during the last decade. The drug is now
available in Japan, the UK, Germany, Switzerland and several other European countries 
for the topical treatment of this disease [26]. Several in vitro and in vivo studies showed 
the effect of tacalcitol on epidermal proliferation and differentiation, and the effect on 
inflammatory processes in skin [8,27-32]. Especially the effect on epidermal proliferation 
has shown to be most substantial [8,27,31]. This finding strongly suggests that the 
antipsoriatic effect of tacalcitol may be mediated by the normalisation of epidermal cell 
cycle kinetics.
An epidermal injury, such as stripping of the epidermis with Sellotape™, results in a 
recruitment of resting keratinocytes (keratinocytes in G0-phase of the cell cycle), an event 
which is also seen in psoriasis [33]. Therefore, tape stripping of the healthy human skin 
provides a useful model to study the effects of topical drugs on the proliferative aspects 
of psoriasis [5,16,33-35].
In the present study, we assessed the effect of tacalcitol ointment (4 pg/g) compared 
with the ointment base on epidermal proliferation following tape stripping. In particular, 
we addressed the question to what extent tacalcitol influences the recruitment of G0- 
cells: does tacalcitol extend the cell cycle time, does tacalcitol reduce the number of cells 
recruited from the G0-phase, or is its antiproliferative effect caused by a combination of 
these two effects? Moreover, we assessed how epidermal differentiation is modulated, 
and how the percentage of nonkeratinocytes is influenced by topical application of tacal­
citol after standardised injury. We used flow cytometry as the methodology to quantify 
these data. Flow cytometry has proved to be an accurate and reproducible method for 
both the assessment of cell cycle characteristics and the quantification of differentiation 
parameters and percentages of nonkeratinocytes [4,8,17,36,37].
Materials and methods
Subjects and biopsies
Fifteen paid volunteers, 7 males and 8 females, were included in the present study after 
they had given informed consent. The age ranged from 19 to 47 years, with a mean of 25 
years. All subjects were healthy with no signs or history of skin disease. On the lower 
back of each volunteer, two sites were tape stripped using Sellotape™ until the surface 
was glistening. After the tape strip procedure, tacalcitol ointment (4 pg/g, supplied by 
Hermal, Reinbek, Germany) was applied on the first stripped site, and the ointment base 
(placebo, Hermal) was applied on the second site. In order to keep the ointments in 
place, a semiocclusive dressing was applied. For this purpose, we used Tegaderm™ (3M, 
Borken, Germany) which is the least occlusive dressing available. Biopsies from the 
lesions were obtained 24, 32, 38, 44, 50 and 56 h after tape stripping, but for ethical 
reasons, each subject was only biopsied at two time intervals. After the first arranged 
time interval, subjects returned to our outpatient department. At that time, the Tegaderm
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was removed and the lesion was cleaned with chlorhexidine. Hereafter, a 3-mm punch 
biopsy (Stiefel, Offenbach am Main, Germany) was taken from each lesion, after local 
anaesthesia with xylocaine/adrenaline 1:100000. After the biopsies had been taken, the 
verum and placebo were reapplied and again covered with Tegaderm until the second 
and final biopsy. After another arranged time interval, subjects returned again, and the 
biopsy procedure was repeated. With this method, we obtained 5 sets of biopsies (verum 
and placebo) for each time interval.
Cell isolation, staining procedure and flow cytometric assessment 
Immediately after the biopsy procedure, biopsies were stored in phosphate buffered 
saline (NPBI, Emmer-Compascuum, The Netherlands) at 5 °C . We used an optimised 
thermolysin-trypsin protocol in order to obtain a single epidermal cell suspension, as 
previously described in detail by Glade et al. [7]. After this procedure, cells were fixed in 
ice-cold ethanol (70 % ) and stored at -20°C until staining and flow cytometric analysis.
For flow cytometric analysis, a triple staining was performed, using a DNA fluoro- 
chrome and two antibodies against intermediate filaments [8]. From each cell suspension 
sample, approximately 2 x 105 cells were stained.
In order to estimate the total amount of DNA, and thus to measure proliferative acti­
vity, we used the DNA fluorochrome TO-PRO-3 iodide (TP3, Molecular Probes, Eugene, 
OR, USA) [38]. Although TP3 intercalates with double-stranded regions of nucleic acids, 
it also affects RNA. For this reason, we used TP3 (2 x 10'6 M) in combination with RNase.
For studying the influence of tacalcitol on nonkeratinocytes in the tape-stripped skin, 
we used the IgG2a-type mouse monoclonal antibody Vim3B4 (Novocastra Laboratories 
Ltd., Newcastle upon Tyne, UK) which is directed against vimentin, an intermediate fila­
ment-type protein that occurs in mesenchymal cells [39-41]. Vim3B4 (dilution 1:15) 
attaches to all nonkeratinocytes, i.e. to polymorphonuclear leucocytes, lymphocytes, 
monocytes, macrophages, melanocytes and Langerhans cells. To quantify the effect of 
tacalcitol on epidermal keratinisation, RKSE60 (Department of Molecular Biology, Univer­
sity of Maastricht, The Netherlands) was used at a dilution of 1:5. This IgG1-type mouse 
monoclonal antibody stains keratin 10, an intermediate filament-type protein that is 
expressed in suprabasal keratinocytes [7,40]. The second step of the indirect immunofluo- 
rescent staining was performed with goat antibodies against mouse IgG2a and IgG1, 
conjugated to fluorescein isothiocyanate (1:50) and phycoerythrin (1:250) respectively 
(Southern Biotechnology Associates, Birmingham, AL, USA). The specificity and cross 
reactivity of these second stage reagents have been described before [7,38].
An EPICS® Elite flow cytometer with a dual laser system (Beckman Coulter, Luton, 
UK) was used to measure and analyse the stained cells. The percentage of basal keratino­
cytes in S-phase of the cell cycle was calculated from DNA histograms, using ModFit™ 
software (Verity Software Inc., Topsham, ME, USA). Percentages of vimentin-positive cells 
and keratin 10-positive cells were calculated after setting gates and counting
TP3 (DNA) ----
Figure 14 Applied method for calculating the number of recruited cells. If the mean peak of 
G0 was on PMT4 channel K (representing DNA content), a 'mid S window' was created at the 
V/2*K ± 5 channels.
approximately 10,000 gated cells, using WinList™ software (Verity Software Inc.).
For gating, controls were measured, omitting primary antibodies.
Additional analysis
In order to calculate the sum of recruited G0-cells, we adapted the method as described 
in detail by Boezeman et al. [5]. In short, a ‘window' was selected in the histograms 
(Figure 14). This window was set relative to the position of the peak of diploid cells 
(G0/G ]). If the peak of the diploid cells was located at channel K, the window was set at 
1'/2*K ± 5 channels (mid S window), assuming that at a distance of 2*K the G2-phase 
occurs, and that the mid S-phase is situated between these two peaks. The WinList 
software showed the percentages of basal cells, on which the histograms had been
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based, and calculated the number of cells in the mid S window. In order to calculate the 
number of cells in the mid S window based upon an equal number of basal cells 
(10,000), we converted the calculated number of cells in the mid S window by multi­
plying it with a factor (100/percentage of basal cells for each histogram).
Statistical analysis
For estimating the significance of the percentages of cells in S-phase, the percentage of 
keratin-10-positive cells and the percentage of vimentin-positive cells, we used the 
analysis of variance test. If this appeared to be significant, we performed a post-hoc com­
parison as well, using the Duncan multiple-range test.
Results
The results of the present study are shown in Table 9. The cross-effect between the time 
intervals on the one hand and the use of placebo and tacalcitol on the other hand, with 
respect to the percentages of cells in S-phase, was significant (p<0.05). A post-hoc com­
parison with the Duncan test showed that the percentages of cells in S-phase for both 
placebo and tacalcitol between 24 and 38 h, 38 and 50 h, and 24 and 50 h were signifi­
cant (p<0.05). This can also be seen in Figure 15, in which the mean percentages of 
basal cells in S-phase ± SEM are depicted. This figure clearly shows that the tape-stripped 
lesions treated with placebo show a peak of the cells in S-phase after 38 h, whereas the 
lesions treated with tacalcitol show this peak only after 50 h.
Table 9 Mean percentages ± SEM of cells in S-phase, keratin-10-positive cells, and vimentin-positive cells for 
different time intervals after standardised injury.
t=24 hours t=32 hours t=38 hours t=44 hours t=50 hours t=56 hours
placebo tacalcitol placebo tacalcitol placebo tacalcitol placebo tacalcitol placebo tacalcitol placebo tacalcitol
%  Cells 
in S-phase
6.3 ± 0.7 4.4 ± 0.9 12.3 ± 3.6 6.2 ± 1.3 28.2 ± 6.1 17.8 ± 7.8 19.5 ± 5.3 18.7 ± 4.9 18.0 ± 4.0 26.6 ± 5.2 23.4 ± 0.8 19.5 ± 0.6
%  Keratin 
10-pos. cells
73.9 ± 3.5 69.5 ± 2.6 68.8 ± 8.6 66.3 ± 9.9 50.6 ± 3.7 58.7 ± 5.2 62.5 ± 5.0 56.4 ± 6.2 61.5 ± 4.7 61.5 ± 7.8 69.3 ± 8.3 71.2 ± 10.1
%  Vimentin- 
pos. cells
0.3 ± 0.1 0.4 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.6 ± 0.3 0.3 ± 0.1 0.4 ± 0.0 0.8 ± 0.4 0.3 ± 0.1 1.1 ± 0.8 1.1 ± 1.0 1.7 ± 1.6
Cells in 
Mid-S-phase
20 ± 5.9 17 ± 6.7 70 ± 28.5 22 ± 7.9 116 ± 48.0 132 ± 69.6 92 ± 28.4 185 ± 90.2 85 ± 43.2 141 ± 59.5 241 ±143.1 364 ± 71.0
Regarding the percentages of keratin-10-positive cells, no significant difference could be 
observed between the placebo- and verum treated lesions. However, a trend towards a 
slight decrease of both placebo- and verum-treated lesions can be observed between 38 
and 44 h, as depicted in Figure 16.
With respect to the percentages of nonkeratinocytes, as represented by the percen­
tage of vimentin-positive cells, no statistically significant differences were observed.
The cumulative number of recruited cells per 10,000 basal keratinocytes from 24 to
56 h after stripping was 2,890 for the placebo-treated lesions and 3,712 for the tacalci- 
tol-treated lesions, as shown in Table 9. The number of recruited cells between placebo 
and tacalcitol did not show a significant difference.
Discussion
The present study clearly showed that tacalcitol inhibits trauma-induced epidermal rege­
neration as represented by the percentages of cells in S-phase. The tape-stripped skin 
treated with tacalcitol showed a recruitment of cycling cells with a maximum 50 h after 
the standardised injury, whereas the placebo-treated injured skin showed a maximum of 
recruited cells already after 38 h. The peak at 38 h as seen in the placebo-treated group 
is in line with the proliferative behaviour of normal untreated keratinocytes after tape 
stripping [5]. Moreover, the present study showed that tacalcitol does not suppress the 
total number of recruited resting keratinocytes as compared with placebo, as there was 
no significant difference between the cumulative number of cells in mid S-phase per
10,000 basal keratinocytes for verum- and placebo-treated lesions. This suggests that the 
ability of tacalcitol to inhibit epidermal proliferation is mainly based on an extension of 
the cell cycle time and/or an extension of the duration of the recruitment process of 
cycling cells. This effect has also been described for other vitamin D3 derivatives [42]. 
Moreover, a similar effect has been reported for topical corticosteroids [34].
The present study did not show differences in keratin 10 expression between placebo 
and tacalcitol. This is in contrast with studies which showed that tacalcitol affects 
keratinisation to some extent [27,31,43]. However, most authors conclude that the effect 
of tacalcitol on differentiation is limited [8,29,32]. The limited bioavailability of tacalci­
tol as a result of the method we used in the present study may account for the very limi­
ted effect as shown in the present study. Both verum and placebo show a slight decrease 
in keratin 10 expression between 38 and 44 h after tape stripping. This remarkable dip in 
keratin 10 expression has also been described by de Mare et al. [21] in a tape strip model 
without the use of topical drugs. They do not have an explanation for this dip, although 
it suggests that this is an effect of the tape strip method rather than the influence of 
topical drugs.
There was no effect of tacalcitol compared with placebo on vimentin expression in
109
EFFEC
T
S 
OF 
A
N
T
I-
P
S
O
R
IA
T
IC
 
T
H
E
R
A
P
IE
S
110
EFFEC
T
S 
OF 
A
N
T
I-
P
S
O
R
IA
T
IC
 
T
H
E
R
A
P
IE
S
□ Placebo
□ Tacalcitol
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elapsed time after tape stripping (h)
Figure 15 Mean percentages ± SEM of cells in S-phase for placebo- and tacalcitol-treated 
tape stripped lesions.
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Figure 16 Mean percentages ± SEM of keratin-10-positive cells for placebo- and tacalcitol- 
treated tape stripped lesions.
the present study. The reason for this is probably the fact that after tape stripping, only 
very few mesenchymal cells remain in the epidermis. Therefore, a tape strip model may 
not be very suitable to evaluate topical treatments by flow cytometry with respect to the 
epidermal anti-inflammatory effect. The time period after stripping used in the present 
study is probably too short to attract inflammatory cells, so that the expression of vimen- 
tin positive cells remains very low. Therefore, we were not able to detect any differences 
between tacalcitol and placebo with respect to the ability to suppress inflammatory pro­
cesses.
The following conclusions were drawn from the present study: 1) The mode of action 
of tacalcitol on proliferation is mainly through an extension of the cell cycle time of kera- 
tinocytes and/or an extension of the duration of the recruitment process of cycling cells, 
whereas the ability to suppress recruitment of resting keratinocytes is not different from 
placebo. 2) The effect of tacalcitol on keratinisation is limited. 3) Flow cytometric evalu­
ation after tape stripping is not a suitable method to evaluate epidermal anti-inflamma­
tory effects of topical treatments. 4) The present study demonstrates that tacalcitol 
interferes with epidermal regeneration in vivo. Combination treatments with agents 
which interfere with keratinisation and or inflammation may therefore be attractive.
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4.3 The effect of long-term treatment with tacalcitol 
on the psoriatic epidermis
Abstract
During the last decade, novel analogues of 1a, 25-dihydroxy vitamin D3 have been 
developed for the treatment of psoriasis. Recently, the efficacy of short-term treatment 
with the novel derivative tacalcitol (1a, 24-dihydroxy vitamin D3) has been documented. 
However, data on the long-term effect of tacalcitol on psoriatic skin are sparse. In this 
study, we assessed cell characteristics of the psoriatic epidermis after treatment with 
tacalcitol for up to 24 weeks. We investigated how long-term treatment with tacalcitol 
modulates the percentages of differentiated keratinocytes, inflammation cells, and basal 
keratinocytes, and the percentage of cells in SG2M-phase in the basal cell population. 
From 11 patients who were treated with tacalcitol for up to 18 months we obtained 
single cell suspensions of a representative psoriatic lesion after 0, 8, 12, 18, and 24 
weeks of treatment. A Psoriasis Area and Severity Index was performed at each visit as 
well. Cell suspensions were stained with markers for inflammation (Vim3B4), differen­
tiation (RKSE60), and proliferation (TO-PRO-3 iodide), and analysed flow cytometrically. 
Clinically, patients improved significantly after 8 weeks of treatment. This clinical effect 
was preserved for the rest of the period of treatment with no further significant improve­
ment. Proliferative activity also decreased significantly after 8 weeks of treatment. Proli­
feration did not show further significant decrease or habituation after 12, 18, and 24 
weeks. For inflammation, no statistically reliable trends could be seen. Differentiation 
improved significantly after 8 weeks of treatment, but decreased again significantly after 
12 weeks. In the period from 12 to 24 weeks, no further significant change was observed. 
We conclude that tacalcitol is an effective antipsoriatic drug. Prolonged treatment with 
tacalcitol will generally maintain improvement at the level reached after 8 weeks. Due to 
the beneficial effect on both clinical state and proliferation, tacalcitol is likely to be an 
adequate maintenance therapy.
Introduction
Since the emergence of vitamin D3 as an important therapeutic factor in psoriasis, novel 
analogues of 1a,25-dihydroxy vitamin D3 (calcitriol) have become available. Recently, the 
efficacy of tacalcitol (1a,24-dihydroxy vitamin D3) has been documented [44]. Previous 
in vitro investigations have already demonstrated that the growth of keratinocytes is pro­
foundly inhibited and that epidermal differentiation is induced by tacalcitol
[31,32,43,45,46]. It has also been shown that epidermal growth is inhibited by tacalcitol 
during treatment of psoriasis [8,29,31]. In clinical studies, changes in proliferative 
activity, and in differentiation and inflammation resulting from tacalcitol have been 
described after 8 weeks [8,29]. Although several studies have documented the efficacy of 
tacalcitol as a short-term treatment, data on the long-term effect of tacalcitol on psoria­
tic skin are sparse. The aim of the present study was to assess cell characteristics of the 
psoriatic epidermis after prolonged treatment with tacalcitol, using multiparameter flow 
cytometry with markers for epidermal inflammation, differentiation, and proliferation 
[47].
Materials and methods
Subjects, biopsies, and cell isolation procedure 
After giving informed consent, 11 patients (nine men and two women, aged 52 ± 3.9 
years (mean ± SEM)) with an active plaque psoriasis were included in the present study. 
At least 7 %  but not more than 20%  of the total body area was involved. They had not 
received any topical treatment for at least 2 weeks before study enrolment, no retinoids 
for the last 12 months, and no photochemotherapy or systemic therapy for psoriasis for at 
least 6 weeks.
Patients were treated once daily with tacalcitol ointment at a concentration of 4 
pg/g (supplied by Hermal, Reinbek, Germany) for up to 18 months. At every visit, the cli­
nical effect was assessed using the Psoriasis Area and Severity Index (PASI) [48]. Only 
patients who had a clinical improvement of more than 3 0 %  after 12 weeks continued 
treatment. After 0, 8, 12, 18, and 24 weeks, 3-mm punch biopsies (Stiefel, Offenbach am 
Main, Germany) were taken from a representative lesion after local anaesthesia with xylo- 
caine/adrenaline 1:100000. After biopsies were taken, single-cell suspensions were 
obtained using an optimised thermolysin-trypsin protocol, as described previously by 
Glade et al. [7]. Cells were fixed in 7 0 %  ethanol and stored at -20°C until use.
Staining procedure and flow cytometric analysis 
For flow cytometrical analysis, a triple staining was performed. From each cell suspension 
sample, approximately 2 x 105 cells were stained. The procedure has been described in 
detail before [8]. The IgG2a-type mouse monoclonal antibody Vim3B4 (Novocastra Labo­
ratories, Newcastle upon Tyne, UK) was used for quantifying inflammation in a 1:15 
dilution. Vim3B4 is directed against vimentin, an intermediate filament-type protein that 
occurs in all mesenchymal cells [39-41]. To assess epidermal differentiation, RKSE60 
(Department of Molecular Biology, University of Maastricht, The Netherlands) was used in 
a dilution of 1:5. This IgG1-type mouse monoclonal antibody stains keratin 10, an inter­
mediate filament-type protein that is only expressed in suprabasal keratinocytes [7,40].
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The second step of the indirect immunofluorescent staining was performed with goat 
antibodies against mouse IgG2a and IgG1, conjugated to fluorescein isothiocyanate 
(GAM-FITC, 1:50) and phycoerythrin (GAM-PE, 1:250), respectively (Southern Biotechno­
logy Associates, Birmingham, AL, USA). The specificity and cross-reactivity of these 
second-stage reagents have been described before [7,38]. We used the DNA fluorochrome 
TO-PRO-3 iodide (2 x 10'6 mol/L, TP3, Molecular Probes, Eugene, OR, USA) to measure 
DNA content and, thus, to measure proliferative activity. An EPICS Elite flow cytometer 
with a dual laser system (Beckman Coulter, Luton, UK) was used to measure and analyse 
the stained cells. Percentages of vimentin-positive cells, keratin 10-positive cells, and 
keratin 10-negative cells were calculated after setting gates and counting 5000 gated 
cells. For gating, controls were measured omitting primary antibodies. Using 3-mm biop­
sies, rather low cell numbers can be obtained and therefore we measured only 5000 cells. 
Larger biopsies were not taken for ethical reasons. The percentage of basal keratinocytes 
in SG2M-phase of the cell cycle was calculated from DNA histograms, using Multicycle 
software (Phoenix Flow Systems, San Diego, CA, USA).
Statistical analysis
In order to determine the statistical reliability of this study, we used the One Way 
Repeated ANOVA test for each pair of data per parameter. To compare flow cytometric 
scores for the several parameters during the long-term treatment, we used the Duncan 
Multiple Range Test.
Table 10 Flow cytometrical and clinical effect of long-term treatment with tacalcitol ointment 
(4 Mg/g) (Mean ± SEM).
Week 0 Week 8 Week 12 Week 18 Week 24 P
PASI 15.8 ± 1.7 7.9 ± 1.1 6.0 ± 1.2 5.9 ± 1.0 5.7 ± 1.0 < 0.0001
Proportion of keratin 10-positive cells 33.5 ± 5.0 55.9 ± 5.4 44.3 ± 4.5 37.1 ± 3.5 35.0 ± 4.0 < 0.002
Proportion of vimentin-positive cells 5.2 ± 0.7 3.7 ± 1.1 4.6 ± 0.7 3.8 ± 0.4 6.3 ± 0.8 < 0.08
Proportion of cells in the SG2M-phase 18.0 ± 2.2 12.3 ± 1.6 9.1 ± 1.2 10.4 ± 1.2 9.3 ± 1.3 < 0.0002
Results
Clinical response
The results of long-term treatment with tacalcitol on the clinical condition of the 
patients, represented by the PASI, are shown in Table 10. Psoriatic plaques improved 
quickly, and maximum results were achieved after 8 weeks of treatment. The mean PASI 
decreased significantly from 15.8 to 7.9 during this period (P<0.0001). Prolonged treat­
ment did not show further improvement, or habituation, as there was no significant diffe­
rence between the PASI scores of week 8, 12, 18, and 24.
«u
o
co
o&o
Figure 17 Depiction of the proportion of keratin 10-positive cells and the proportion of basal 
cells in SG2M-phase after prolonged treatment with tacalcitol ointment (4 Mg/g).
Inflammation and differentiation 
Owing to a relatively large variation of flow cytometric data, no statistically reliable 
trends could be seen on inflammation. As shown in Table 10, the P-level of the collected 
data was not significant. The effect on keratinisation by tacalcitol is shown in Table 10 
and Figure 17. The percentage of keratin 10-positive cells was significantly increased from
115
EFFEC
T
S 
OF 
A
N
T
I-
P
S
O
R
IA
T
IC
 
T
H
E
R
A
P
IE
S
116
EFFEC
T
S 
OF 
A
N
T
I-
P
S
O
R
IA
T
IC
 
T
H
E
R
A
P
IE
S
33.5%  to 55.9% in the present study after 8 weeks of treatment (P<0.0006). However, 4 
weeks later, the percentage of suprabasal cells decreased to 44.3%. Again, this was a 
statistically significant change (P<0.05). In the period from 12 to 24 weeks, no further 
significant change was observed.
Proliferation
The proliferative activity of basal keratinocytes was determined using the percentage of 
cells in the SG2M-phase. The data are shown in Table 10 and Figure 17. The mean percen­
tage before treatment was 18.0%. After only 8 weeks of treatment, this percentage 
decreased significantly to 12.3% (P<0.005). Prolonged treatment with tacalcitol did not 
influence this percentage significantly: the amount of proliferating cells remained low 
and did not show further improvement or habituation.
Discussion
This study reconfirms the clinical efficacy of tacalcitol ointment as an antipsoriatic 
therapy. The 5 0 %  decrease in PASI after 8 weeks of treatment is in line with previous stu­
dies showing a decrease in PASI of 4 8 %  and 4 9 %  after a period of 8 weeks [8,29]. In a 
long-term clinical efficacy study on tacalcitol, van de Kerkhof et al. recently showed an 
immediate improvement after starting therapy, and they found maintenance of the clini­
cal effect after 4 weeks [28], which is confirmed by the present study. Moreover, they 
noticed a steadily increasing improvement from week 4 to week 20. However, we could 
not confirm this tendency, as the PASI did not change significantly in the present study 
after 12, 18, and 24 weeks of treatment. An earlier quantitative study has already shown 
that the effect of tacalcitol on inflammation is minimal [8]. The present study confirms 
that tacalcitol does not influence inflammatory processes in the epidermis significantly.
Concerning the effect of tacalcitol on differentiation, this study showed a significant 
effect shortly after starting treatment. This effect has been described earlier [8,29]. The 
proportion of keratin 10-positive cells of 55.9% after 8 weeks of treatment with tacalci- 
tol corresponds to the percentage in normal human skin and in the uninvolved skin of 
psoriasis patients [7,8,49]. It is remarkable, however, that prolonged treatment did not 
maintain this effect, as the proportion of keratin 10-positive cells and keratin 10-negative 
cells had already reverted to the pre-treatment level after 12 weeks of continued treat­
ment. The long-term persistence of the clinical effect and the effect on epidermal prolife­
ration is inconsistent with this short-term effect on differentiation. Although, at present, 
experimental proof is not available, it is attractive to hypothesise that the relapse to pre­
treatment values may be caused by habituation to the effect of tacalcitol on differen­
tiation. The active form of vitamin D3 is inactivated by 24-hydroxylation. This process is 
induced by vitamin D3 analogues. Continued treatment with tacalcitol may have
activated the hydroxylation process, undoing the effect of tacalcitol on differentiation.
In the present study, prolonged treatment with tacalcitol showed a sustained inhibi­
tory effect on the proliferation of keratinocytes, indicated by the reduced percentage of 
cells in the SG2M-phase. Such an effect confirms earlier studies in which the effect of 
tacalcitol on proliferation in vivo was always substantial [8,29]. We found a decrease of 
3 2 %  in cycling cells after 8 weeks of treatment. This is in line with the study of Glade et 
al. who found a decrease of 3 4 %  in the percentages of cells in the SG2M-phase after 8 
weeks of treatment with tacalcitol in a flow cytometric study [8]. The percentage 
decrease of cycling cells after 8 weeks of treatment was significant, although this percen­
tage did not decrease to the level of 8 .8%  found in normal human skin [8]. However, no 
objective data are available on the long-term effect of tacalcitol on proliferation. The pre­
sent study showed that the effect on proliferation was achieved shortly after starting 
therapy and that this effect persisted for months. This is in line with the reduction in the 
PASI scores, which also remained reduced without any sign of habituation.
The PASI and epidermal proliferation activity do not become habituated to the effect 
of long-term treatment with tacalcitol, but differentiation does. On the other hand, pro­
longed treatment does not influence inflammatory processes in the epidermis. Because of 
the beneficial effect on both the PASI and proliferation, tacalcitol is likely to be an ade­
quate maintenance therapy. It is interesting to speculate on the effect of combination 
therapy. As corticosteroids have a profound effect on inflammation, it may be possible to 
combine tacalcitol with topical corticosteroids. Especially during the first 8 weeks, it may 
be valuable to treat psoriasis with both corticosteroids and tacalcitol. Subsequently, pro­
longed treatment with tacalcitol may keep the improved effect at the same level. Another 
combination therapy may be the combination of tacalcitol and tazarotene. This retinoid 
has proved to be a valuable therapeutic approach to psoriasis, and it influences differen­
tiation, whereas no long-term effect on differentiation has been shown for tacalcitol. For 
this reason, long-term combination treatment with tazarotene may have an additional cli­
nical effect. Further clinical trials on these combination treatments are indicated.
We conclude that tacalcitol is an effective antipsoriatic drug. The clinical and cytome­
tric effects appear quickly and are at a maximum after 8 weeks of treatment. The effect 
after 8 weeks is representative of the total long-term effect that can be expected, and 
prolonged treatment with tacalcitol will generally preserve the improvement at the level 
reached after 8 weeks.
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4.4 Clobetasol under hydrocolloid occlusion in psoriasis 
results in a complete block of proliferation and in a 
rebound of lesions following discontinuation
Abstract
It is a well-established fact that very potent corticosteroids are highly effective in the 
treatment of psoriatic plaques, and that the addition of a hydrocolloid occlusive dressing 
(HCD) enhances its efficacy. It is known that topical steroids induce normal differen­
tiation and diminish hyperproliferation during treatment of psoriatic plaques. These chan­
ges are reflected by an increase of keratin 10 and a decrease of keratin 6 respectively. 
However, the influence of class IV corticosteroids under HCD on keratin 10 and keratin 6 
subpopulations has never been studies. The present study was performed to study quanti­
tatively the influence of a class IV topical steroid under HCD on the dynamics of keratin 
10 and keratin 6 subpopulations. In the present study we treated moderately severe 
stable psoriatic plaques with clobetasol-17-propionate under HCD until clearance was 
achieved. We took biopsies prior to treatment, after clearance, and at relapse. Using flow 
cytometry, we studied the dynamics of keratin 10 and keratin 6 subpopulations. Prior to 
treatment, 41.8% of all cells expressed keratin 6. After treatment-induced clearance, this 
proportion decreased to 1.2%. At relapse, pre-treatment levels were observed again. A 
trend of an increasing number of basal cells and an increase of the proliferative activity 
of these basal cells at relapse compared to the stable situation prior to treatment was 
observed. We concluded that clobetasol under hydrocolloid occlusion induces virtually a 
total block of proliferation of the basal cell population and decreases hyperproliferation- 
associated keratins dramatically. Furthermore, based upon epidermal cell characteristics, 
we concluded that a rebound phenomenon occurs following discontinuation of therapy 
with clobetasol under hydrocolloid occlusion.
Introduction
Topical corticosteroids are widely used for the treatment of psoriasis, a skin disorder that 
is characterised by disturbed keratinisation and hyperproliferation. Topical treatment with 
potent steroids results in an improved keratinisation and in a decrease of epidermal pro­
liferation. This effect can be enhanced by the addition of a hydrocolloid occlusive dres­
sing (HCD). Thus, even recalcitrant plaques can be treated effectively [50].
The changes in differentiation pattern as seen in psoriasis are reflected by changes in 
keratin-expression. In disturbed differentiation, the proportion of keratin 10 (K10) 
positive cells decreases [7,51]. K10 is only expressed in suprabasal keratinocytes [49].
Under hyperproliferative circumstances, the hyperproliferation-associated keratin 6 (K6) is 
upregulated [52]. K6 is expressed only in the suprabasal compartment as well [53]. In 
psoriasis, in which both differentiation is disturbed and cells are hyperproliferative, 
expression of both K10 and K6 can be observed. Moreover, it has been shown that co­
expression of K10 and K6 appears [54,55]. By using a method which simultaneously 
measures the expression of K10 and K6, four subpopulations of keratinocytes can be dis­
tinguished: a subpopulation of cells which exclusively expresses K10, a subpopulation of 
cells which exclusively expresses K6, a subpopulation of cells which co-expresses K10 and 
K6, and a subpopulation of cells which expresses neither of these two keratins [55].
Although it is known that topical steroids influence both epidermal keratinisation 
and hyperproliferation, it remains unclear which subpopulation is influenced most by ste­
roids. Furthermore, it is known that lesions treated with topical steroids tend to relapse 
quickly. It has been suggested that this may be the effect of inhibition of cell cycle 
progression, rather than the effect on the number of recruited cells from the basal com­
partment [34]. However, the effect of steroids on cells which co-express markers for both 
differentiation and hyperproliferation has never been studied. Therefore, in the present 
study we investigated to what extent clobetasol-17-propionate, a class IV corticosteroid, 
in combination with a hydrocolloid occlusive dressing influences K6 and K10 subpopula­
tions. In particular, we studied the dynamics of K6 and K10 subpopulations prior to treat­
ment with clobetasol, after clobetasol-induced remission, and after relapse. For assess­
ment of the subpopulations, we used flow cytometry.
Materials and methods
Patients and biopsy procedure 
After given informed consent, 7 patients with stable plaque psoriasis were included in 
the present study. Patients should have at least one psoriatic lesion of 16 cm2 that had 
not spread during the last few weeks. The lesion should be of moderate severity with a 
sum of scores (SUM score) for erythema, scaling and induration of at least 6 on a five- 
point scale with a minimum score of 1 for each parameter, according to the Psoriasis 
Area and Severity Index (PASI) [48]. Moreover, this lesion should not have been treated 
topically for the 4 weeks prior to study enrolment, and no phototherapy of systemic the­
rapy was allowed in the 3 months prior to the start of the study. Another exclusion crite­
rion was the use of systemic drugs which could have interfered with the psoriasis.
After inclusion, the test lesion was treated with clobetasol-17-propionate lotion (Der- 
movate® lotion, Glaxo Wellcome, Zeist, The Netherlands) under occlusion of a hydro­
colloid dressing (HCD, Duoderm extra thin®, ConvaTec, Woerden, The Netherlands). The 
HCD stayed on the lesion for a week, when patients returned to our outpatient depart­
ment for application of clobetasol lotion under HCD, until clearance was reached.
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Clearance was defined as a sum of scores for the treated lesion of less than 1. If re­
mission had not been induced after 6 weeks of treatment, patients were withdrawn from 
the study. Three 3-mm punch biopsies (Stiefel, Offenbach am Main, Germany) were taken 
from each patient: one from the stable lesion at the start of the study, one of the cleared 
lesion after effective clobetasol therapy, and one from the relapsed lesion. Relapse was 
defined as a SUM score of at least 3, with a minimum score of 1 for each parameter.
Cell suspensions and staining procedure 
For flow cytometric analysis of the biopsies, single epidermal cell suspensions were 
required, using an optimised thermolysin-trypsin protocol [7]. Than, cells were stained 
and analysed flow cytometrically. The staining procedure, which enables simultaneous 
measurement of K6, K10, and DNA content, has been described in detail before [55]. In 
short: The proportion of keratin 10-expressing cells was assessed using the IgG1 isotype 
mouse monoclonal antibody RKSE60 (Sanbio, Uden, The Netherlands) at a dilution of 
1:20 [49]. To assess the expression of keratin 6, we used the IgG2a isotype mouse mono­
clonal antibody LHK6B (Novocastra Laboratories, Newcastle upon Tyne, UK). LHK6B 
exclusively stains keratin 6 and it was used at a dilution of 1:50 [53]. The second step of 
the indirect immunofluorescent staining was performed with goat antibodies against 
mouse IgG1 and IgG2a, conjugated to phycoerythrin (GAM-PE, 1:250) and fluorescein 
isothiocyanate (GAM-FITC, 1:50) respectively (Southern Biotechnology Associates, 
Birmingham, AL, USA). For measuring the proliferative activity of the K10 and K6 sub­
populations, we used the DNA fluorochrome TO-PRO-3 iodide (2 x 10'6 M, TP3; Molecular 
Probes, Eugene, OR, USA). This DNA intercalating dye measures DNA content, and is 
therefore a marker for proliferative activity [38].
Flow cytometric assessment 
The stained cells were analysed with an EPICS® Elite flow cytometer (Beckman Coulter, 
Luton, UK) with a dual laser system. Fluorescence was measured at 525 nm (FITC), 575 
nm (PE) and 675 nm (TP3). Debris was excluded using the ratio area/peak of the red 
signal (TP3, DNA), which enables discrimination between doublets of diploid cells and 
real tetraploid cells. Gates were set after measuring controls, omitting the primary anti­
bodies, as previously described [55]. Than, using WinList software (WinList 4.0, Verity 
Software House Inc., Topsham, ME, USA), the proportion of only keratin 10-positive cells 
(A), keratin 6 /  keratin 10 co-expressing cells (B), cells which were both keratin 10 and 
keratin 6-negative (C, basal cells), and only keratin 6-positive cells (D) was calculated. 
Moreover, the sum of all keratin 10 positive cells (A+B), and of all keratin 6 positive cells 
(B+D) was calculated. Using ModFit software (ModFit LT 2.0, Verity Software House Inc.), 
the proportion of cells in the SG2M-phase of all these K6 and K10 subpopulations was 
calculated from DNA histograms.
Statistical analysis
We compared the data between the situation prior to treatment and after clearance, 
between clearance and relapse, and between the situation prior to treatment and relapse, 
using the Wilcoxon-signed rank test.
Table 1  Proportions of subpopulations (Mean %  ± SEM) prior to treatment, after 
clobetasol-induced clearance, and after relapse. Letters A-D refer to the regions as depicted in 
Figure 6d.
Pre-treatment P Clearance P Relapse
%  K10 pos. cells (A) 18.7 ± 6.6 < 0.01 66.7 ± 6.7 < 0.01 9.9 ± 4.0
%  K10 and K6 co-expressing cells (B) 29.9 ± 6.5 < 0.01 0.9 ± 0.3 < 0.01 27.0 ± 6.9
%  K10 and K6 neg. cells (basal cells, C) 39.6 ± 5.7 32.1 ± 6.7 53.3 ± 7.5
%  K6 pos. cells (D) 11.9 ± 4.9 < 0.05 0.2 ± 0.0 < 0.05 9.8 ± 1.7
%  all K10 pos. cells (A+B) 48.6 ± 9.7 67.6 ± 6.7 36.9 ± 7.2
%  all K6 pos. cells (B+D) 41.8 ± 5.2 < 0.01 1.2 ± 0.3 < 0.01 36.8 ±7.9
Results
All patients reached clearance within 6 weeks of treatment with clobetasol, and thus 
biopsies were obtained from all 7 patients before treatment, after clearance, and at 
relapse. A representative picture of the flow cytometric results is depicted in Figure 6d. In 
this figure, the four different subpopulations marked as A to D can be distinguished. The 
results of the flow cytometric analysis are summarised in Tables 11 and 12.
Table 11 shows the results of the proportion of cells expressing K10, K6, both 
keratins, and non of these keratins. It can be seen that a significant difference was 
present between pre-treatment and clearance on one hand, and between clearance and 
relapse on the other hand with respect to all subpopulations, except the K10 single­
expressing cells and the basal cells.
For any of the assessed subpopulations, the difference between the situation before 
treatment and at relapse was not significant. This holds true for the proportion of basal 
cells as well, which are the cells that did express neither keratin 10 nor keratin 6. How­
ever, a trend can be observed: the proportion of basal cells increased from 39.6%  at pre­
treatment to 53.3% at relapse. The proportion of all keratin 10-expressing cells did not 
change significantly either during the different stages of treatment, but again a trend 
was seen: after clearance, the proportion of all K10-positive cells increased from 48.6% 
to 67.6%. At relapse, the proportion had decreased again to 36.9%.
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Table 12 Proliferative activity of epidermal subpopulations, represented by the proportion of 
cells in the SG2M-phase (Mean ± SEM) prior to treatment, after clobetasol-induced clearance, 
and after clinical relapse. (a) Means that the number of measured cells was too low to perform a 
reliable DNA analysis.
Pre-treatment P Clearance P Relapse
%  K10 and K6 neg. cells in SG2M-phase 12.7 ± 2.3 < 0.01 1.2 ± 0.3 < 0.01 16.0 ± 2.6
%  All K6 pos. cells in SG2M-phase 3.5 ± 0.6 (a) 5.8 ± 1.4
%  K10 and K6 co-expr. cells in SG2M-phase 2.0 ± 0.2 (a) 3.6 ± 0.8
%  K6 pos. cells in SG2M-phase 4.5 ± 1.0 (a) 9.7 ± 3.8
Table 12 depicts the proportion of the proliferating cells in the different subpopulations. 
As can be seen in this table, only the basal cells showed a significant decrease in prolife­
ration activity after treatment with clobetasol. At relapse, their proportion had changed 
significantly again. This proportion was not significantly different from that at pre-treat­
ment, but a trend can be observed: the proportion of basal cells which were in prolifera­
tion was 12.7% prior to treatment and increased to 16.0% at relapse. The proliferative 
activity of all other subpopulations did not significantly change during the course of 
treatment. Moreover, because of the very profound effect of clobetasol under HCD on 
keratin 6 expressing cells, the number of K6-expressing cells after clearance was to low to 
perform a reliable DNA analysis. Therefore, in Table 12 no data are given for these sub­
populations after clearance.
Discussion
Clobetasol-17-propionate under hydrocolloid occlusion has shown to be very effective in 
the treatment of moderately severe psoriatic plaques. In all patients treated in the pre­
sent study, clearance was induced within 6 weeks of treatment. On the other hand, all 
patients showed a relapse of the treated lesion within an average of 4 weeks. Several 
other authors have reported both this fast response and the early re-appearance of 
lesions [56,57].
It is remarkable that in the present study the proportion of cells which expressed 
keratin 6 decreased dramatically after treatment with clobetasol under hydrocolloid 
occlusion. In fact, the proportion decreased 35-fold from 41.8% to 1.2%. This decrease 
was equally distributed over the K6-K10 co-expressing cells and the cells which exclu­
sively expressed keratin 6. The former subpopulation decreased from 29.9% to 0 .9%  and 
the latter from 11.9% to 0.2%. The remaining proportion of keratin 6-expressing cells of 
1.2% was only slightly higher than the proportion of keratin 6 expression in distant unin­
volved skin of psoriatic patients, and in normal skin of healthy volunteers, which are both 
approximately 0 .5%  [54,55]. Apparently, clobetasol is able to suppress the hyperprolife­
ration-associated keratins as seen in psoriasis almost completely. This suppression was 
reflected in a similar increase of keratin 10: after clearance-induction, the proportion of 
cells which expressed keratin 10 increased from 48.6%  to 67.6%, which is in the same 
range as the proportion as seen in normal skin of healthy volunteers [7,49].
After clearance-induction, the proportion of proliferating basal cells decreased to 
1.2%. This is far below the normal range. In normal skin of healthy volunteers, the pro­
portion of basal cells in SG2M-phase is between 2.7 and 8 .8%  [7,58]. Recently, a similar 
finding was reported in an immunohistochemical study [59]. One could speculate that 
the profound suppression of proliferation to subnormal levels destabilises the basal com­
partment of the diseased skin, and that therefore a rebound of lesions with disturbed 
differentiation and hyperproliferation will occur after withdrawal of the treatment with 
very potent corticosteroids.
The clinical relapse as seen shortly after the treatment-induced remission is also 
reflected by the changes in keratin expression: the proportion of all measured K10 and 
K6 subpopulations reversed to pre-treatment levels at the time of relapse, with no 
statistically significant differences. Thus, at the cellular level, the relapse after initial 
treatment with potent corticosteroids is complete. This is even more remarkable if one 
realises that the clinical severity at relapse was only half of that prior to treatment, as the 
definitions for inclusion and relapse with respect to the SUM score were >6 and >3 
respectively. Although not statistically significant, a trend can be observed for the propor­
tion of basal cells, at relapse compared with the pre-treatment situation: As the mean 
proportion of basal cells was 39.6%  prior to treatment, whereas this proportion was 
53.3% at relapse, it seems that in incipient lesions, erupted after clobetasol-induced cle­
arance, more basal cells are present. Moreover, the increase in the number of proliferating 
basal cells (12.7% versus 16.0%) suggests that the basal cells are also more proliferative 
at relapse than at the stable situation prior to treatment. Apparently, withdrawal of very 
potent corticosteroids after remission does not only result in a increase of the number of 
basal cells, but also in the proliferative activity of these cells, compared with the situ­
ation prior to treatment. With these trends in mind, it is feasible that after clearance- 
induction by potent corticosteroids the re-appearance of a lesion is more a rebound 
phenomenon rather than a relapse. Therefore, maintenance therapy after corticosteroid- 
induced clearance may be worthwhile in order to maintain the suppression of the hyper­
proliferative basal cells.
From the present study, the following conclusions were drawn. 1) Clobetasol under 
hydrocolloid occlusion induces a fast clinical clearance of the psoriatic plaque. 2) Clobe- 
tasol under occlusion completely blocks proliferation of the basal cell population and 
decreases hyperproliferation-associated keratins dramatically. 3) After clearance, lesions 
will re-appear within several weeks and this tends to be a rebound phenomenon. 4) 
Maintenance therapy after corticosteroid-induced clearance may be worthwhile to 
prevent a rebound.
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4.5 VML 295 (LY-293111), a novel LTB4 antagonist, is not 
effective in the prevention of relapse in psoriasis
Abstract
Leukotriene B4 (LTB4) receptor antagonists have been the subject of several studies in the 
treatment of inflammatory diseases, including psoriasis. A novel oral LTB4 antagonist, 
VML 295 (LY-293111) has recently been developed and has a pronounced effect on epi­
dermal inflammatory parameters. However, oral treatment of psoriasis for 4 weeks did 
not result in a decrease in disease severity. The present study was performed in order to 
investigate whether prolonged treatment with VML 295 up to 8 weeks has a beneficial 
effect on the overall severity of psoriasis. Moreover, we studied to what extent VML 295 
is able to prevent relapse in psoriasis. In the present study, 35 patients with stable chro­
nic plaque psoriasis were included. A representative plaque of at least 16 cm2 was 
initially treated with clobetasol-17-propionate under hydrocolloid occlusion in all 
patients. Clearance was achieved within 6 weeks in 31 patients. After clearance, the 
patients were randomised and received orally administered VML 295 capsules 200 mg 
twice daily or placebo during eight weeks. 25 Patients completed the study. The psoriasis 
area and severity index (PASI) was assessed prior to treatment, at clearance, and at days 
15, 29, 43, and 57 of the treatment period. Biopsies were taken from the treated lesion 
prior to treatment, after clearance and at relapse, and cells were analysed flow cytometri- 
cally with markers for differentiation (keratin 10), inflammation (vimentin), and prolifera­
tion (DNA content). After 8 weeks of treatment, 14 out of 15 VML 295-treated patients 
had relapsed and 11 out of 16 placebo-treated patients had relapsed. A total of 6 
patients were withdrawn. The time to relapse and the number of relapsed patients was 
not significantly different comparing the treatment groups. There was no significant 
difference in PASI scores between VML 295-treated patients and placebo-treated patients 
after 8 weeks of treatment. Flow cytometric parameters for differentiation, inflammation 
and proliferation did not show significant differences between VML 295 and placebo 
treated patients. We conclude that oral VML 295 (LY-293111) is not effective in preven­
ting relapse in psoriasis, either clinically or at the cellular level, and that in our group of 
patients VML 295 had no beneficial effect on overall psoriasis severity. Moreover, we con­
clude that further development of LTB4 modulating drugs for the treatment of psoriasis is 
not indicated.
In tro d u ctio n
Disturbed differentiation, epidermal hyperproliferation, and cutaneous inflammation are 
the most important hallmarks of psoriasis. In early psoriasis, polymorphonuclear leuco­
cytes (PMN) are attracted in large amounts into the epidermis, causing micropustules and 
microabscesses [60-62]. The invasion of PMN in the psoriatic epidermis is induced by 
several chemoattractants, which are present in the epidermis in large amounts [63,64]. 
The most potent chemoattractant is Leukotriene B4 (LTB4), a pro-inflammatory mediator 
derived from 5-lipoxygenase-dependent metabolism of arachidonic acid [65-68]. Applica­
tion of LTB4 on normal human skin results in dose-dependent induction of microabscesses 
[69-71]. Elevated levels of LTB4 have been reported in a variety of human inflammatory 
diseases, including psoriasis [68]. Several effects of LTB4 on PMN are known; it is 
involved in adhesion, chemotaxis, migration, and degranulation of PMN [66,72-75]. 
Because of its important role in inflammatory processes, inhibition of the activity of LTB4 
in order to treat inflammatory diseases has been the object of several studies during the 
last decade [76-78]. The use of LTB4 blockers has also been studied for the treatment of 
psoriasis. So far, some 5-lipoxygenase inhibitors, which reduce the availability of LTB4, 
have been studied, with mixed results: some authors claim an antipsoriatic effect [79-81], 
whereas others failed to show such an effect [82-84].
Recently, a new specific oral LTB4 receptor antagonist, VML 295 (LY-293111), was 
developed [85-87]. This compound provided a new approach to antagonise LTB4 in vivo 
in psoriasis. In vitro, this specific agent has proved to be a very potent drug in blocking 
LTB4-induced human neutrophil stimulation, resulting in a profound inhibition of CD11b 
up-regulation on both isolated neutrophils and whole human blood, as well as inhibition 
of chemotactic activity, and calcium generation [87]. At a dose of 200 mg twice daily, 
almost complete suppression of ex vivo human neutrophil LTB4-induced CD11b up-regula­
tion was demonstrated. In bronchoalveolar lavage fluid from mild asthmatics, the number 
of neutrophils reduced significantly after one week of treatment with VML 295 at 112 mg 
three times a day [88].
An additional study has shown that VML 295 has a potent inhibitory effect on epi­
dermal PMN accumulation and epidermal hyperproliferation, induced in vivo by the epi- 
cutaneous application of LTB4 to healthy volunteers [89]. Moreover, it has been shown 
that VML 295 is able to block the ex vivo LTB4-induced CD11b up-regulation on peri­
pheral blood PMNs of healthy volunteers treated orally for 10 days [87,89], and that 
there is a strong dose-relationship with respect to these effects, with a maximum effect 
on a 200 mg twice a day regime [90]. Because of these very marked effects, a double 
blind randomised study in psoriatic patients was performed [91]. This study, in which 
patients with psoriasis were treated with VML 295 or placebo for 4 weeks, showed that 
VML 295 is a safe and well tolerated drug, with no evident side effects. Moreover, it was 
shown that after 4 weeks of treatment, there was a significant difference between
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treatment groups with respect to LTB4-induced CD11b upregulation on the cell surface of 
PMNs derived from peripheral blood. Ex vivo CD11b in the VML 295 treated patients was 
completely inhibited after 7 days of treatment, whereas there was no change in the 
placebo treated patients. However, this study also showed that the overall severity of pso­
riasis, represented by the PASI, was not significantly different between treatment groups 
after 4 weeks of treatment. Moreover, there was no significant difference in markers for 
cutaneous inflammation and epidermal proliferation, assessed by immunohistochemistry. 
However, it might be argued that the duration of treatment might have been to short to 
show an antipsoriatic effect. Moreover, it is possible that the compound is able to prevent 
the appearance of new lesions in psoriatic patients after effective topical treatment of 
the lesions.
Because of the pronounced inhibiting effect of VML 295 on CD11b upregulation, and 
the preponderance of PMN in early psoriasis, we performed the present study, in which 
we focused on the efficacy of VML 295 in psoriasis with respect to the prevention of 
relapse. In particular, we addressed the following questions. 1) Is VML 295 able to 
prevent relapse in patients with psoriasis? 2) To what extent does oral administration of 
VML 295 influence overall reduction of stable plaque psoriasis during prolonged treat­
ment, represented by the Psoriasis Area and Severity Index (PASI)? 3) To what extent are 
parameters for epidermal differentiation, inflammation, and proliferation modulated by 
VML 295? A quantitative flow cytometric analysis was performed focusing on parameters 
of epidermal proliferation, differentiation, and inflammation. Flow cytometry has proved 
to be an objective and reproducible method to quantify clinical parameters of psoriatic 
treatments [4,8,36,47,92].
Materials and methods
Patient population
Patients with stable plaque psoriasis were mainly recruited from our outpatient depart­
ment. In addition, patients were recruited who had heard about the trial from other 
patients. To be eligible for the trial, patients had to have stable plaque psoriasis, with at 
least two representative lesions of at least 16 cm2. For assessment of the severity of the 
psoriasis, we used the PASI [48]. Each of the two selected plaques had to have a sum of 
scores for erythema, scaling, and thickening of at least 6, with a minimum score of 1 for 
each parameter.
The following exclusion criteria were used: Use of any topical antipsoriatic therapy 
(other than emollients) during the two weeks prior to study enrolment, receipt of any sys­
temic retinoid therapy within 1 year prior to enrolment, use of any other systemic anti­
psoriatic therapy or phototherapy during the prior four weeks, use of cholesterol lowering
drugs, systemic immunosuppressive drugs, antibiotics, or anticoagulants at randomisation.
All patients gave informed consent prior to study enrolment and the ethics committee 
of our university approved the study protocol. Patients were studied as part of a larger, 
multi-center clinical trial which enrolled a total of 93 patients at 7 centres (data not 
reported here).
Study design and visits 
The study was divided into two parts. At study entry, the PASI was assessed, as well as 
the sum of scores for the two selected lesions. The area of these lesions was measured 
using acetate templates. After a maximum of two weeks, depending on the necessity for 
a two week wash out period of topical treatment, patients were enrolled into part 1. In 
this part of the study, one of the two selected plaques of all patients was pre-treated with 
clobetasol-17-propionate lotion (Dermovate® lotion, Glaxo Wellcome, Zeist, The Nether­
lands) under occlusion with a hydrocolloid dressing (HCD, Duoderm extra thin®, Conva- 
Tec, Woerden, The Netherlands) until remission was induced, in order to study the effect 
of VML 295 on relapse. The other selected lesion was left untreated as a control. No 
other antipsoriatic treatments except emollients were allowed during the whole study 
period. During part 1, which lasted a maximum of 6 weeks, patients came to the out­
patient department once weekly, for application of clobetasol lotion under HCD, until 
clearance was reached. Clearance was defined as a sum of scores for the treated lesion of 
less than 1. Every visit, the area of both the treated and the control lesion were 
measured. Patients who did not reach clearance after 6 weeks of treatment with clobeta- 
sol under occlusion, were withdrawn from the study.
Once clearance was observed, patients were enrolled into part 2 of the study. At that 
time, the sum of scores for the selected lesions, and a PASI was assessed. In part 2 of the 
study, patients were randomised and received capsules of VML 295 200 mg twice daily or 
placebo capsules twice daily for eight weeks. Randomisation was blinded by the sponsor, 
and the capsules containing VML 295 or placebo were identical. Patients returned to our 
clinic every two weeks. Every visit, the PASI was assessed, as well as the sum of scores of 
the pre-treated and control lesions. A sum of scores for the pre-treated lesion of >3 was 
defined as a relapse. For safety reasons, routine blood and urine samples were taken at 
screening, in part 1 on day 1, and in part 2 on days 1, 29, and 57. Eight weeks (57 days) 
after start of the VML 295 or placebo medication, the study was stopped, and patients 
were allowed to restart topical or systemic antipsoriatic therapy.
Biopsies, staining, and flow cytometric assessment.
In order to quantify the clinical observations, we performed a flow cytometric assessment 
on single cell suspensions obtained from skin samples. Three 3-mm punch biopsies 
(Stiefel, Offenbach am Main, Germany) were taken from every subject from the clobetasol 
treated lesion under local anaesthesia with xylocaine/adrenaline 1:100000: in part 1 on
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day 1, and in part 2 on days 1 and 57. Where the pre-treated lesion relapsed before day 
57, the third biopsy was taken at the first visit after relapse, instead of the biopsy 
scheduled at day 57. By using an optimised thermolysin-trypsin protocol, epidermal single 
cell suspensions were obtained from these biopsies, as previously described in detail [7]. 
Cells were fixed in ice-cold ethanol (70% ) and stored at -20°C until staining and flow 
cytometric analysis.
For flow cytometric staining, we used a triple staining protocol in order to measure 
parameters for epidermal differentiation, inflammation, and proliferation, using specific 
monoclonal antibodies for these parameters [47]. The multiparameter flow cytometric 
assessment as used in the present study has proved to correlate highly significantly with 
the clinical parameters scaling, erythema, and induration [47].
To quantify differentiation, RKSE60 (Department of Molecular Biology, University of 
Maastricht, The Netherlands) was used in a dilution of 1:5. This IgG1-type mouse mono­
clonal antibody stains keratin 10, an intermediate filament-type protein that is expressed 
in differentiating keratinocytes [7,40,93]. For flow cytometric analysis of RKSE60, we 
used the 1:250 diluted fluorochrome phycoerythrin which was conjugated to antibodies 
against mouse IgG1 (GAM-PE, Southern Biotechnology Associates, Birmingham, AL, USA).
For studying inflammatory processes, we used the IgG2a-type mouse monoclonal anti­
body Vim3B4 (Novocastra Laboratories Ltd., Newcastle upon Tyne, UK) which is directed 
against vimentin, an intermediate filament-type protein that occurs in mesenchymal cells 
[39-41]. Vim3B4 (dilution 1:15) binds to all non-keratinocytes, i.e. polymorphonuclear 
leucocytes, lymphocytes, monocytes, macrophages, melanocytes and Langerhans cells. For 
flow cytometric measuring of Vim3B4, the fluorochrome fluorescein-isothiocyanate, which 
was conjugated to goat antibodies against mouse IgG2a, was used in a dilution of 1:50 
(GAM-FITC, Southern Biotechnology Associates).
In order to estimate the total amount of DNA, and thus to measure proliferative acti­
vity, we used the DNA fluorochrome TO-PRO-3 iodide (TP3, Molecular Probes, Eugene, 
OR, USA), which gives good results with only very little spectral overlap [38]. Although 
TP3 intercalates with double-stranded regions of nucleic acids, it also affects RNA. For 
this reason, we used TP3 (2 x 10'6 M) in combination with RNase.
Flow cytometric analysis 
After staining, cells were measured and analysed with an EPICS Elite flow cytometer 
(Beckman Coulter, Luton, UK) with a dual laser system. An air-cooled argon ion laser exci­
ted both FITC and PE at a wavelength of 488 nm at 20 mW. A second Helium-Neon laser 
(10 mW, 633 nm) excited TP3. Because of the difference in excitation wavelength of PE 
and TP3, spectral overlap was minimal, and easily compensated for electronically. Fluo­
rescence was measured using bandpass filters at 525 nm (FITC, green signal), 575 nm 
(PE, orange signal) and 675 nm (TP3, red signal). To discriminate between doublets of 
diploid cells and real tetraploid cells, the ratio area/peak of the red signal (TP3, DNA)
was used. Percentages of vimentin-positive, keratin 10-positive, and keratin 10-negative 
cells were calculated after setting appropriate gates and counting approximately 10,000 
gated cells, using WinList™ software (WinList 4.0, Verity Software House Inc., Topsham, 
ME, USA). For gating, controls were measured, omitting primary antibodies. Using 
ModFit™ software (ModFit LT 2.0, Verity Software House Inc.), the percentage of basal 
keratinocytes in SG2M-phase of the cell cycle was calculated from DNA histograms.
Statistical Analysis
For statistical analysis of the difference in number of patients who relapsed we used the 
chi-square test. The time to relapse between treatment groups was considered to be 
interval-censored data. For statistical analysis, a log rank test for censored data was per­
formed. The differences in PASI (part 2 day 57 minus part 1 day 1) within each treatment 
group were analysed using the Wilcoxon signed rank test. In order to substantiate the 
differences in the area of the pre-treated lesion between the VML 295 treated patients 
and placebo treated patients, we used the Analysis of Variance (ANOVA) test. For esti­
mating the changes in sum-scores, and to estimate the significance of the flow cytometric 
parameters, the ANOVA test was also used. If this test showed a significant value, we per­
formed a post-hoc comparison as well, using the Duncan Multiple Range test.
Results
Patients and safety parameters 
At our outpatient department, 35 patients started treatment with clobetasol in part 1. In 
31 patients, the pre-treated lesion cleared after an average of 18.5 days. One patient was 
withdrawn from the study because he did not reach clearance after 6 weeks of treatment. 
Another 2 patients were withdrawn because the area of the control lesion decreased to 
less than 16 cm2. One patient was withdrawn in part 1 because of an adverse event that 
required prohibited medication (for reasons of angina pectoris, coumarin derivatives were 
prescribed). Thus, 31 patients entered part 2 and were randomised; 16 received VML 295, 
and 15 received placebo. From this group of 31 patients, 25 completed the study. All 6 
patients who were withdrawn in part 2 were in the placebo group. One patient was 
withdrawn because of a lack of compliance, three patients were withdrawn after they had 
withdrawn consent because of a relapse, and two patients were withdrawn because of 
adverse events. One of them developed an exacerbation of psoriasis, and the other one 
developed thyroid dysfunction. The following side effects were reported and categorised 
as treatment-related in the VML 295 group: diarrhoea, headache, and hyperlipidaemia. 
However, all side effects were mild. In the present study, no significant differences 
between treatment groups were documented with respect to the investigated routine 
laboratory parameters.
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Relapse and clinical efficacy 
Out of the patients who received VML 295 (n=15), 14 patients relapsed after an average 
of 6 weeks, and one patient maintained clearance of the pre-treated lesion. From the 
placebo treated group (n=16), 11 patients relapsed after an average of 4 weeks, while 
three out of 16 patients did not show relapse. In 2 patients, relapse could not be 
evaluated, as they were withdrawn from the study because of a lack of compliance and 
an exacerbation of psoriasis, respectively. The difference in numbers of relapsed patients 
between the treatment groups was not statistically significant. The difference with 
respect to time to relapse between treatment groups was not significant either.
With respect to the sum-score of the pre-treated lesion, the mean scores ± SEM in 
part 1 on day 1 and in part 2 on days 1 and 57 were 8.7 ± 0.5, 0.8 ± 0.1, and 6.3 ± 0.8 
respectively for the VML 295-treated patients, and 8.9 ± 0.5, 0.8 ± 0.1, and 5.2 ± 0.9 
respectively for the placebo-treated patients. The differences between these visits were 
statistically significant, both within the VML 295-treated group and within the placebo- 
treated group, although there was no significant difference between the sum of scores 
comparing part 1 day 1 and part 2 day 57. However, there was no significant difference
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Figure 18 Graphical overview of the mean percentages ± SEM values of PASI and flow cytome­
tric parameters for differentiation (keratin 10-positive cells), inflammation (vimentin-positive 
cells), and epidermal proliferation (basal cells in the SG2M-phase) of VML 295 and placebo- 
treated patients.
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between part 1 day 1, part 2 day 1 and part 2 day 57 between treatment groups. For the 
control lesion, no significant changes with respect to the sum-score were observed during 
the study in either the VML 295-treated group or the placebo-treated group.
The area of the lesion that was to be pre-treated with clobetasol-17-propionate was
35.0 cm2 ± 3.6 for the VML 295-treated group and 31.7 cm2 ± 3.8 for the placebo- 
treated group at part 1 day 1. These mean values are based on the patients who 
completely finished the study (n=25). In part 2 on day 1, when the lesion had reached 
clearance, it was sometimes difficult to assess the area of the treated lesion. In a sub­
stantial number of cases, the lesion had disappeared completely, and no remaining in­
volvement could be measured (n=10). In 11 out of 25 patients, the remaining erythema 
was indicative for the area of the lesion. However, in 4 out of 25 patients this erythema 
was so ill defined that the area of the pre-treated lesion could not be measured. In order 
to assess the influence of the study medication on the area of the pre-treated lesion, we 
restricted the statistical analysis to the data of those patients that did not show any sign 
of clinical involvement after treatment with clobetasol-17-propionate: 5 VML 295-treated 
patients and 5 placebo-treated patients. For these patients, the area in part 2 on day 1 
was 0. For the VML 295 group, the mean areas in part 1 on day 1 and in part 2 on day
57 were 28.2 cm2 ± 5.0 and 9.0 cm2 ± 5.3 respectively, whereas these areas were 31.9 
cm2 ± 4.5 and 15.9 cm2 ± 6.3 for the placebo group. However, the influence of treatment 
on the area of the pre-treated lesion was not significant.
The PASI for both VML 295 and placebo-treated patients is depicted in Figure 18. 
This figure demonstrates that both treatment groups had the same PASI at the start of 
the study (8.5 ± 0.9). The VML 295-treated group had a slightly higher PASI at initiation 
of VML 295 medication (8.9 ± 1.1) compared to the patients who received placebo (8.6 ± 
1.1), but this difference was not statistically significant. At the end of the study, in part 2 
on day 57, the mean PASI for the VML 295 group and the placebo group was 8.6 ± 1.1 
and 7.3 ± 1.8 respectively. Again, this difference was not significant.
Table 13 Mean percentages ± SEM values of flow cytometric parameters for differentiation 
(keratin 10-positive cells), inflammation (vimentin-positive cells), and epidermal proliferation 
(basal cells in the SG2M-phase) of VML 295 and placebo-treated patients.
VML 295 Placebo
Part 1 Part 2 Part 1 Part 2
day 1 day 1 day 57 day 1 day 1 day 57
%  Keratin 10-positive cells 27.07 ± 2.94 48.39 ± 3.42 30.91 ± 4.31 27.96 ± 3.22 51.52 ± 3.32 28.85 ±3.10
%  Vimentin-positive cells 4.75 ± 1.03 3.60 ± 0.65 4.46 ± 0.50 3.75 ± 0.31 2.57 ± 0.47 4.74 ± 0.51
%  Cells in SG2M-phase 17.25 ± 2.90 1.32 ± 0.29 16.14 ± 1.64 15.61 ± 1.64 1.53 ± 0.26 13.05 ±1.84
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Flow cytometric analysis 
Data of the flow cytometric analysis are shown in Figure 18 and Table 13. With respect to 
the proportion of keratin 10-positive cells, the marker for differentiation, no statistically 
significant differences were seen between treatment groups: The effect of VML 295 on 
differentiation was not significantly different from placebo. Pre-treatment with clobetasol 
under HCD increased the number of keratin 10 expressing cells significantly in both 
groups. However, despite treatment with VML 295 or placebo during 8 weeks, the percen­
tage keratin 10-positive cells decreased again to pre-treatment levels.
Regarding vimentin expression, no statistically significant differences were observed, 
both between treatment groups and visits, as can be seen in Figure 18 and Table 13.
The proportion of proliferating keratinocytes, defined as basal keratinocytes in SG2M- 
phase, did not reveal a statistically significant difference comparing the treatment 
groups. Both in the VML 295-treated patients as in the placebo-treated patients, prolife­
ration was significantly reduced by the pre-treatment with clobetasol under HCD, but 
increased again after 8 weeks of treatment with study medication. The proportion of pro­
liferating cells after 8 weeks of treatment did not show a significant difference compared 
to the situation at the start of the study. This is true for both the VML 295 and placebo 
groups.
Discussion
The present study clearly showed that the LTB4 antagonist VML 295 is well tolerated in a 
200 mg twice a day regime during 8 weeks. Treatment related side effects were 
diarrhoea, headache, and hyperlipidaemia, but these effects were mild and no VML 295 
treated patient had to stop the study because of these side effects. This confirms and 
extends the findings of Van Pelt et al, who also found that VML 295 is a well tolerated 
drug during 4 weeks of treatment [89,91].
With respect to the clinical efficacy of VML 295 compared to placebo, no differences 
between treatment groups were found. The present study does not provide any evidence 
that an 8 week treatment period with VML 295 reduces existing psoriatic plaques, and 
particularly indicates that relapse is not prevented. It is known that after abrupt cessa­
tion of topical treatment with very potent corticosteroids, a quick relapse with rebound 
phenomena may occur [94,95]. One could speculate that because of this rebound pheno­
menon the effect of VML 295 on relapse is biased, and that VML 295 could have effect 
on relapse after treatment with low or even moderate potency steroids. However, 
studying relapse in psoriasis by using high potency topical corticosteroids is an esta­
blished methodology [96], and therefore we adopted this method.
The parameters for epidermal differentiation, proliferation, and inflammation were 
not significantly different between treatment groups. Therefore, the flow cytometric
assessment was compatible with the clinical scores. It can be well understood that treat­
ment with clobetasol has a marked effect on both clinical signs and cellular markers. The 
present study showed that the proportion of keratin 10-positive cells and of basal cells in 
SG2M-phase changed significantly after pre-treatment with clobetasol under occlusion. 
This is in line with the findings of a previous comparable flow cytometric study of Glade 
et al. in which these parameters were investigated after treatment with clobetasol under 
HCD [96]. However, after eight weeks of treatment with either VML 295 or placebo, the 
proportion of keratin 10-positive cells, vimentin-positive cells, as well as the proportion of 
basal cells in SG2M-phase reverted to pre-treatment levels. The proportions of these mar­
kers were not significantly different at relapse compared to the situation prior to treat­
ment with clobetasol. This was true for both VML 295-treated patients and placebo- 
treated patients.
The absence of any effect of VML 295 on existing lesions and relapse prevention 
during an 8 week treatment period is at variance with the in vivo results of VML 295 on 
LTB4-induced inflammation, using the same dosage of VML 295. Therefore, it is feasible 
that accumulation of PMN does not play a relevant role in either early or existing 
psoriasis.
The following conclusions were drawn from the present study. 1) VML 295 is not 
effective in preventing relapse in psoriasis. 2) VML 295 does not influence overall PASI 
compared to placebo during 8 weeks of treatment. 3) Parameters of epidermal differen­
tiation, inflammation, and proliferation are not affected by VML 295. 4) Further develop­
ment of LTB4 modulating drugs for the treatment of psoriasis is not indicated.
133
EFFEC
T
S 
OF 
A
N
T
I-
P
S
O
R
IA
T
IC
 
T
H
E
R
A
P
IE
S
134
EFFEC
T
S 
OF 
A
N
T
I-
P
S
O
R
IA
T
IC
 
T
H
E
R
A
P
IE
S
References
1. Bata Csorgo Z, H am m erberg  C, Voorhees JJ, C ooper KD. Flow cy tom etric  id e n tif ic a tio n  o f 
p ro life ra tive  su b p o p u la tio n s  w ith in  n o rm a l h u m a n  ep id e rm is  and  th e  lo c a liza tio n  o f 
th e  p rim ary  hy p erp ro life ra tiv e  p o p u la tio n  in  psoriasis. J Exp Med 1993; 178: 1271-1281.
2. Laporte M, H eenen M. The h e te ro g en eity  o f  th e  g e rm in a tiv e  co m p a rtm e n t in  h u m a n  
ep id e rm is  and  its im p lica tio n s  in  pa thogenesis . Dermatology 1994; 189: 340-343.
3. S taiano Coico L, D arzynkiew icz Z, M cM ahon CK. C u ltu red  h u m a n  kera tinocy tes: 
d isc r im in a tio n  o f d iffe ren t cell cycle c o m p a rtm en ts  based  u p o n  m e a su re m e n t o f n u c lea r 
RNA o r to ta l c e llu la r  RNA co n te n t. Cell Tissue Kinet 1989; 22: 235-243.
4. B auer FW, C rom bag NHCMN, de G rood RM, de Jongh  GJ. Flow cy to m etry  as a too l for th e  
study  o f  cell k in e tic s  in  ep iderm is . B r J D ermatol 1980; 102: 629-639.
5. B oezem an JBM, B auer FW, de G rood RM. Flow cy tom etric  analysis o f th e  re c ru itm e n t o f 
G0 cells in  h u m a n  ep id e rm is  in  vivo follow ing tap e  s tripp ing .
Cell Tissue Kinet 1987; 20: 99-107.
6 . R andall MB, G eisinger KR, Kute TE, Buss DH, e t al. DNA co n te n t and  p ro life ra tive  index  in 
cu ta n eo u s  squam ous cell carc in o m a  and  k e ra to acan th o m a.
A m  J Clin Pathol 1990; 93: 59-262.
7. Glade CP, Seegers BAMPA, M eulen  EF, van  H ooijdonk CAEM, et al. M u ltip a ram ete r flow  
cy tom etric  c h a rac te riz a tio n  o f ep id e rm a l cell su spensions p rep ared  from  n o rm a l and 
h y p erp ro life ra tiv e  h u m a n  skin  u sing  an  o p tim ized  th e rm o ly s in -try p sin  protocol.
Arch Dermatol Res 1996; 288: 203-210.
8 . G lade CP, van  Erp PEJ, van  H ooijdonk CAEM, Elbers ME, e t al. Topical tre a tm e n t o f 
p so ria tic  p laques w ith  1 a lpha , 24 d ih y d roxyv itam in  D3: a m u ltip a ra m e te r  flow  
cy to m etrica l analysis o f  e p id e rm a l g ro w th , d iffe ren tia tio n  and  in flam m a tio n .
Acta Derm Venereol 1995; 75: 381-385.
9. P inkus H. Tape s trip p in g  in  d e rm ato lo g ica l research . A review  w ith  em phasis  on  
ep id e rm a l biology. G Ita l Dermatol M inerva Dermatol 1966; 107: 1115-1126.
10. Fry L, A lm eyda J, M cM inn RM. Effect o f p lastic  occlusive d ressings on  p so ria tic  ep iderm is. 
Br J D ermatol 1970; 82: 458-462.
11. Baxter DL, S tough ton  RB. M itotic index  o f p so ria tic  lesions tre a te d  w ith  a n th ra lin , 
g lu co co rtico ste rio d  and  occlu sion  only. J Invest Dermatol 1970; 54: 410-412.
12. van  V lijm en-W illem s IMJJ, C hang A, B oezem an JBM, van  de K erkhof PCM. The 
im m u n o h is to ch em ica l effect o f  a hyd roco llo id  occlusive d ressing  (DuoDERM E) in 
psoriasis vu lgaris . Dermatology 1993; 187: 257-262.
13. G ottlieb  AB, S ta iano Coico L, C ohen SR, V arghese M, e t al. Occlusive hydroco llo id  
dressings decrease  k e ra tin o cy te  p o p u la tio n  g ro w th  frac tio n  and  c lin ica l scale and  skin 
th ick n ess  in  active p so ria tic  plaques. J Dermatol Sci 1990; 1: 93-96.
14. van  de K erkhof PCM, de M are S, A rno ld  WP, van  Erp PEJ. E p iderm al reg en era tio n  and 
occlusion . Acta Derm Venereol 1995; 75: 6 -8 .
15. Fisher LB, M aibach HI. The effect o f  occlusive and  sem ip erm eab le  d ressings o n  th e  
m ito tic  activ ity  o f  n o rm al and  w ounded  h u m a n  ep iderm is.
Br J D ermatol 1972; 8 6 : 593-600.
16. W illiam s MG, H u n te r R. S tudies on  e p id e rm a l reg e n era tio n  by m eans o f  th e  strip  
m ethod . J Invest Dermatol 1957; 29: 407-413.
17. B auer FW, B oezem an JBM. Flow cy tom etric  m e thods in  h u m a n  skin  w ith  re spec t to cell 
cycle k ine tics. In: Psoriasis: cell proliferation  (W right NA, C am plejohn  RS, eds), E d inburgh : 
C hurch ill L ivingstone, 1983; 104-116.
18. C rissm an HA, S teinkam p JA. Rapid, s im u ltan eo u s  m e a su rem en t o f  DNA, p ro te in , and  cell 
vo lum e in  single  cells from  la rge  m a m m alian  cell p o p u la tio n s .
J Cell Biol 1973; 59: 766-771.
19. K rishan A. Rapid flow  cy to flu o ro m etr ic  analysis o f  m a m m alian  cell cycle by p ro p id iu m  
iod ide s ta in ing . J Cell Biol 1975; 6 6 : 188-193.
20. R abinovitch  PS, Torres RM, Engel D. S im u ltan eo u s cell cycle analysis and  tw o-color
surface im m u n o flu o re sc en ce  u sing  7-am ino-actinom ycin  D and  single  la se r excita tion : 
ap p lica tio n s  to study  o f  cell a c tiv a tio n  and  th e  cell cycle o f m u rin e  Ly-1 B cells.
J Im m unol 1986; 136: 2769-2775.
21. de M are S, van  Erp PEJ, R am aekers FC, van  de K erkhof PCM. Flow cy tom etric  
q u a n tif ic a tio n  o f  h u m a n  ep id e rm a l cells exp ressing  k e ra tin  16 in  vivo a fte r s tan d ard ized  
trau m a . Arch Dermatol Res 1990; 282: 126-130.
22. van  de K erkhof PCM, van  Rennes H, de Grood RM, de Jongh  GJ, e t al. Response o f th e  
c lin ically  un invo lved  sk in  o f  p so ria tic  p a tien ts  to s tan d a rd ized  in jury .
B r J Dermatol 1983; 109: 287-294.
23. P roksch  E, H olleran  WM, M enon GK, Elias PM, e t al. B arrier fu n c tio n  regu la tes  ep id e rm al 
lip id  and  DNA syn thesis . Br J Dermatol 1993; 128: 473-482.
24. F isher LB, M aibach HI. Physical occlu sion  c o n tro llin g  ep id e rm a l m itosis.
J Invest Dermatol 1972; 59: 106-108.
25. F isher LB, M aibach HI, T ranc ik  RJ. V ariably occlusive tap e  system s and  th e  m ito tic  
activ ity  o f s trip p ed  h u m a n  ep iderm is . Effects w ith  and  w ith o u t hyd roco rtisone .
Arch Dermatol 1978; 114: 727-729.
26. Peters DC, Balfour JA. T acalcitol. Drugs 1997; 54: 265-271.
27. M om m ers JM, C astelijns FACM, Seegers BAMPA, van  Rossum  MM, e t al. The effect o f long ­
te rm  tre a tm e n t w ith  taca lc ito l on  th e  p so ria tic  ep iderm is . A flow  cy tom etric  analysis.
B r J Dermatol 1998; 139: 468-471.
28. van  de K erkhof PCM, van  d e r V leu ten  CJM, G erritsen  MJP, G lade CP, e t al. Long-term  
efficacy and  safety o f  once daily  t re a tm e n t o f c h ro n ic  p laque  p soriasis  w ith  tacalc ito l 
o in tm e n t. Eur J D ermatol 1997; 7: 421-425.
29. G erritsen  MJP, Boezem an JBM, van  V lijm en-W illem s IMJJ, van  de K erkhof PCM. The effect 
o f ta ca lc ito l (1,24(OH)2D3) on  cu tan eo u s  in f lam m a tio n , ep id e rm a l p ro life ra tio n  and 
k e ra tin iz a tio n  in  psoriasis: a p lacebo-con tro lled , doub le-b lind  study.
B r J Dermatol 1994; 131: 57-63.
30. Kato T, Rokugo M, Terui T, Tagam i H. Successful t re a tm e n t o f p soriasis w ith  top ica l 
a p p lic a tio n  o f  active v ita m in  D3 analogue, 1 alpha,24-d ihydroxycholecalcifero l.
B r J Dermatol 1986; 115: 431-433.
31. M atsum oto  K, H ash im oto  K, Kiyoki M, Y am am oto M, e t al. Effect o f
1 ,24R-dihydroxyvitam in D3 on  th e  g ro w th  o f h u m a n  ke ra tinocy tes.
J Dermatol 1990; 17: 97-103.
32. Kawara S, H atta  N, H irone K. Effect o f ex te rn a lly  app lied  1_,24(R)-(OH)2 D3  on  th e  
k ine tics  o f  ep id e rm a l kera tinocy tes  in  th e  p so ria tic  focus.
Japanese Journal o f Dermatology 1989; 99: 1407-1408.
33. Pinkus H. E xam ina tion  o f th e  ep id e rm is  by th e  tap e  strip  m ethod . II. B iom etric d a ta  on 
reg e n era tio n  o f th e  h u m a n  ep iderm is . J Invest Dermatol 1951; 19: 431-447.
34. B auer FW, B oezem an JBM, Rijzewijk JJ, de G rood RM. Topical co rtico stero id s  delay th e  
p ro life ra tive  response  to se llo tape  s trip p in g . Skin Pharmacol 1989; 2: 204-209.
3 5. R ijzewijk JJ, B oezem an JBM, B auer FW. S ynchron ized  g ro w th  in  h u m a n  ep ide rm is
follow ing tap e  s trip p in g : its im p lic a tio n  for cell k in e tic  studies.
Cell Tissue Kinet 1988; 21: 227-229.
36. B auer FW, C rom bag NHCMN, B oezem an JBM, de Grood RM. Flow cy tom etry  as a too l for 
th e  study  o f  cell k in e tic s  in sk in  2. Cell k in e tic  d a ta  in  psoriasis.
B r J Dermatol 1981; 104: 271-276.
37. M arks R, B arton SP, S h u ttlew o rth  D, Finlay AY. A ssessm ent o f  d isease  p rogress in 
psoriasis [see com m ents]. Arch Dermatol 1989; 125: 235-240.
38. van  H ooijdonk CAEM, Glade CP, van  Erp PEJ. TO-PRO-3 iodide: a novel HeNe 
laser-excitab le DNA s ta in  as an  a lte rn a tiv e  for p ro p id iu m  iod ide in  m u ltip a ra m e te r  flow  
cytom etry . Cytom etry 1994; 17: 185-189.
39. B auer FW, B oezem an JBM, van  E ngelen L, de G rood RM, e t al. M onoclonal an tib o d ies  for 
ep id e rm a l p o p u la tio n  analysis. J Invest Dermatol 1986; 87: 72-75.
40. R am aekers FC, Puts JJ, M oesker O, K ant A, e t al. A ntibod ies to in te rm e d ia te  filam en t
135
EFFEC
T
S 
OF 
A
N
T
I-
P
S
O
R
IA
T
IC
 
T
H
E
R
A
P
IE
S
136
EFFEC
T
S 
OF 
A
N
T
I-
P
S
O
R
IA
T
IC
 
T
H
E
R
A
P
IE
S
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60. 
61.
p ro te in s  in  th e  im m u n o h is to c h em ic a l id e n tif ic a tio n  o f  h u m a n  tu m o u rs : an  overview.
Histochem  J 1983; 15: 691-713.
de W aal RM, Sem eijn JT, C orne lissen  MH, R am aekers FC. E p iderm al L angerhans cells 
c o n ta in  in te rm ed ia te -s ized  filam en ts  o f  th e  v im e n tin  type: an im m unocy to log ic  study.
J Invest Dermatol 1984; 82: 602-604.
van  Bokhoven MG, de M are S, C zarne tzk i BM, van  Erp PEJ, e t al. Active v ita m in  D3 does 
n o t suppress re c ru itm e n t o f  G0 cells follow ing in ju ry . Br J Dermatol 1988; 119: 737-742. 
M atsunaga T, Y am am oto M, M im ura H, O hta T, e t al. 1 ,24(R )-dihydroxyvitam in D3, a novel 
active form  o f v ita m in  D3 w ith  h ig h  activ ity  for in d u c in g  ep id e rm a l d iffe re n tia tio n  b u t 
decreased  hypercalcem ic  activity. J Dermatol 1990; 17: 135-142.
N ish im ura  M, H ori Y, N ishiyam a S, N akam izo Y. Topical 1_, 24 (R)-dihydroxyvitam in D3 
for th e  tre a tm e n t o f  psoriasis. Review o f  th e  lite ra tu re . E urJ Dermatol 1993; 3: 255-261. 
Kobayashi T, O kum ura H, A zum a Y, Kiyoki M, e t al. 1 alpha,24R -d ihydroxyvitam in  D3 has 
an ab ility  com parab le  to th a t  o f  1 a lpha,25 -d ihyd roxyv itam in  D3 to induce  kera tinocy te  
d iffe ren tia tio n . J Dermatol 1990; 17: 707-709.
Kato T, T erui T, Tagam i H. Topically active v itam in  D3 analogue, 1 a lpha,24-dihydroxy- 
cho leca lc ife ro l, has an  an ti-p ro life ra tive  effect on  th e  ep id e rm is  o f  g u in ea  pig sk in  
[letter]. B r J Dermatol 1987; 117: 528-530.
Glade CP, van  Erp PEJ, B oezem an JBM, van  de K erkhof PCM. M u ltip a ram ete r flow  
cy tom etry  as a tool to evaluate  a n tip so ria tic  therapy . Br J Dermatol 1997; 137: 367-375. 
Fredriksson  T, Pe tte rsson  U. Severe psoriasis-oral th e ra p y  w ith  a new  re tin o id . 
Dermatologica  1978; 157: 238-244.
van  Erp PEJ, R ijzewijk JJ, B oezem an JBM, Leenders J, e t al. Flow cy tom etric  analysis o f 
ep id e rm a l su b p o p u la tio n s  from  n o rm a l and  p so ria tic  sk in  using  m onoc lona l an tibod ies  
again st in te rm e d ia te  filam en ts . A m  J Pathol 1989; 135: 865-870.
H ughes J, R ustin  MHA. C orticostero ids. In: Textbook o f psoriasis (van de K erkhof PCM, ed),
1 edn ., Oxford: Blackwell Science, 1999; 148-159.
M om m ers JM, van  Rossum  MM, van  H ooijdonk CAEM, van  Erp PEJ, e t al. Q u an tific a tio n  
o f ep id e rm a l cell p o p u la tio n s  in  th e  c e n tre  and  m arg in  o f s table p laque  psoriasis.
Arch Derm Res 1999; 291: 88-92.
de M are S, van  Erp PEJ, van  de K erkhof PCM. E piderm al h y p e rp ro life ra tio n  assessed by 
th e  m o n o c lo n a l an tib o d y  Ks8.12 on  frozen  sections. J Invest Dermatol 1989; 92: 130-131. 
N avarro JM, C asatorres J, Jo rcano  JL. E lem ents c o n tro llin g  th e  exp ression  and  in d u c tio n  
o f th e  sk in  h yperp ro life ra tion -assoc iated  k e ra tin  K6 . J Biol Chem  1995; 270: 21362-21367. 
M om m ers JM, van  Rossum  MM, van  Erp PEJ, van  de K erkhof PCM. Changes in  k e ra tin  6  
and  k e ra tin  1 0  (co-)expression in  lesional and  sym ptom less sk in  o f sp read ing  psoriasis. 
Dermatology 1999; (In Press)
M om m ers JM, Goossen JW, van  Erp PEJ, van  de K erkhof PCM. A novel fu n c tio n a l 
m u ltip a ra m e te r  flow  cy tom etric  assay to ch a rac te riz e  p ro life ra tio n  in  skin. 
C om munications in  Clinical Cytometry 1999; (In Press)
Volden G. Successful t re a tm e n t o f ch ro n ic  sk in  d iseases w ith  c lobe taso l p ro p io n a te  and  a 
h ydroco llo id  occlusive d ressing . Acta Derm Venereol 1992; 72: 69-71.
van  de K erkhof PCM, C hang A, van  d e r W alle HB, van  V lijm en-W illem s IMJJ, e t al. W eekly 
tre a tm e n t o f psoriasis w ith  a hyd roco llo id  d ressing  in co m b in a tio n  w ith  tr iam c in o lo n e  
aceton ide. A co n tro lled  com para tive  study. Acta Derm Venereol 1994; 74: 143-146.
Glade CP, B oterm ans RJ, van  Erp PEJ, van  de K erkhof PCM. The dynam ics o f th e  response 
o f n o rm a l sk in  to single  and  m u ltip le  ep icu tan e o u s  leu k o trien e  B4 ap p lica tio n s  analysed 
by th ree -c o lo u r flow  cytom etry . Acta Derm Venereol 1995; 75: 437-441.
C astelijns FACM, G erritsen  MJP, van  V lijm en-W illem s IMJJ, van  Erp PEJ, e t al. The 
ep id e rm a l ph en o ty p e  d u rin g  in itia tio n  o f  th e  p so ria tic  lesion  in  th e  sym ptom less 
m arg in  o f  re lap sin g  psoriasis. J A m  Acad Dermatol 1999; 40: 901-909.
van  de K erkhof PCM, Lam m ers AM. In trae p id e rm a l a cc u m u la tio n  o f  p o ly m o rp h o n u clea r 
leucocytes in  ch ro n ic  stab le  p laque  psoriasis. D ermatologica 1987; 174: 224-227.
Cox AJ. P o lym o rp h o n u c lea r leucocytes in  psoriasis. In: Psoriasis. Proceedings o f the Third
International Sym posium  (Farber EM, Cox AJ, eds), New York: G rune and  S tra tton ,
1981; 233-234.
62. Braun-Falco O, C hris tophers  E. S tru c tu ra l aspects o f  in itia l p so ria tic  lesions.
Arch Dermatol Forsch 1974; 251: 95-110.
63. Greaves MW, Cam p RD. P rostag land ins , leu k o trien e s , p h o spho lipase , p la te le t activating  
factor, and  cytokines: an  in teg ra ted  ap p ro ach  to in f lam m a tio n  o f h u m a n  skin.
Arch Dermatol Res 1988; 280 Suppl:
64. Sch roder JM. In flam m ato ry  m ed ia to rs  and  c h em o a ttrac ta n ts .
Clin Dermatol 1995; 13: 137-150.
65. S am uelsson B. Leukotrienes: m ed ia to rs  o f im m ed ia te  h y p ersen sitiv ity  reactions  and 
in flam m atio n . Science 1983; 220: 568-575.
6 6 . Ford H u tch in so n  AW, R ackm an A. Leukotrienes as m ed ia to rs o f sk in  in flam m a tio n .
B r J Dermatol 1983; 109 Suppl 25:
67. Voorhees JJ. Leukotrienes and  o th e r  lipoxygenase  p ro d u c ts  in  th e  pa th o g en esis  and  th e  
rapy o f p soriasis and  o th e r  derm atoses. Arch D ermatol 1983; 119: 541-547.
6 8 . B rain SD, Camp R, Dowd P, Black AK, e t al. The release o f  le u k o trie n e  B4-like m a te ria l in 
b io log ically  active am o u n ts  from  th e  lesional sk in  o f p a tien ts  w ith  psoriasis.
J Invest Dermatol 1984; 83: 70-73.
69. Camp R, Jones RR, B rain SD, W oollard  PM, e t al. P ro duction  o f  in tra e p id e rm a l 
m icroabscesses by to p ica l a p p lic a tio n  o f  leu k o trie n e  B4.
J Invest Dermatol 1984; 82: 202-204.
70. van  de K erkhof PCM, B auer FW, M aassen de G rood RM. M eth o trex ate  in h ib its  th e  
leu k o trien e  B4 induced  in trae p id e rm a l accu m u la tio n  o f  p o ly m o rp h o n u c lea r leucocytes. 
B r J Dermatol 1985; 113: 251a-255a.
71. B auer FW, van  de K erkhof PCM, M aassen de G rood RM. E piderm al h y p e rp ro life ra tio n  
follow ing th e  in d u c tio n  o f  m icroabscesses by le u k o trien e  B4.
B r J Dermatol 1986; 114: 409-412.
72. Ford H u tch in so n  AW, Bray MA, Doig MV, Shipley ME, e t al. L eukotriene B, a p o te n t 
ch em o k in e tic  and  a gg regating  substance  re leased  from  p o ly m o rp h o n u c le a r leucocytes. 
Nature 1980; 286: 264-265.
73. L indstrom  P, Lerner R, Palm blad  J, Patarroyo M. Rapid adhesive responses o f  e n d o th e lia l 
cells and  o f n e u tro p h ils  induced  by le u k o trien e  B4 are m ed ia ted  by leucocy tic  adhesion  
p ro te in  CD18. Scand J Im m unol 1990; 31: 737-744.
74. Lewis RA, A usten  KF, Soberm an  RJ. L eukotrienes and  o th e r  p ro d u c ts  o f  th e  
5-lipoxygenase pathw ay. B iochem istry  and  re la tio n  to p a thob io logy  in  h u m a n  diseases.
N  Engl J Med 1990; 323: 645-655.
75. O sborn L. Leucocyte adh esio n  to en d o th e liu m  in  in flam m a tio n . Cell 1990; 62: 3-6.
76. W olle rt PS, M enconi MJ, O’Sullivan  BP, W ang H, e t al. LY255283, a novel le u k o trie n e  B4 
recep to r a n tag o n is t, lim its  a c tiv a tio n  o f  n e u tro p h ils  and  p reven ts  acu te  lu n g  in ju ry  
induced  by en d o to x in  in pigs. Surgery 1993; 114: 191-198.
77. A llen DL, H offm an WP, M arder P, M atche tt MR, e t al. The effects o f LY293111Na, a 
leu k o trien e  B4 recep to r an tag o n ist, on  th e  p u lm o n a ry  n e u tro p h ilia  and  CD11b 
exp ression  caused  by in h a la tio n  o f a leu k o trien e  B4 aerosol in  rhesus m onkeys.
J Pharmacol Exp Ther 1996; 277: 341-349.
78. F retland  DJ, A nglin  CP, W idom ski D, Baron DA, e t al. Pharm aco log ical activ ity  o f th e  
second g en era tio n  le u k o trien e  B4 recep to r an tag o n ist, SC-53228: effects on  acu te  colonic 
in f lam m a tio n  and  h ep a tic  fu n c tio n  in  roden ts . In flam m ation  1995; 19: 503-515.
79. Black AK, Cam p RD, M allet AI, C u n n in g h am  FM, et al. P harm acolog ic  and  c lin ica l effects 
o f lo n ap a len e  (RS 43179), a 5- lipoxygenase in h ib ito r , in  psoriasis.
J Invest Dermatol 1990; 95: 50-54.
80. K ragballe K, H erlin  T. B enoxaprofen im proves psoriasis. A double-b lind  study.
Arch Dermatol 1983; 119: 548-552.
81. D egreef H, Dockx P, De D oncker P, De Beule K, e t al. A double-b lind  veh ic le-con tro lled  
study  o f  R 6 8  151 in  psoriasis: a top ica l 5-lipoxygenase inh ib ito r.
137
EFFEC
T
S 
OF 
A
N
T
I-
P
S
O
R
IA
T
IC
 
T
H
E
R
A
P
IE
S
138
EFFEC
T
S 
OF 
A
N
T
I-
P
S
O
R
IA
T
IC
 
T
H
E
R
A
P
IE
S
J A m  Acad Dermatol 1990; 22: 751-755.
82. van  de K erkhof PCM, van Pelt H, Lucker GP, Steijlen  PM, e t al. Topical R-85355, a p o te n t 
and  selective 5-lipoxygenase in h ib ito r , fails to  im prove psoriasis.
Skin Pharmacol 1996; 9: 307-311.
83. de Jong  EMGJ, van  V lijm en-W illem s IMJJ, Scholte JC, B un tinx  A, e t al. C lin ical and  
b io ch em ica l effects o f an  o ra l leu k o trie n e  b io syn thesis  in h ib ito r  (MK8 8 6 ) in  psoriasis. 
Skin Pharmacol 1991; 4: 278-285.
84. H egem ann  L, H a tze lm an n  A, G rewig S, S chm id t BH. P o ten t a n tag o n ism  o f  c a lm o d u lin  
activ ity  in  v itro , b u t lack  o f a n tip ro life ra tiv e  effects o n  k era tinocy tes  by th e  novel 
leu k o trien e  b io syn thesis  in h ib ito r  MK-8 8 6 . Br J D ermatol 1995; 133: 41-47.
85. Sofia MJ, F lo reancig  P, Bach N, Baker SR, e t al. The discovery  o f LY293111, a novel, p o te n t 
and  o ra lly  active leu k o trie n e  B4 re cep to r a n ta g o n is t o f  th e  b ip h en y lp h en o l class.
A dv Exp Med Biol 1997; 400A: 381-386.
8 6 . Sawyer JS, Bach NJ, Baker SR, B aldw in RF, e t al. S yn the tic  and  s tru c tu re /ac tiv ity  studies 
on  ac id -su b stitu ted  2- a ry lp h en o ls : discovery o f 2-[2-propyl-3-[3-[2-ethyl-4-(4- flu o rophe- 
nyl)-5- hydroxyphenoxy]-propoxy]phenoxy]benzoic acid , a h ig h -a ff in ity  leu k o trien e  B4 
recep to r a n tag o n is t. J Med Chem 1995; 38: 4411-4432.
87. M arder P, Sawyer JS, Froelich  LL, M ann LL, e t al. B lockade o f h u m a n  n e u tro p h il  activa  
tio n  by 2-[2-propyl-3-[3-[2- ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]propoxy]phe- 
noxy]benzoic acid  (LY293111), a novel le u k o trien e  B4 recep to r an tag o n ist.
Biochem Pharmacol 1995; 49: 1683-1690.
8 8 . Evans J. The in f lam m a to ry  response  to  a lle rg en  ch a llen g e  in  a top ic  a s th m atic s  is 
m o d u la ted  by th e  leu k o trien e  B4  a n ta g o n is t LY293111.
A m  J Respir Crit Care Med 1998; (In Press)
89. van  Pelt JP, de Jong  EMGJ, van  Erp PEJ, M itchell MI, e t al. The re g u la tio n  o f CD11b 
in te g rin  levels on  h u m a n  b lood  leucocytes an d  le u k o trien e  B 4-stim ulated  sk in  by a 
specific le u k o trien e  B4 rec ep to r a n ta g o n is t (LY293111).
Biochem Pharmacol 1997; 53: 1005-1012.
90. Seegers BAMPA, A ndriessen  MP, van  H ooijdonk CAEM, de Bakker ESM, e t al. 
Pharm oco log ica l effects o f  a specific  le u k o trien e  B4 recep to r a n ta g o n is t (VML 295) on  
b lood  leucocytes, cu tan eo u s  in f la m m a tio n  and  ep id e rm a l p ro life ra tio n .
Br J D ermatol 1998; (In Press)
91. van  Pelt JPA, de Jong  EMGJ, Seyger MM, van  H ooijdonk CAEM, e t al. Investiga tion  on  a 
novel an d  specific leu k o trie n e  B4 re cep to r a n ta g o n is t in  th e  t re a tm e n t o f stab le  p laque  
psoriasis. Br J Dermatol 1998; 139: 396-402.
92. Z e tte rg ren  JG, Peterson  LL, W u ep p er KD. K erato lin in : th e  so luble  su b stra te  o f ep id e rm al 
tra n sg lu ta m in a se  from  h u m a n  an d  bovine tissue.
Proc Natl Acad Sci U S A  1984; 81: 238-242.
93. Leigh IM, P ulford  KA, R am aekers FC, Lane EB. Psoriasis: m a in ten an ce  o f an  in ta c t 
m ono layer b asa l cell d iffe re n tia tio n  c o m p a rtm e n t in  sp ite  o f  hyp e rp ro life ra tio n .
Br J D ermatol 1985; 113: 53-64.
94. van  de K erkhof PCM, C hang  A, van  d e r W alle HB, van  V lijm en-W illem s IMJJ, e t al. W eekly 
tre a tm e n t o f psoriasis  w ith  a hyd roco llo id  d ressin g  in  co m b in a tio n  w ith  tr iam c in o lo n e  
ace ton ide . A co n tro lle d  com para tive  study. Acta Derm Venereol 1994; 74: 143-146.
95. M om m ers JM, van  Erp PEJ, van  de K erkhof PCM. C lobetasol u n d e r  hyd roco llo id  occlu sion  
in  p soriasis  re su lts  in  a com plete  b lock  o f  p ro life ra tio n  an d  in  a re b o u n d  o f  lesions 
fo llow ing d isco n tin u a tio n . Dermatology 1999; (In Press)
96. Glade CP, van  Erp PEJ, W erner-Schlenzka H, van  de K erkhof PCM. A c lin ica l a n d  flow  
cy tom etric  m odel to study  rem issio n  and  re lapse  in  psoriasis.
Acta Derm Venereol Suppl Stockh 1998; 78: 180-185.
Chapter
S U M M A R Y  A N D  
G E N E R A L  D I S C U S S I O N
S U M M A R Y  A N D  G E N E R A L  D I S C U S S I O N
The dynamics of epidermal cell populations during pathogenesis and treatment of psoria­
sis is the central issue in this thesis. In section 1.6, three aims were defined which 
focused on the characterisation of epidermal cell populations, each from a different point 
of view.
The first aim focused on the methods to assess characteristics of epidermal cell popu­
lations. The usability of an existing three-parameter flow cytometric protocol was to be 
confirmed, and the development of a new flow cytometric protocol that would supply 
additional information on epidermal cellular characteristics was aimed for. These aspects 
will be discussed in section 5.1.
The second aim of this thesis was to assess key markers for epidermal differentiation, 
inflammation, and proliferation in symptomless and lesional psoriatic skin, and in the 
transitional phases of a psoriatic plaque. A general discussion on this aim is pointed out 
in section 5.2.
To study to what extent a selection of existing and experimental anti-psoriatic thera­
pies interfere with epidermal cell populations was the third aim of this thesis. This will be 
discussed in section 5.3.
Finally, suggestions for improved quantitative assessment of epidermal cell popu­
lations are given in section 5.4.
5.1 Three parameter flow cytometric assessment 
of epidermal subpopulations
Usability of flow cytometry for the assessment 
of epidermal cell characteristics
The flow cytometric methodology to assess epidermal cell populations has proved to be a 
practical approach. As described in section 2.2, the biopsy procedure with punch biopsies 
is appropriate to obtain the whole epidermis, not only in normal skin, but also in hyper­
proliferative skin disorders. Because only the epidermis is required, a relatively superficial 
biopsy that comprises the epidermis and at least a small specimen of the dermis is suffi­
cient. The flow cytometric assessment is easy to perform, and the technical skills to 
operate the flow cytometer are relatively easy to learn. A great benefit is the computeri­
sed data acquisition, which results in an accurate and objective collection of data, with 
no interobserver bias. A relative drawback of flow cytometric analysis is the technical 
complexity of the apparatus. Sometimes, technical problems appear which prevent a 
straightforward measurement, but skilled technicians can easily solve these problems in 
most cases. Another more important drawback is the fact that using flow cytometry all 
topographic information is lost due to the necessity of cell suspensions. Despite these
141
S
U
M
M
A
R
Y
 
AN
D
 
G
E
N
E
R
A
L
 
D
IS
C
U
S
S
IO
N
142
S
U
M
M
A
R
Y
 
AN
D
 
G
E
N
E
R
A
L
 
D
IS
C
U
S
S
IO
N
drawbacks, the reproducibility and objectivity of data strongly is in favour of the use of 
flow cytometry in comparative studies.
It is important to realise that in flow cytometry usually relative cell numbers are 
measured instead of absolute numbers as in immunohistochemistry. The issue of measu­
ring relative versus absolute cell numbers is not an issue of flow cytometry in general, but 
of the flow cytometric approach as described in this thesis. If all epidermal cells derived 
from a standardised biopsy (for example 3-mm punch biopsies) would be suspended in a 
standardised volume, and if a standardised amount of reference beads would be added 
to this suspension, than an absolute estimation of the number of cells per biopsy can be 
made. However, using the flow cytometric methodologies as described in this thesis, no 
absolute cell numbers are counted, but rather the occurrence of a subpopulation as a 
proportion of the total number of cells, or in case of double or triple labelling the occur­
rence of a subpopulation as a proportion of another subpopulation. It is known that in 
psoriasis the total number of cell layers and the total number of epidermal cells are 
markedly increased compared to normal healthy skin [1]. Table 14 provides a concise 
overview of the total number of cells, the number of differentiated cells, and the number 
of germanitive cells, both in normal and psoriatic skin [1]. In this table, it is easily seen 
that if normal skin contains 100 keratinocytes, 70 out of them (70% ) are differentiated. 
The table also shows that compared to normal skin, psoriatic skin contains a four-fold 
number of keratinocytes. 200 of these keratinocytes are differentiated (3 times the 
number in normal skin), which accounts for 5 0 %  of the total population of keratinocytes, 
whereas this proportion is 7 0 %  in normal skin. Therefore, although it is well established 
that in psoriasis differentiation is impaired, this does not mean that the total number of 
differentiated cells is decreased. On the contrary, the number of differentiated cells has 
increased compared to normal skin: from 70 to 200 in this example. If it is stated that in 
psoriasis differentiation is decreased, it is meant that the relative number of 
differentiated cells compared to the reference population is decreased: from 7 0%  to 50%  
in this example.
Table 14 Estimates of cell kinetic data on healthy and psoriatic skin. Data refer to an 
imaginary surface area covering a hundred viable keratinocytes in normal skin.
Normal epidermis Psoriatic epidermis
Total number of keratinocytes 
Number of differentiated keratinocytes 
Number of germanitive keratinocytes
100
70
30
400
200
200
After effective treatment of psoriasis, the clinical hallmarks erythema, scaling, and 
induration will diminish. The clinical improvement is represented at the cellular level by 
an absolute decrease of the number of all cells, a decrease of the absolute number of 
inflammation cells, and a decrease in the absolute number of differentiated cells, but an 
increase in the relative number of differentiated cells as a proportion of all keratinocytes. 
Theoretically, it is possible that the proportion of the number of cells in the reference 
population decreases to the same extent as the proportion of the number of cells of one 
of the subpopulations. In that case, the relative change is 0% . If, for example, prior to 
treatment, 1000 diploid cells are measured; 950 keratinocytes and 50 mesenchymal cells, 
then the proportion of mesenchymal cells is 5%. If treatment results in a decrease of the 
total number of cells in the reference population to 500; 475 keratinocytes and 25 
mesenchymal cells, then the proportion of mesenchymal cells is still 5% , although the 
absolute number of mesenchymal cells is only half of that prior to treatment. In this 
thesis, the reference population for vimentin expression was the entire epidermal DNA­
diploid cell population. For the assessment of keratin 10, the reference population was 
the vimentin negative population, which should represent all non-mesenchymal cells, and 
thus all keratinocytes. In two clinical studies, described in sections 4.3 and 4.5, the pro­
portion of vimentin expressing-cells did not change significantly after treatment with 
tacalcitol and clobetasol under occlusion respectively. Earlier immunohistochemical 
studies on the epidermal infiltrate, however, showed significant changes with respect to 
inflammation parameters after these treatments, using exactly the same treatment 
protocols. With respect to the effects on epidermal inflammation of tacalcitol treatment 
during eight weeks of treatment, Gerritsen et al [2] found significant changes in the 
number of PMN, T Lymphocytes, and CD14-positive cells, whereas these changes were not 
significant in placebo. This immunohistochemical study measured these cells with a five 
point scale: 0, no staining; 1, sporadic staining; 2, minimal staining; 3, moderate 
staining; 4, pronounced staining. Thus, data are not relative to a reference population, 
but rather approximate total cell numbers. In contrast, in section 4.3 it was shown that 
the proportion of vimentin-expressing cells related to the total epidermal cell population 
does not change significantly after 8 weeks of treatment with tacalcitol. Such may there­
fore be explained by the limitations of our flow cytometric methodology that measures 
relative numbers of cells. This may also account for the finding in section 4.5 that treat­
ment of clobetasol under hydrocolloid occlusion does not induce a significant change in 
the expression of vimentin, since on the other hand an immunohistochemical study of 
Van der Vleuten et al [3] showed a very profound effect on epidermal inflammation para­
meters. In this study, both markers for T lymphocytes (CD2) and PMN (elastase) de­
creased significantly after clearance induction. Again, the cell numbers were assessed 
using a five-point scale. Moreover, this study revealed that at clearance the number of 
cell layers was 12, whereas this number was 25 prior to treatment. Taken into account the 
opposite findings between flow cytometric assessment of vimentin on one hand and
143
S
U
M
M
A
R
Y
 
AN
D
 
G
E
N
E
R
A
L
 
D
IS
C
U
S
S
IO
N
144
S
U
M
M
A
R
Y
 
AN
D
 
G
E
N
E
R
A
L
 
D
IS
C
U
S
S
IO
N
assessment of inflammation parameters by immunohistochemistry on the other hand, it 
can be concluded that flow cytometric assessment of epidermal inflammation using the 
monoclonal antibody vimentin is not conclusive for inflammation parameters. In order to 
overcome the limitations of measuring cells relative to the total population, it is worth­
while to assess the occurrence of a marker as a percentage of the relevant subpopulation 
by using a representative reference marker. Such an assessment is discussed in the next 
paragraph.
New flow cytometric developments for assessing 
epidermal cell characteristics
In psoriasis, cells are more proliferative than in normal skin. Because of a certain stres­
sing factor that has been unknown so far, cells that were in the resting phase of the cell 
cycle, the G0-phase, start to proliferate. Several immunohistochemical studies suggested 
the same ‘order of events'. The process of recruitment of cycling epidermal cells is initia­
ted by inflammation. Following the appearance of infiltrate cells in the margin zone, 
increased recruitment of cycling epidermal cells can be observed [4]. However, it should 
be taken into account that the expression of certain antibodies which are chosen to 
characterise a certain parameter, does not always indicate the time-point of the onset of 
the corresponding epidermal process. It is known that some proteins are expressed only 
hours after initial changes, and that their antibodies thus only come into expression after 
a certain time-interval. Moreover, every antibody has a certain detection threshold. There­
fore, data on the order of events should be considered critically.
It is a consistent feature that recruitment of cycling epidermal cells is anticipated by 
the expression of keratin 6 and keratin 16, not only in the margin zone of spreading 
psoriatic plaques, but also following standardised injury and by dithranol induced irrita­
tion of normal skin [5-7]. Keratins 6 and 16 are hyperproliferation markers that are only 
expressed in the suprabasal compartment of the epidermis. In order to avoid the limita­
tions as described in the previous paragraph, flow cytometric assessment of keratins 6 or 
16 should be related to another marker of the suprabasal compartment. Keratin 10 is 
such a marker that is also expressed only suprabasally. Therefore, a protocol was 
developed which enables simultaneous assessment of the expression of keratin 6 and 
keratin 10. Thus, the occurrence of keratin 6-positive cells was related not only to the 
total population of epidermal cells, but also to the very population of keratin 10-positive 
cells, as keratin 10-positive cells approximate the number of suprabasal cells. This newly 
developed protocol is described in section 2.5. If psoriatic skin is assessed using the pro­
tocol as described in section 2.5, it becomes clear that individual cells are able to express 
both keratin 10 and keratin 6 at the same time. This so-called co-expression had been 
observed earlier qualitatively in immunohistochemical studies [8]. Owing to this flow
cytometric protocol, this has now been proved quantitatively. Moreover, keratinocytes 
which express only keratin 10 or only keratin 6 were also observed. This methodology 
enables assessment of the proliferative activity of keratin 10-positive and -negative sub­
populations, of keratin 6-positive and -negative subpopulations, and of the keratin 10 /  
keratin 6 co-expressing subpopulation. However, as the proportion of all cells which 
express keratin 6 in psoriatic skin is rather low (±18%, section 2.5), too small number of 
cells might be available for reliable DNA analysis. In the studies described in section 3.1 
and 4.4 this was unfortunately the case. A 3-mm punch biopsy of psoriatic skin supplies 
approximately 1,500,000 cells. In principle, measuring all cells in one time would supply 
enough keratin 6-positive cells or K10/K6 co-expressing cells for reliable DNA analysis. 
However, normally it is not practical to use all of the cell suspension derived from one 
biopsy. For additional analyses or for re-measurement of the same sample, only half of 
the suspension is often used for a staining procedure. Therefore, at least 4-mm biopsies 
are required for assessment of the proliferative activity of all subpopulations. This, how­
ever, causes more inconveniences for the patient, as a larger wound is created and the 
risk of scarring is higher. For future experiments on the analysis of keratin 6 and keratin 
10 subpopulations, the proportion of measured cells and thus the minimally required 
number of cells in the cell suspension is an aspect to be taken into account.
For the assessment of keratin 10, the monoclonal antibody RKSE60 has been used in 
our department during the last years. RKSE60 is the longest available antibody directed 
against keratin 10. It is named after professor Ramaekers from the Department of Mole­
cular Biology of the University of Maastricht (Ramaekers Keratin of Suprabasal Epider­
mis), who firstly produced it. Recently it has also become commercially available. Another 
anti-keratin 10 monoclonal antibody was recently introduced as well: DE-K10. In a com­
parative study described in section 4.1, we used both RKSE60 and DE-K10 and compared 
the results. This study revealed that if RKSE60 is used for assessing keratin 10, 
statistically higher proportions of keratin 10-expressing cells are found compared to DE- 
K10. On the other hand, DE-K10 appears to be more sensitive in distinguishing positive 
and negative fluorescence signals. As in previous studies RKSE60 is the most frequently 
used anti-keratin 10 antibody, this antibody may be considered to be the standard for 
assessment of keratin 10-expression in epidermal keratinocytes. Therefore, in order to be 
able to compare future studies with available data in literature, the use of RKSE60 as the 
monoclonal antibody against keratin 10 remains the most practical approach.
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5.2. From symptomless to lesional psoriatic skin: 
epidermal subpopulations in the evolution 
of psoriatic plaques
In studies on the pathogenesis of psoriasis, the search for the order of events from sympt- 
omless to lesional skin is an important approach. Previously, histological, immunohisto- 
chemical, and biochemical methods have helped to estimate the order of events [4,6,9­
11]. So far, these studies suggest a ‘three stage' model.
The first stage is the symptomless skin, characterised by an increase in the epidermis 
of several enzymes involved in signal transduction (Table 1): protein kinase C is 
decreased, and phospholipase A2 is increased; CD4 and CD8-positive cells are slightly 
increased and fibroblasts show an increased glycosaminoglycan synthesis. Most authors 
agree that in symptomless skin, parameters for epidermal growth are slightly but signifi­
cantly increased as compared to normal skin of healthy volunteers. In this respect, it is 
important to emphasise that the distant uninvolved skin might be different from un­
involved skin adjacent to a lesion. However, most authors do not specify the site of 
biopsies from symptomless skin in relation to the distance from a lesion.
The second stage is the interphase between lesional and symptomless skin. Previous 
studies (immunohistochemistry, biochemical analyses, and laser doppler flow 
measurements) suggest a first involvement of the dermis with increased activity of alka- 
line-phosphatase in the capillaries, and increased expression of the extracellular matrix 
molecule tenascin [9,11-13]. Subsequently, expression of keratin 6 and 16 in the supra­
basal compartment with accumulation of T lymphocytes is observed.
In the final stage, an increased recruitment of cycling epidermal cells is observed, 
together with a sharp interruption of the formation of the stratum granulosum with the 
appearance of a parakeratotic stratum corneum [4].
A limitation of the above mentioned study approaches is the qualitative assessment 
instead of a quantitative approach. In sections 3.1 and 3.2, the percentages of epidermal 
cells expressing keratin 6, keratin 10, vimentin, and the proportion of basal cells in the 
SG2M-phase of the cell cycle were quantified using flow cytometry. The observations are 
summarised in Table 15. The most important conclusions in these sections were:
1. In stable plaques, quantitative parameters show a large interindividual variability.
2. The proportion of differentiated cells is significantly higher in the margin than in the 
centre of stable lesions, but parameters for inflammation and proliferation between 
the centre and margin are not significantly different.
3. Individual epidermal cells can co-express keratin 6 and keratin 10.
4. In psoriasis, there is a unique subpopulation of cells which express only keratin 6 but 
not keratin 10.
5. The proportion of co-expressing cells and cells which only express keratin 6 is signifi­
cantly different in the involved margin of a spreading psoriatic plaque compared to 
the uninvolved skin.
Using the multiparameter flow cytometric assessment, it is of importance that the distant 
uninvolved skin and normal skin do not show any statistically significant difference. 
Recently, we confirmed that, using flow cytometric approach, the response of distant 
uninvolved psoriatic skin to standardised injury is not different from that in normal skin 
[14]. Other qualitative studies also reported that the distant uninvolved skin is not signi­
ficantly different from normal skin of healthy volunteers [13]. However, a discrepancy 
between the immunohistochemical and flow cytometric approach is seen with respect to 
keratin 6 expression: in the flow cytometric studies described in this thesis, a simul­
taneous increase of keratin 6-expressing cells and the proportion of cells in the SG2M- 
phase was seen in the interface of lesional and unaffected skin, whereas immunohisto­
chemical studies showed an increase of keratin 16 in the suprabasal compartment prior 
to the increase of recruitment of cycling epidermal cells [6,10]. In these immunohisto­
chemical studies, counts of Ki-67 stained nuclei were used as measure for proliferation. 
The Ki-67 epitope is expressed about 20 hours after the transition of G0-cell to Gr cell, 
which artificially delays the appearance of the Ki-67-postive cells [15]. This lag time may 
explain the discrepancy between the immunohistochemical and flow cytometric results.
Table 15 Overview of data as described in sections 2.5, 3.1, and 3.2 with respect to the proportion of 
keratin 6 and keratin 10 subpopulations, basal cells in SG2M-phase, and vimentin-positive cells. Data are 
derived from symptomless and lesional skin, and comprise both stable and incipient lesions.
Lesional psoriatic skin Uninvolved skin Normal healthy 
skin
Margin zone
Reference Stable or Centre or Inner Outer Distant
incipient at random involved uninvolved uninvolved skin
lesions in the lesion margin margin
%  Keratin Section 3.2 Stable 28,8 ± 5,7 39,4 ± 14,7
10-positive cells Section 2.5 Stable and 27,4 ± 3,2 70,0 ± 3,6
Section 3.1
incipient
Incipient 24,5 ± 5,7 49,1 ± 3,0 56,3 ± 4,8 72,1 ± 4,7
%  Keratin Section 2.5 Stable and 18,0 ± 3,9 0,6 ± 0,1
6-positive cells
Section 3.1
incipient
Incipient 12,7 ± 4,9 2,5 ± 1,9 0,5 ± 0,2 0,4 ± 0,1
%  K10-K6 Section 2.5 Stable and 10,5 ± 2,2 0,4 ± 0,1
co-expressing cells
Section 3.1
incipient
Incipient 6,0 ± 2,1 2,0 ± 1,6 0,2 ± 0,1 0,2 ± 0,1
%  Basal cells Section 3.2 Stable 14,0 ± 5,0 15,5 ± 6,3
in the SG2M-phase Section 2.5 Stable and 15,4 ± 1,9 4,7 ± 1,2
Section 3.1
incipient
Incipient 10,0 ± 2,5 3,1 ± 0,5 2,5 ± 0,4 4,4 ± 1,3
%  Vimentin-positive Section 3.2 Stable 2,0 ± 0,8 2,2 ± 1,2
cells
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As has been explained in section 5.1, the expression of a parameter relative to an 
adequate reference parameter improves quantitative assessment by flow cytometry. It was 
explained that the adequate reference population for keratin 6 is keratin 10, as keratin 6 
is expressed in the suprabasal compartment, which roughly coincides with the keratin 10 
population. Therefore, we calculated the keratin 6 /  keratin 10 ratio of the inner margin 
of spreading plaques, of the outer margin, of the distant uninvolved skin, and of normal 
skin of healthy volunteers as a more adequate approximation for the keratin 6-positive 
subpopulation of suprabasal (i.e. keratin 10-positive) cells. Table 16 summarises these 
data, which are computed from section 3.1. In this table, it can be seen that the range of 
the K6/K10 ratios comparing symptomless and lesional skin is vastly increased compared 
to the proportion of keratin 6 or keratin 10-positive cells relative to the total epidermal 
cell population. Table 16 illustrates that the ratio in lesional skin is almost 150 fold 
(0.894/0.006) increased compared to normal skin. However, using this improved metho­
dology a significant difference is seen only between the inner and the outer margin: The 
difference between the ratio of the inner margin and the outer margin was statistically 
significant (p<0.02) using the ANOVA test and the Duncan Multiple Range test. The 
differences between the outer margin, the distant uninvolved skin, and normal skin of 
healthy volunteers were not significant. On the other hand, this methodology shows that 
in some patients the K6/K10 ratio remains low from distant uninvolved skin right into 
the inner margin (for example in patient 1 and 2), whereas an increase already in the 
outer margin is seen in patient 4.
In conclusion, using advanced cytometric quantification, expression of keratin 6 
appears simultaneously with an increase of the proportion of cells in the SG2M-phase 
during the appearance of the psoriatic lesion.
Table 16 Keratin 6 /  Keratin 10 ratios of the inner margin, the outer margin, and the distant 
uninvolved skin (DUI) of spreading psoriatic plaques, and of normal skin. Ratios are computed 
from the data as presented in section 3.1.
Patient no. Inner margin Outer margin DUI Normal
1 0,007 0,009 0,008 0,016
2 0,014 0,014 0,006 0,006
3 2,355 0,014 0,003 0,003
4 3,171 0,446 0,005 0,003
5 0,276 0,03 0,004 0,003
6 1,22 0,006 0,024 0,006
7 0,031 0,005 0,007 0,009
8 0,078 0,003 0,004 0,003
Mean 0,894 0,066 0,008 0,006
SEM 0,439 0,054 0,002 0,002
5.3 From lesional to symptomless skin: 
the effects of anti-psoriatic therapies 
on epidermal subpopulations.
General conclusions
The dynamics of epidermal differentiation, inflammation, and (hyper)proliferation
following several anti-psoriatic therapies has been described in chapter 4. From these
studies, the following conclusions were drawn:
1. Occlusion of standardised injured skin results in a decrease of the hyperproliferative 
response, and in an increased keratinisation. The more occlusive the dressing, the 
more pronounced this effect (section 4.1).
2. In a tape-strip model, tacalcitol ointment extents the cell cycling time of proliferating 
keratinocytes, or extents the duration of the recruitment process of cycling cells, but 
does not suppress the recruitment of resting keratinocytes (section 4.2).
3. Clinically, long-term treatment with tacalcitol ointment results in a significant im­
provement of psoriatic lesions after already 8 weeks of treatment. This clinical 
result maintains at the level reached after 8 weeks, with no further improvement 
(section 4.3).
4. On the cellular level, tacalcitol ointment improves keratinisation significantly after 8 
weeks of treatment. Subsequently, this effect is significantly less after 12 weeks, and 
than remains stable. Proliferation improves significantly after 8 weeks, and this effect 
is preserved during the rest of the treatment period. The effect of tacalcitol on the 
inflammation marker vimentin does not change significantly (section 4.3).
5. Clobetasol under hydrocolloid occlusion induces a fast clearance of psoriatic plaques. 
Owing to this therapy, proliferation is almost completely blocked, but on the other 
hand, lesions reappear soon. This reappearance tends to be a rebound phenomenon 
since cellular parameters of epidermal keratinisation and (hyper-) proliferation are 
already at pre-treatment levels when the clinical picture only shows a mild relapse 
(section 4.4).
6. The LTB4-antagonist VML 295 is not able to prevent a relapse in psoriasis. Moreover, 
orally administered VML 295 200 mg twice daily during 8 weeks does not show signi 
ficant changes in overall psoriasis severity, as represented by the PASI. Vimentin, 
Keratin 10, and the DNA-content of basal cells do not change significantly either 
after 8 weeks of treatment with VML 295 (section 4.5).
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Cellular aspects
Multiparameter flow cytometric assessment proved to be an adequate approach to 
quantify the effect of anti-psoriatic treatments on epidermal proliferation and keratini- 
sation. Chapter 4 describes that occlusion, tacalcitol, and topical corticosteroids interfere 
with epidermal proliferation. In line with the clinical efficacy, epidermal proliferation 
assessed by flow cytometry and compared to untreated samples was reduced by 57%  
following moderate occlusion in a tape-strip model (11.4/26.7, section 4.1), by 3 2 %  
following 8 weeks of tacalcitol treatment (12.3/18.0, section 4.3), and by 91% following 
treatment with a corticosteroid under hydrocolloid occlusion (1.2/12.7, section 4.4).
The pronounced, virtually total inhibition of epidermal proliferation by corticosteroids 
under occlusion as described in section 4.4 is intriguing. The total block, below the 
normal range, clearly suggests a direct effect of corticosteroids on epidermal hyper­
proliferation and not a secondary effect such as a normalisation following reduction of 
inflammation.
Flow cytometric methodology
Analogous to the calculation of the K6/K10 ratio as described in sections 5.1 and 5.2, 
we calculated this ratio for the results as described in section 4.4 on the treatment of 
psoriasis with a topical corticosteroid under occlusion. An overview of these calculations 
is presented in Table 17. As can be seen in this table, the treatment results in a 75-fold 
(1.361/0.018) reduction of the K6/K10 ratio. Again, the ratio is able to make distinction 
between the various moments of assessment. An ANOVA test revealed that the
Table 17 Keratin 6 /  Keratin 10 ratios of psoriatic lesions prior to clobetasol under HCD 
treatment, after treatment induced clearence, and at relapse. Ratios are calculated from the 
data as presented in section 4.4.
Patient Pre-treatment Clearance Relapse
1 2,403 0,009 1,176
2 3,687 0,033 2,104
3 0,966 0,007 1,04
4 0,397 0,013 0,768
5 0,987 0,039 1,438
6 0,552 0,013 0,49
7 0,532 0,008 0,875
Mean 1,361 0,018 1,127
SEM 0,465 0,005 0,199
differences between the ratios of pre-treatment level, after clearance, and at relapse are 
highly significant (P<0.005). Post-hoc comparison with a Duncan Multiple Range test 
showed a significant difference of the ratios between ‘pre-treatment' and ‘clearance' 
(P<0.01), and between ‘clearance' and ‘relapse' (P<0.01). The difference between ‘pre­
treatment' and ‘relapse' was not significant.
Clinical aspects
In sections 4.4 and 4.5, the pronounced clinical efficacy of clobetasol under a hydro­
colloid occlusive dressing was reconfirmed. Indeed, this approach can be used in recal­
citrant plaques. The principle of weekly applications of the hydrocolloid occlusive treat­
ment can function as a more general ‘topical drug depot' which guarantees optimal 
patient compliance and optimal drug bioavailability.
Tacalcitol, a vitamin D3 analogue, is now available in several countries. In Japan it 
has been the mainstay of anti-psoriatic treatments for already a decade. The sustained 
efficacy of tacalcitol as a maintenance treatment was well appreciated by the patients. 
Tacalcitol is part of the innovation in topical treatments of psoriasis. In our country, calci- 
potriol was introduced as a vitamin D3 principle in 1992. Recently, a new retinoic acid for 
topical use was introduced: tazarotene. The topical treatment of psoriasis has been 
improved with safer medium-strength antipsoriatics. These developments will permit a 
more focussed use of topical corticosteroids.
The absence of any clinical effect of VML 295, a LTB4 receptor antagonist, has practi­
cal implications. In a series of studies, it was shown that VML 295 at the concentrations 
used in this thesis (200 mg twice daily) inhibits ex vivo CD11b upregulation and inhibits 
in vivo LTB4 induced inflammation in the skin. The failure of VML 295 at biologically 
active concentrations to diminish overall psoriasis severity and to prevent a relapse as 
described in this thesis, demonstrates that further development of LTB4 receptor anta­
gonists is of no use for the treatment of psoriasis.
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5.4 Future suggestions
Based on the discussion of sections 5.1 to 5.3, we would like to suggest that further 
development of quantification of epidermal cell suspensions should focus on the assess­
ment of a parameter relative to the appropriate subpopulation. Besides the assessment of 
suprabasal cells measuring keratin 6 relative to the expression of keratin 10, it would be 
worthwhile to use the same strategy in future studies for the basal compartment (for 
example Ki-67 positive nuclei related to the number of keratin 14-positive cells), and for 
the inflammatory cells (for example number of elastase-positive cells related to the 
number of vimentin positive cells).
The keratin 6 /  keratin 10 ratio is 0.009 ± 0.002 in normal skin (Mean ± SEM, 
section 2.5), and 0.889 ± 0.250 in psoriatic skin (section 2.5). Thus, the ratio proves to 
be a marker which is 99-fold increased in psoriatic skin compared to skin of healthy 
volunteers, and which may be reduced 75-fold as a result of anti-psoriatic therapy (sec­
tion 5.3). The ratio of a parameter relative to its subpopulation, such as the K6/K10 
ratio, may therefore serve as a “therapeutic index" for the evaluation of antipsoriatic 
therapies.
Flow cytometric analysis targeted on characterisation of epidermal subpopulations is 
a challenging approach that provides unbiased, highly reproducible data of different 
stages in the induction and therapeutic regression of the psoriatic process.
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In d it p roefschrift staan de veranderingen centraal die bij psoriasis in de epidermis 
optreden. Deze veranderingen kenmerken zich door een verstoorde d iffe ren tia tie , door in- 
flam m atie , en door hyperproliferatie van de epidermale keratinocyten. Om deze verande­
ringen te bestuderen, is gebruik gemaakt van flow  cytometrie, een techniek die het 
m ogelijk m aakt objectieve en reproduceerbare data te verkrijgen. In d it p roefschrift 
worden 3 doelstellingen geformuleerd: het eerste doel was te bestuderen in hoeverre een 
reeds bestaand flow  cytometrisch protocol bruikbaar is voor de karakterisering van de 
epidermale veranderingen, en o f  het daarnaast m ogelijk zou zijn een nieuw protocol te 
ontw ikkelen welke aanvullende in form atie  zou verschaffen over het gedrag van de ver­
schillende epidermale subpopulaties in psoriasis. Ten tweede werd als doel gesteld de 
veranderingen in kaart te brengen ten aanzien van epidermale d iffe ren tia tie , in- 
flam m atie , en pro life ra tie  in aangedane en onaangedane psoriasishuid, en in de over­
gangsfase hiervan. Het laatste doel van d it p roefschrift was het nagaan in hoeverre 
enkele bestaande en experimentele psoriasis therapieën d iffe ren tia tie , in flam m atie  en 
pro life ra tie  beïnvloeden. Voor de bestudering van de processen welke zich bij psoriasis in 
de epidermis voltrekken, werden de veranderingen van een aanta l specifieke epidermale 
celpopulaties bestudeerd, te weten de keratine 10-positieve cellen, keratine 6-positieve 
cellen, vim entine-positieve cellen, en prolifererende epidermale cellen. Deze 
veranderingen werden steeds vergeleken met de klinische veranderingen door m iddel van 
de Psoriasis Area and Severity Index (PASI).
In hoo fds tuk  1 w ordt een algemene in le id ing over psoriasis gegeven. Achtereenvolgens 
worden in d it hoofdstuk de epidem iologie, de klinische en histologische aspecten, de 
e tio log ie, en de pathogenese van psoriasis besproken. Daarnaast worden de belangrijkste 
therapeutische mogelijkheden genoemd. De doelstellingen van d it proefschrift, alsmede 
de klinische en experimentele modellen die in d it p roefschrift zijn gebru ikt, besluiten d it 
hoofdstuk.
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In h o o fds tuk  2 staat flo w  cytometrie als methodiek voor de bestudering van epidermale 
cellen centraal. A llereerst w ordt in paragraaf 2.1 een algemene in le id ing gegeven over de 
algemene principes van flow  cytometrie. Bij flow  cytometrie w ordt in ind ividuele cellen de 
expressie gemeten van bepaalde markers. In paragraaf 2.2 w ordt kort besproken welke 
methode gehanteerd is om van humane epidermis een cel suspensie te  verkrijgen. Para­
g raa f 2.3 geeft een overzicht van de markers die gebru ikt zijn in d it proefschrift. Het gaat 
hierbij ondermeer om een tw eeta l keratines, te weten keratine 10 en keratine 6. Keratine
10 (K10) is een filam en t da t u its lu itend in goed gedifferentieerde keratinocyten to t 
expressie komt. Daarom is keratine 10 een ind ica to r voor epidermale d iffe ren tia tie . Kera­
tine  6 (K6) daarentegen is een filam en t dat alleen aantoonbaar is in hyperproliferatieve 
epidermale cellen, en is dus een maat voor hyperproliferatie. Daarnaast is v im entine als 
marker gebruikt, een proteïne dat in mesenchymale cellen wordt geproduceerd. In psoria­
tische epidermis vormen ontstekingscellen de meerderheid van de mesenchymale cellen. 
Om die reden is vim entine een maat voor epidermale in flam m atie. Tenslotte is het fluoro- 
chrome To-Pro-3 iodide gebru ikt da t zich direct inbouw t in het DNA van de epidermale 
cellen en daardoor een maat is voor de hoeveelheid DNA in deze cellen.
Een eerder ontw ikkelde methode voor het s im ultaan meten van keratine 10, v im en­
tine, en DNA inhoud w ordt aangehaald in paragraaf 2.4. Kwantificering van deze cel- 
parameters is een goede manier gebleken voor het objectiveren van anti-psoriatische 
therapieën. M et d it doel is deze methode aangewend in een aanta l klinische studies die 
beschreven zijn in hoofdstuk 4, in de paragrafen 4.1, 4.2, 4.3, en 4.5. U it deze studies is 
echter gebleken da t lokale o f systemische therapieën weinig invloed hebben op de 
epidermale vim entine expressie. Daarom is een nieuwe flow  cytometrische methode 
ontw ikkeld die naast keratine 10 en DNA-inhoud, keratine 6-expressie meet. Deze 
methode is beschreven in paragraaf 2.5. Deze nieuwe flow  cytometrische methode is to e ­
gepast in de studies die beschreven zijn in de paragrafen 3.1 en 4.4.
In hoo fds tuk  3 wordt nader ingegaan op de veranderingen in de expressie van keratine
6, keratine 10, v im entine en DNA-inhoud bij stabiele en onstabiele psoriasis. In para­
g raa f 3.1 is gekeken naar de verschillen in K6, K10, en DNA-inhoud tussen de aangedane 
rand van een groeiende psoriasis plaque, de klinisch niet-aangedane rand, en de gezonde 
huid op een afstand van deze plek. Daarnaast zijn, te r vergelijk ing, dezelfde parameters 
gemeten bij normale huid van gezonde vrijw illigers. Paragraaf 3.2 beschrijft de ver­
schillen binnen een stabiele psoriasis plaque: het verschil tussen het centrum van een 
lesie en de aangedane randzone is beschreven met betrekking to t  de expressie van K10, 
vim entine, en DNA-inhoud.
In hoo fds tuk  4 staan de effecten centraal van enkele bestaande en experimentele 
therapieën op de dynam iek van de expressie van K10, K6, vim entine, en DNA-inhoud. 
Beschreven zijn deze effecten van achtereenvolgens: occlusieven (paragraaf 4.1), het
vitam ine D-analogon taca lc ito l (paragraaf 4.2 en 4.3), van het klasse IV corticosteroid 
clobetasol (paragraaf 4.4), en van de LTB4 an tagonist VML 295 (paragraaf 4.5).
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Samenvattend kunnen u it d it  p roefschrift de volgende conclusies worden getrokken:
1. Flow cytometrie als methode voor epidermale fenotypering is een praktische 
benadering die objectieve en reproduceerbare data oplevert. Keratine 10 is een goede 
marker voor de kwantificering van epidermale d iffe ren tia tie , en de DNA-inhoud van 
de keratinocyten is een goede maat voor proliferatie. De epidermale expressie van 
vim entine m oduleert slechts matig (paragrafen 3.2, 4.1, 4.2, 4.3, en 4.5). D it wordt 
m ogelijk veroorzaakt doordat in het protocol waarbij v im entine gemeten wordt, de 
vim entine subpopulatie w ordt gemeten ten opzichte van de to ta le  celpopulatie  
(paragraaf 5.1). D it kan ondervangen worden door de expressie van een subpopulatie 
te  meten ten opzichte van een subpopulatie die aan de eerste subpopulatie 
gerelateerd is. Een voorbeeld hiervan is het meten van een suprabasaal gelokaliseerd 
keratine (bv K10), ten opzichte van een ander suprabasaal gelokaliseerd keratine
(bv K6, paragraaf 5.1).
2. Het sim ultaan meten van keratine 10, keratine 6, en DNA-inhoud van epidermale 
keratinocyten is een nieuwe en reproduceerbare m ethodiek die waardevolle 
in form atie  verschaft over d iffe ren tia tie  en (hyper)pro liferatie  in psoriatische epidermis 
(paragraaf 2.5). Deze methodiek komt bovendien tegem oet aan de wens om sub- 
populaties te meten welke aan elkaar gerelateerd zijn. Cellen zijn in staat beide kera- 
tines tege lijke rtijd  to t  expressie te brengen (paragraaf 2.5 en 3.1). De expressie van 
keratine 6 is bovendien sterk a fhanke lijk  van het psoriasis stadium ; Er is een groot 
verschil in expressie tussen aangedane en onaangedane huid (paragraaf 3.1). Voor 
het bepalen van de p ro life ra tieac tiv ite it van alle K6- en K10-subpopulaties is het 
noodzakelijk een voldoende aanta l cellen te  meten (paragraaf 2.5, 3.1, en 5.2).
3. De mate van d iffe ren tia tie  is in de rand van stabiele psoriasis plaques s ign ifican t 
hoger dan in het centrum (paragraaf 3.2).
H o o fds tuk  5 behelst een algemene discussie waarin de doelstellingen van d it proef­
schrift worden besproken aan de hand van de resultaten van de studies zoals beschreven 
in de hoofdstukken 2, 3, en 4. Paragraaf 5.1 bediscussieert de eerste doelstelling, para­
g raa f 5.2 de tweede, en paragraaf 5.3 de derde doelstelling. In paragraaf 5.4 tenslotte  
worden aanbevelingen gedaan voor toekom stige studies waarbij flo w  cytometrie gebru ikt 
w ordt voor epidermale fenotypering.
4. Occlusie onderdrukt de hyperproliferatieve respons na tape stripp ing, en bevordert de 
keratinisatie. D it e ffect neemt toe met de mate van occlusie (paragraaf 4.1).
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5. Tacalcitol is een e ffe c tie f anti-psoria ticum , ook op de lange term ijn . Het klinisch 
e ffect w ordt met name teweeggebracht door een remming van de pro life ra tie  van de 
basale keratinocyten (paragraaf 4.2 en 4.3).
6. Topicale behandeling met clobetasol onder occlusie doet een psoriasis plaque snel 
verdwijnen. De pro liferatie  a c tiv ite it van de basale keratinocyten w ordt hierdoor 
vrijwel geheel geblokkeerd. Na het staken van de medicatie treedt echter een rebound 
fenomeen op (paragraaf 4.4).
7. VML 295, een LTB4-antagonist, is n iet in staat een relapse bij psoriasis te voorkomen. 
Daarnaast heeft VML 295 na acht weken behandeling noch effect op de to ta le  
klinische u itgebreidheid van psoriasis, noch op de epidermale parameters K1G, 
vim entine en DNA-inhoud (paragraaf 4.5).
8. Bij de evaluatie van antipsoriatische therapieën door m iddel van het 3-parameter 
flow  cytometrie protocol waarbij keratine G, keratine 10, en DNA-inhoud w ordt geme­
ten, kan de ratio  KG/K1G dienen als een “therapeutische index" (paragraaf 5.4).
D A N K W O O R D
159
“ I am tied to  the stake, and I must stand the course" (Shakespeare, King Lear, act 111, v ii)
Gelukkig is onderzoek doen geen solita ire  bezigheid. Dankzij de hulp van vele mensen is 
m ijn proefschrift geworden wat het nu is. Het is ondoenlijk  om op deze plaats iedereen 
persoonlijk hiervoor te bedanken, maar een aanta l mensen w il ik toch met name noemen.
Allereerst ben ik veel dank verschuldigd aan mijn promotor, Prof. dr. dr. P.C.M. van de 
Kerkhof. Peter, j i j was degene die me de kans bood onderzoek te komen doen op je 
a fdeling, en legde daarmee de basis voor deze promotie. Je vele ideeën en je prag­
matische, resultaatgerichte aanpak spraken me zeer aan, en daardoor heb ik onze samen­
werking steeds als heel prettig  en constructie f ervaren. Dank ook dat je  me na mijn 
promotie de kans b iedt om me verder in de derm atologie te bekwamen.
Daarnaast w il ik m ijn co-promotor, dr. PE.J. van Erp bedanken. Piet, ik kan de dagen 
n iet te llen  die we al metend achter de flow  cytometer hebben doorgebracht, daarbij 
discussierend over de problemen die we tegen kwamen. Maar dankzij je  grote ervaring in 
de flow  cytometrie en je  vele ideeën, kwamen we er a ltijd  wel weer uit, en hebben we 
zelfs een nieuwe weg in epidermale fenotypering in kunnen slaan. Bedankt voor je hulp!
Op de derde plaats w il ik mijn collega M ichelle van Rossum bedanken. M ichelle, we 
begonnen als ‘tandem ', en hoewel j ij a ltijd  beweert da t ji j  degene was die onze ‘tandem ' 
moest besturen, houd ik vol dat ik harder trap te ! De vele persoonlijke gesprekken die we 
daarnaast hadden, maakten dat we behalve collega's ook vrienden zijn geworden.
M ijn kamergenote en collega Fransje Castelijns w il ik harte lijk  bedanken voor de vele 
gezellige uren die we op onze kamer doorgebracht hebben. Bedankt ook voor je  re la ti­
verend vermogen, je koekjes en snoepjes, je persoonlijke belangstelling, en voor onze 
Brabantse onderonsjes! En onder het m otto ‘never trus t a doctor whose office plants are 
dead', be loof ik da t ik voortaan wat beter voor mijn plantjes zal zorgen.
M ijn collega AGNIO's en AGIO's; Conrad, Carine, Astrid, Monique, Han, Marieke, 
Mandy, Quintus, Rob, M ilan, Jürgen, en Maurice w il ik bedanken voor hun co lleg ia lite it 
en voor de gezellige pauzes die we, in wisselende samenstelling, gezamenlijk hadden.
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Rolf, M iriam , Fred, Patrick, Ivonne, Bas, Arno, en Mieke: bedankt voor de samenwerking 
op het lab, en voor ju llie  hulpvaardigheid. Een speciaal woord van dank aan Candida van 
Hooijdonk die mij de beginselen van de flow  cytometrie heeft b ijgebracht en me steeds 
met raad en daad terzijde heeft gestaan. Gijs de Jongh w il ik in het bijzonder bedanken 
voor zijn tijd  en geduld bij het oplossen van mijn statistische problemen.
Marisol Kooijmans heeft als research-verpleegkundige veel werk verzet voor mijn 
trials. Alles was a ltijd  perfect geregeld in kamer 2, en de koffie a ltijd  vers. Bedankt! Ook 
dank aan Hanneke Metsers die haar t ijd e lijk  in deze functie  vervangen heeft. Veel dank 
ben ik verschuldigd aan alle patiënten en vrijw illigers: zonder hun bere idw illige mede­
werking hadden deze studies n iet uitgevoerd kunnen worden. Anne te r Meulen en Hans 
Goossen bedank ik voor de belangrijke bijdragen die zij, als wetenschappelijke stagiaires 
in het kader van hun artsople id ing, geleverd hebben aan de to tstandkom ing van twee 
artikelen.
Marie-Louise Dusée w il ik bedanken voor de fraaie vormgeving van d it proefschrift, en 
Rudger Smits voor zijn enthousiasme en crea tiv ite it bij de fo togra fie  voor de omslag. 
Dank aan Koen Loose voor zijn bereidheid model hiervoor te zijn.
M ijn vrienden w il ik heel erg bedanken voor hun interesse, hun aangenaam gezel­
schap, hun luisterend oor, hun gevraagde en ongevraagde adviezen, maar bovenal voor 
hun trouwe vriendschap. De laatste ste lling  is speciaal voor hen. Herwin Machiels en 
W ilbert van Rooij w il ik in het bijzonder bedanken om dat ze mijn paranimfen w ilden zijn.
Als laatste w il ik m ijn ouders bedanken, die er a ltijd  voor me zijn als ik ze nodig heb. 
Pa en ma, ju llie  onvoorwaardelijke steun heeft me vaak door moeilijke perioden heen 
geholpen. Daarom draag ik aan ju llie  d it p roefschrift op.
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proefschrift.
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